Compositions and methods for degradation of misfolded proteins
By employing TRIM proteins and STUbLs as modulators, the degradation of misfolded proteins is enhanced, effectively addressing the accumulation of these proteins and reducing the risk of associated diseases.
Patent Information
- Application Number
- JP2024135688
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2015-05-29
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current technologies are inadequate in effectively addressing the accumulation and degradation of misfolded proteins within cells, particularly in the nucleus, which can lead to various debilitating human diseases such as neurodegenerative disorders and amyloidosis, due to insufficient understanding of protein quality control systems.
The use of TRIM proteins and SUMO-targeted ubiquitin ligases (STUbLs) as modulators to enhance the expression or activity of these proteins, promoting the degradation of misfolded proteins through compositions that include compounds, peptides, antibodies, and nucleic acids, which facilitate the recognition and targeting of misfolded proteins for degradation.
Enhances the degradation of misfolded proteins, thereby reducing their harmful effects on cellular function and preventing or treating diseases associated with protein aggregates, including neurodegenerative disorders and amyloidosis.
Smart Images

Figure 2024161501000001_ABST
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 168,309, filed May 29, 2015, the contents of which are incorporated herein by reference in their entirety.
[0002] STATEMENT REGARDING U.S. GOVERNMENT-SPONSORED RESEARCH OR DEVELOPMENT This invention was made with government support under grants CA088868, GM060911, CA182675, CA184867, and P30 AI045008 awarded by the National Institutes of Health. The U.S. government has certain rights in this invention.
[0003] Background of the Invention Proteins are the most abundant macromolecules in cells and are critical to virtually all physiological processes. To perform their biological functions, most proteins must fold into and maintain their native conformation. Although a protein's native conformation is determined by its amino acid sequence, the folding process is extraordinarily complex and highly error-prone, and its usefulness may be further limited in situations of genetic mutation, biogenetic inaccuracy, and post-translational damage (Dobson, 2003, Nature, 426: 884-890; Goldberg, 2003, Nature, 426: 895-899). Abnormally conformational proteins and the aggregates they form pose a constant threat to cell viability and function. Failure to eliminate these proteins has been closely linked to the pathogenesis of a variety of debilitating human diseases (Selkoe, 2003, Nature, 426: 900-904; Taylor et al., 2002, Science, 296: 1991-1995).
[0004] To combat protein misfolding, cells employ two extensive sets of protein quality control (PQC) systems: systems that assist proteins in achieving their native conformation, and systems that eliminate misfolded proteins once they are formed. The former primarily consists of numerous molecular chaperones and their co-chaperones that protect proteins in their non-native states and reduce misfolding and aggregation in an ATP-dependent manner. Well-known examples include (1) heat shock protein 70 (Hsp70), which aids in the folding of a wide variety of proteins; (2) Hsp60 / chaperone, which forms a macromolecular cage to encapsulate relatively small proteins for subsequent folding; and (3) HSP90, which most commonly acts on proteins involved in cell signaling and transcription (Hartl et al., 2011, Nature, 475: 324-332).
[0005] Systems for removing misfolded proteins include protein disaggregation enzymes. For example, Hsp100 proteins in prokaryotes or lower eukaryotes (e.g., ClpB in bacteria and Hsp104 in yeast) can function in concert with Hsp70 and its co-chaperone, Hsp40, to resolubilize protein aggregates (Glover and Linquist, 1998, Cell, 94: 73-82). Nevertheless, given that protein misfolding is unavoidable and often cannot be reversed due to mutations, biogenetic errors, or irreparable damage, cells ultimately rely on degradation systems to maintain protein quality. However, these systems remain poorly understood. The ubiquitin-proteasome pathway, along with autophagy, must be an important part of these systems, but the key question of how they selectively recognize misfolded proteins and target them for degradation remains unresolved (Goldberg, 2003, Nature, 426: 895-899; Tyedmers et al, 2010, Nat Rev Mol Cell Biol, 11: 777-788).
[0006] Furthermore, compared to other cellular compartments such as the endoplasmic reticulum (Buchberger et al., 2010, Mol Cell, 40: 238-252), the PQC system in the nucleus is significantly less clear. Misfolded proteins in the nucleus can be particularly damaging to postmitotic mammalian cells (e.g., neurons and cardiomyocytes), which are unable to remove these proteins through nuclear envelope degradation during mitosis. The importance of elucidating PQC in this cellular compartment is highlighted by the formation of neuronal intranuclear inclusions, which are associated with various dominantly inherited neurodegenerative disorders, including Huntington's disease (HD) and some forms of spinocerebellar ataxia (SCA). These diseases are caused by the amplification of CAG repeats within the relevant genes, which encode polyQ expansions. They become apparent when polyQ expansions exceed a disease-specific threshold length and become progressively more severe as their length increases (Orr and Zoghbi, 2007, Annu Rev Neurosci, 30: 575-621).
[0007] Thus, there is a need in the art for compositions and methods for eliminating misfolded proteins. The present invention satisfies this unmet need.
[0008] Summary of the Invention In one aspect, the present invention provides a composition for treating or preventing a disease or disorder associated with misfolded proteins or protein aggregates, the composition comprising a modulator of one or more TRIM proteins. In one embodiment, the modulator increases the expression or activity of one or more TRIM proteins. In one embodiment, the modulator is at least one of a compound, a protein, a peptide, a peptidomimetic, an antibody, a ribozyme, a small molecule compound, a nucleic acid, a vector, and an antisense nucleic acid.
[0009] In one embodiment, the modulator increases the expression or activity of at least one of human TRIM3, TRIM4, TRIM5, TRIM6, TRIM7, TRIM9, TRIM11, TRIM13, TRIM14, TRIM15, TRIM16, TRIM17, TRIM19 (also referred to herein as "PML"), TRIM20, TRIM21, TRIM24, TRIM25, TRIM27, TRIM28, TRIM29, TRIM32, TRIM34, TRIM39, TRIM43, TRIM44, TRIM45, TRIM46, TRIM49, TRIM50, TRIM52, TRIM58, TRIM59, TRIM65, TRIM67, TRIM69, TRIM70, TRIM74, and TRIM75; and mouse TRIM30.
[0010] In one embodiment, the composition comprises an isolated peptide comprising one or more TRIM proteins. In one embodiment, the isolated peptide further comprises a cell-penetrating peptide (CPP) that enables the isolated peptide to enter a cell. In one embodiment, the CPP comprises the protein transduction domain of HIV tat.
[0011] In one embodiment, the composition comprises an isolated nucleic acid molecule encoding one or more TRIM proteins.
[0012] In one embodiment, the disease or disorder is a polyQ disorder. In one embodiment, the disease or disorder is a neurodegenerative disease or disorder selected from the group consisting of spinocerebellar ataxia (SCA) type 1 (SCA1), SCA2, SCA3, SCA6, SCA7, SCA17, Huntington's disease, dentatorubral-pallidoluysian atrophy (DRPLA), Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), transmissible spongiform encephalopathies (prion diseases), tauopathies, and frontotemporal lobar degeneration (FTLD). In one embodiment, the disease or disorder is selected from the group consisting of AL amyloidosis, AA amyloidosis, familial Mediterranean fever, senile systemic amyloidosis, familial amyloidotic polyneuropathy, hemodialysis-associated amyloidosis, apolipoprotein AI amyloidosis, apolipoprotein AII amyloidosis, apolipoprotein AIV amyloidosis, hereditary amyloidosis of the Finnish type, lysozyme amyloidosis, fibrinogen amyloidosis, hereditary cerebral amyloid angiopathy of the Icelandic type, type II diabetes mellitus, medullary thyroid carcinoma, atrial amyloidosis, hereditary cerebral hemorrhage with amyloidosis, pituitary prolactinoma, amyloidosis confined to injection sites, aortic medial amyloidosis, hereditary lattice corneal dystrophy, corneal amyloidosis associated with trichiasis, cataract, calcifying epithelial odontogenic tumor, pulmonary alveolar proteinosis, inclusion body myositis, and cutaneous lichen amyloidosis. In one embodiment, the disease or disorder is cancer associated with aggregates of mutant p53.
[0013] In one aspect, the present invention provides a method for treating or preventing a disease or disorder associated with misfolded proteins or protein aggregates in a subject in need thereof, the method comprising administering to the subject a composition comprising a modulator of one or more TRIM proteins. In one embodiment, the modulator increases the expression or activity of one or more TRIM proteins. In one embodiment, the modulator is at least one of a compound, a protein, a peptide, a peptidomimetic, an antibody, a ribozyme, a small molecule compound, a nucleic acid, a vector, and an antisense nucleic acid.
[0014] In one embodiment, the modulator increases the expression or activity of at least one of human TRIM3, TRIM4, TRIM5, TRIM6, TRIM7, TRIM9, TRIM11, TRIM13, TRIM14, TRIM15, TRIM16, TRIM17, TRIM19 (also referred to herein as "PML"), TRIM20, TRIM21, TRIM24, TRIM25, TRIM27, TRIM28, TRIM29, TRIM32, TRIM34, TRIM39, TRIM43, TRIM44, TRIM45, TRIM46, TRIM49, TRIM50, TRIM52, TRIM58, TRIM59, TRIM65, TRIM67, TRIM69, TRIM70, TRIM74, and TRIM75; and mouse TRIM30.
[0015] In one embodiment, the composition comprises an isolated peptide comprising one or more TRIM proteins. In one embodiment, the isolated peptide further comprises a cell-penetrating peptide (CPP) that enables the isolated peptide to enter a cell. In one embodiment, the CPP comprises the protein transduction domain of HIV tat.
[0016] In one embodiment, the composition comprises an isolated nucleic acid molecule encoding one or more TRIM proteins.
[0017] In one embodiment, the disease or disorder is a polyQ disorder. In one embodiment, the disease or disorder is a neurodegenerative disease or disorder selected from the group consisting of spinocerebellar ataxia (SCA) type 1 (SCA1), SCA2, SCA3, SCA6, SCA7, SCA17, Huntington's disease, dentatorubral-pallidoluysian atrophy (DRPLA), Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), transmissible spongiform encephalopathies (prion diseases), tauopathies, and frontotemporal lobar degeneration (FTLD). In one embodiment, the disease or disorder is selected from the group consisting of AL amyloidosis, AA amyloidosis, familial Mediterranean fever, senile systemic amyloidosis, familial amyloidotic polyneuropathy, hemodialysis-associated amyloidosis, apolipoprotein AI amyloidosis, apolipoprotein AII amyloidosis, apolipoprotein AIV amyloidosis, hereditary amyloidosis of the Finnish type, lysozyme amyloidosis, fibrinogen amyloidosis, hereditary cerebral amyloid angiopathy of the Icelandic type, type II diabetes mellitus, medullary thyroid carcinoma, atrial amyloidosis, hereditary cerebral hemorrhage with amyloidosis, pituitary prolactinoma, amyloidosis confined to injection sites, aortic medial amyloidosis, hereditary lattice corneal dystrophy, corneal amyloidosis associated with trichiasis, cataract, calcifying epithelial odontogenic tumor, pulmonary alveolar proteinosis, inclusion body myositis, and cutaneous lichen amyloidosis. In one embodiment, the disease or disorder is cancer associated with aggregates of mutant p53.
[0018] In one embodiment, the method comprises administering the composition to at least one neuronal cell of a subject.
[0019] In one aspect, the present invention provides a composition for treating or preventing a disease or disorder associated with degradation of functional mutant proteins, the composition comprising a modulator of one or more TRIM proteins. In one embodiment, the modulator increases the expression or activity of one or more TRIM proteins. In one embodiment, the modulator is at least one member of the group consisting of a compound, a protein, a peptide, a peptidomimetic, an antibody, a ribozyme, a small molecule compound, a nucleic acid, a vector, and an antisense nucleic acid. In one embodiment, the disease or disorder is cystic fibrosis.
[0020] In one aspect, the present invention provides a method for treating or preventing a disease or disorder associated with degradation of functional mutant proteins in a subject in need thereof, the method comprising administering to the subject a composition comprising a modulator of one or more TRIM proteins. In one embodiment, the modulator increases the expression or activity of one or more TRIM proteins. In one embodiment, the modulator is at least one member of the group consisting of a compound, a protein, a peptide, a peptidomimetic, an antibody, a ribozyme, a small molecule compound, a nucleic acid, a vector, and an antisense nucleic acid. In one embodiment, the disease or disorder is cystic fibrosis.
[0021] In one aspect, the present invention provides a composition for treating or preventing a disease or disorder associated with misfolded proteins or protein aggregates, the composition comprising a modulator of one or more SUMO-targeting ubiquitin ligases (STUbls). In one embodiment, the modulator increases the expression or activity of one or more STUbls. In one embodiment, the modulator is at least one of a compound, a protein, a peptide, a peptidomimetic, an antibody, a ribozyme, a small molecule compound, a nucleic acid, a vector, and an antisense nucleic acid. In one embodiment, the modulator increases the expression or activity of RNF4.
[0022] In one aspect, the present invention provides a method for treating or preventing a disease or disorder associated with misfolded proteins or protein aggregates in a subject in need thereof, the method comprising administering to the subject a composition comprising a modulator of one or more STUbLs. In one embodiment, the modulator increases the expression or activity of one or more STUbLs. In one embodiment, the modulator is at least one of a compound, a protein, a peptide, a peptidomimetic, an antibody, a ribozyme, a small molecule compound, a nucleic acid, a vector, and an antisense nucleic acid. In one embodiment, the modulator increases the expression or activity of RNF4.
[0023] In one aspect, the invention provides a method for producing a recombinant protein, the method comprising administering to a cell modified to express the recombinant protein a modulator of one or more TRIM proteins. In one embodiment, the modulator comprises an isolated peptide comprising one or more TRIM proteins. In one embodiment, the modulator comprises an isolated nucleic acid molecule encoding one or more TRIM proteins.
[0024] The following detailed description of the preferred embodiments of the invention will be better understood when read in conjunction with the accompanying drawings. For the purpose of illustrating the invention, there are shown in the drawings embodiments which are presently preferred. It should be understood, however, that the invention is not limited to the exact arrangements and instrumentalities of the embodiments shown in the drawings. [Brief explanation of the drawings]
[0025] [Figure 1A]Figure 1, including Figures 1A to 1L, shows the results of example experiments demonstrating that PML promotes the degradation of Atxn1 82Q and other misfolded nuclear proteins. (Figure 1A) HeLa cells transfected with Atxn1 82Q-GFP were stained with anti-PML antibody (red) and DAPI (blue). Individual and merged images are shown. Scale bar, 10 μm. (Figure 1B) Atxn1 82Q-GFP was expressed in HeLa cells alone or together with PML. Left: Fluorescence images of representative cells. Scale bar, 20 μm. Right: Quantification of cells based on the size of Atxn1 82Q-GFP inclusions. (Figure 1C) Atxn1 82Q-GFP was expressed in HeLa cells alone or together with PML (left), or in HeLa cells pretreated with control (-) or PML siRNA. Cell lysate fractions (where indicated) and whole cell lysates (WCL) were analyzed by filter phase contrast assay (for the SR fraction) or Western blot (WB; for the remainder). Molecular weight standards (in kDa) and the relative ratios of SS or SR Atxn1 to actin are shown. (Figure 1D) Steady-state levels of FLAG-Atxn1 82Q or 30Q analyzed by WB when expressed alone or together with PML in HeLa cells (left), or when expressed alone in HeLa cells treated with control or PML siRNA (right). (Figure 1E) Effect of PML on the stability of total FLAG-Atxn1 82Q protein analyzed by pulse-chase assay and autoradiography. The relative amounts of 35S-labeled Atxn1 82Q are shown. (Figure 1F and Figure 1G) Effect of PML overexpression (Figure 1F) and knockdown (Figure 1G) on the stability of Atxn1 82Q-GFP analyzed by treatment with CHX and WB. (Figure 1H) Effect of PML on Atxn1 82Q-GFP levels in the absence or presence of MG132. (Figure 1I) Top: Relative proportions of Httex1p97QP-expressing cells with cytoplasmic (left) and nuclear (right) inclusions in the absence or presence of PML (mean + standard deviation, n = 3). Bottom: Representative fluorescent images of transfected cells immunostained with anti-Htt antibody.Arrowheads indicate Httex1p97QP aggregates. (Fig. 1J and 1K) Levels of HA-Httex1p97QP and HA-Httex1p97QP(KR) (Fig. 1J) and GFP-TDP-43 (Fig. 1K) in cells with and without PML overexpression. Virtually all Htt aggregates were in the SR fraction. (Fig. 1L) Stability of nFucDM-GFP in control and PML-depleted cells treated with CHX and analyzed by WB. [Figure 1B]Figure 1, including Figures 1A to 1L, shows the results of example experiments demonstrating that PML promotes the degradation of Atxn1 82Q and other misfolded nuclear proteins. (Figure 1A) HeLa cells transfected with Atxn1 82Q-GFP were stained with anti-PML antibody (red) and DAPI (blue). Individual and merged images are shown. Scale bar, 10 μm. (Figure 1B) Atxn1 82Q-GFP was expressed in HeLa cells alone or together with PML. Left: Fluorescence images of representative cells. Scale bar, 20 μm. Right: Quantification of cells based on the size of Atxn1 82Q-GFP inclusions. (Figure 1C) Atxn1 82Q-GFP was expressed in HeLa cells alone or together with PML (left), or in HeLa cells pretreated with control (-) or PML siRNA. Cell lysate fractions (where indicated) and whole cell lysates (WCL) were analyzed by filter phase contrast assay (for the SR fraction) or Western blot (WB; for the remainder). Molecular weight standards (in kDa) and the relative ratios of SS or SR Atxn1 to actin are shown. (Figure 1D) Steady-state levels of FLAG-Atxn1 82Q or 30Q analyzed by WB when expressed alone or together with PML in HeLa cells (left), or when expressed alone in HeLa cells treated with control or PML siRNA (right). (Figure 1E) Effect of PML on the stability of total FLAG-Atxn1 82Q protein analyzed by pulse-chase assay and autoradiography. The relative amounts of 35S-labeled Atxn1 82Q are shown. (Figure 1F and Figure 1G) Effect of PML overexpression (Figure 1F) and knockdown (Figure 1G) on the stability of Atxn1 82Q-GFP analyzed by treatment with CHX and WB. (Figure 1H) Effect of PML on Atxn1 82Q-GFP levels in the absence or presence of MG132. (Figure 1I) Top: Relative proportions of Httex1p97QP-expressing cells with cytoplasmic (left) and nuclear (right) inclusions in the absence or presence of PML (mean + standard deviation, n = 3). Bottom: Representative fluorescent images of transfected cells immunostained with anti-Htt antibody.Arrowheads indicate Httex1p97QP aggregates. (Fig. 1J and 1K) Levels of HA-Httex1p97QP and HA-Httex1p97QP(KR) (Fig. 1J) and GFP-TDP-43 (Fig. 1K) in cells with and without PML overexpression. Virtually all Htt aggregates were in the SR fraction. (Fig. 1L) Stability of nFucDM-GFP in control and PML-depleted cells treated with CHX and analyzed by WB. [Figure 1C]Figure 1, including Figures 1A to 1L, shows the results of example experiments demonstrating that PML promotes the degradation of Atxn1 82Q and other misfolded nuclear proteins. (Figure 1A) HeLa cells transfected with Atxn1 82Q-GFP were stained with anti-PML antibody (red) and DAPI (blue). Individual and merged images are shown. Scale bar, 10 μm. (Figure 1B) Atxn1 82Q-GFP was expressed in HeLa cells alone or together with PML. Left: Fluorescence images of representative cells. Scale bar, 20 μm. Right: Quantification of cells based on the size of Atxn1 82Q-GFP inclusions. (Figure 1C) Atxn1 82Q-GFP was expressed in HeLa cells alone or together with PML (left), or in HeLa cells pretreated with control (-) or PML siRNA. Cell lysate fractions (where indicated) and whole cell lysates (WCL) were analyzed by filter phase contrast assay (for the SR fraction) or Western blot (WB; for the remainder). Molecular weight standards (in kDa) and the relative ratios of SS or SR Atxn1 to actin are shown. (Figure 1D) Steady-state levels of FLAG-Atxn1 82Q or 30Q analyzed by WB when expressed alone or together with PML in HeLa cells (left), or when expressed alone in HeLa cells treated with control or PML siRNA (right). (Figure 1E) Effect of PML on the stability of total FLAG-Atxn1 82Q protein analyzed by pulse-chase assay and autoradiography. The relative amounts of 35S-labeled Atxn1 82Q are shown. (Figure 1F and Figure 1G) Effect of PML overexpression (Figure 1F) and knockdown (Figure 1G) on the stability of Atxn1 82Q-GFP analyzed by treatment with CHX and WB. (Figure 1H) Effect of PML on Atxn1 82Q-GFP levels in the absence or presence of MG132. (Figure 1I) Top: Relative proportions of Httex1p97QP-expressing cells with cytoplasmic (left) and nuclear (right) inclusions in the absence or presence of PML (mean + standard deviation, n = 3). Bottom: Representative fluorescent images of transfected cells immunostained with anti-Htt antibody.Arrowheads indicate Httex1p97QP aggregates. (Fig. 1J and 1K) Levels of HA-Httex1p97QP and HA-Httex1p97QP(KR) (Fig. 1J) and GFP-TDP-43 (Fig. 1K) in cells with and without PML overexpression. Virtually all Htt aggregates were in the SR fraction. (Fig. 1L) Stability of nFucDM-GFP in control and PML-depleted cells treated with CHX and analyzed by WB. [Figure 1D]Figure 1, including Figures 1A to 1L, shows the results of example experiments demonstrating that PML promotes the degradation of Atxn1 82Q and other misfolded nuclear proteins. (Figure 1A) HeLa cells transfected with Atxn1 82Q-GFP were stained with anti-PML antibody (red) and DAPI (blue). Individual and merged images are shown. Scale bar, 10 μm. (Figure 1B) Atxn1 82Q-GFP was expressed in HeLa cells alone or together with PML. Left: Fluorescence images of representative cells. Scale bar, 20 μm. Right: Quantification of cells based on the size of Atxn1 82Q-GFP inclusions. (Figure 1C) Atxn1 82Q-GFP was expressed in HeLa cells alone or together with PML (left), or in HeLa cells pretreated with control (-) or PML siRNA. Cell lysate fractions (where indicated) and whole cell lysates (WCL) were analyzed by filter phase contrast assay (for the SR fraction) or Western blot (WB; for the remainder). Molecular weight standards (in kDa) and the relative ratios of SS or SR Atxn1 to actin are shown. (Figure 1D) Steady-state levels of FLAG-Atxn1 82Q or 30Q analyzed by WB when expressed alone or together with PML in HeLa cells (left), or when expressed alone in HeLa cells treated with control or PML siRNA (right). (Figure 1E) Effect of PML on the stability of total FLAG-Atxn1 82Q protein analyzed by pulse-chase assay and autoradiography. The relative amounts of 35S-labeled Atxn1 82Q are shown. (Figure 1F and Figure 1G) Effect of PML overexpression (Figure 1F) and knockdown (Figure 1G) on the stability of Atxn1 82Q-GFP analyzed by treatment with CHX and WB. (Figure 1H) Effect of PML on Atxn1 82Q-GFP levels in the absence or presence of MG132. (Figure 1I) Top: Relative proportions of Httex1p97QP-expressing cells with cytoplasmic (left) and nuclear (right) inclusions in the absence or presence of PML (mean + standard deviation, n = 3). Bottom: Representative fluorescent images of transfected cells immunostained with anti-Htt antibody.Arrowheads indicate Httex1p97QP aggregates. (Fig. 1J and 1K) Levels of HA-Httex1p97QP and HA-Httex1p97QP(KR) (Fig. 1J) and GFP-TDP-43 (Fig. 1K) in cells with and without PML overexpression. Virtually all Htt aggregates were in the SR fraction. (Fig. 1L) Stability of nFucDM-GFP in control and PML-depleted cells treated with CHX and analyzed by WB. [Figure 1E]Figure 1, including Figures 1A to 1L, shows the results of example experiments demonstrating that PML promotes the degradation of Atxn1 82Q and other misfolded nuclear proteins. (Figure 1A) HeLa cells transfected with Atxn1 82Q-GFP were stained with anti-PML antibody (red) and DAPI (blue). Individual and merged images are shown. Scale bar, 10 μm. (Figure 1B) Atxn1 82Q-GFP was expressed in HeLa cells alone or together with PML. Left: Fluorescence images of representative cells. Scale bar, 20 μm. Right: Quantification of cells based on the size of Atxn1 82Q-GFP inclusions. (Figure 1C) Atxn1 82Q-GFP was expressed in HeLa cells alone or together with PML (left), or in HeLa cells pretreated with control (-) or PML siRNA. Cell lysate fractions (where indicated) and whole cell lysates (WCL) were analyzed by filter phase contrast assay (for the SR fraction) or Western blot (WB; for the remainder). Molecular weight standards (in kDa) and the relative ratios of SS or SR Atxn1 to actin are shown. (Figure 1D) Steady-state levels of FLAG-Atxn1 82Q or 30Q analyzed by WB when expressed alone or together with PML in HeLa cells (left), or when expressed alone in HeLa cells treated with control or PML siRNA (right). (Figure 1E) Effect of PML on the stability of total FLAG-Atxn1 82Q protein analyzed by pulse-chase assay and autoradiography. The relative amounts of 35S-labeled Atxn1 82Q are shown. (Figure 1F and Figure 1G) Effect of PML overexpression (Figure 1F) and knockdown (Figure 1G) on the stability of Atxn1 82Q-GFP analyzed by treatment with CHX and WB. (Figure 1H) Effect of PML on Atxn1 82Q-GFP levels in the absence or presence of MG132. (Figure 1I) Top: Relative proportions of Httex1p97QP-expressing cells with cytoplasmic (left) and nuclear (right) inclusions in the absence or presence of PML (mean + standard deviation, n = 3). Bottom: Representative fluorescent images of transfected cells immunostained with anti-Htt antibody.Arrowheads indicate Httex1p97QP aggregates. (Fig. 1J and 1K) Levels of HA-Httex1p97QP and HA-Httex1p97QP(KR) (Fig. 1J) and GFP-TDP-43 (Fig. 1K) in cells with and without PML overexpression. Virtually all Htt aggregates were in the SR fraction. (Fig. 1L) Stability of nFucDM-GFP in control and PML-depleted cells treated with CHX and analyzed by WB. [Figure 1F]Figure 1, including Figures 1A to 1L, shows the results of example experiments demonstrating that PML promotes the degradation of Atxn1 82Q and other misfolded nuclear proteins. (Figure 1A) HeLa cells transfected with Atxn1 82Q-GFP were stained with anti-PML antibody (red) and DAPI (blue). Individual and merged images are shown. Scale bar, 10 μm. (Figure 1B) Atxn1 82Q-GFP was expressed in HeLa cells alone or together with PML. Left: Fluorescence images of representative cells. Scale bar, 20 μm. Right: Quantification of cells based on the size of Atxn1 82Q-GFP inclusions. (Figure 1C) Atxn1 82Q-GFP was expressed in HeLa cells alone or together with PML (left), or in HeLa cells pretreated with control (-) or PML siRNA. Cell lysate fractions (where indicated) and whole cell lysates (WCL) were analyzed by filter phase contrast assay (for the SR fraction) or Western blot (WB; for the remainder). Molecular weight standards (in kDa) and the relative ratios of SS or SR Atxn1 to actin are shown. (Figure 1D) Steady-state levels of FLAG-Atxn1 82Q or 30Q analyzed by WB when expressed alone or together with PML in HeLa cells (left), or when expressed alone in HeLa cells treated with control or PML siRNA (right). (Figure 1E) Effect of PML on the stability of total FLAG-Atxn1 82Q protein analyzed by pulse-chase assay and autoradiography. The relative amounts of 35S-labeled Atxn1 82Q are shown. (Figure 1F and Figure 1G) Effect of PML overexpression (Figure 1F) and knockdown (Figure 1G) on the stability of Atxn1 82Q-GFP analyzed by treatment with CHX and WB. (Figure 1H) Effect of PML on Atxn1 82Q-GFP levels in the absence or presence of MG132. (Figure 1I) Top: Relative proportions of Httex1p97QP-expressing cells with cytoplasmic (left) and nuclear (right) inclusions in the absence or presence of PML (mean + standard deviation, n = 3). Bottom: Representative fluorescent images of transfected cells immunostained with anti-Htt antibody.Arrowheads indicate Httex1p97QP aggregates. (Fig. 1J and 1K) Levels of HA-Httex1p97QP and HA-Httex1p97QP(KR) (Fig. 1J) and GFP-TDP-43 (Fig. 1K) in cells with and without PML overexpression. Virtually all Htt aggregates were in the SR fraction. (Fig. 1L) Stability of nFucDM-GFP in control and PML-depleted cells treated with CHX and analyzed by WB. [Figure 1G]Figure 1, including Figures 1A to 1L, shows the results of example experiments demonstrating that PML promotes the degradation of Atxn1 82Q and other misfolded nuclear proteins. (Figure 1A) HeLa cells transfected with Atxn1 82Q-GFP were stained with anti-PML antibody (red) and DAPI (blue). Individual and merged images are shown. Scale bar, 10 μm. (Figure 1B) Atxn1 82Q-GFP was expressed in HeLa cells alone or together with PML. Left: Fluorescence images of representative cells. Scale bar, 20 μm. Right: Quantification of cells based on the size of Atxn1 82Q-GFP inclusions. (Figure 1C) Atxn1 82Q-GFP was expressed in HeLa cells alone or together with PML (left), or in HeLa cells pretreated with control (-) or PML siRNA. Cell lysate fractions (where indicated) and whole cell lysates (WCL) were analyzed by filter phase contrast assay (for the SR fraction) or Western blot (WB; for the remainder). Molecular weight standards (in kDa) and the relative ratios of SS or SR Atxn1 to actin are shown. (Figure 1D) Steady-state levels of FLAG-Atxn1 82Q or 30Q analyzed by WB when expressed alone or together with PML in HeLa cells (left), or when expressed alone in HeLa cells treated with control or PML siRNA (right). (Figure 1E) Effect of PML on the stability of total FLAG-Atxn1 82Q protein analyzed by pulse-chase assay and autoradiography. The relative amounts of 35S-labeled Atxn1 82Q are shown. (Figure 1F and Figure 1G) Effect of PML overexpression (Figure 1F) and knockdown (Figure 1G) on the stability of Atxn1 82Q-GFP analyzed by treatment with CHX and WB. (Figure 1H) Effect of PML on Atxn1 82Q-GFP levels in the absence or presence of MG132. (Figure 1I) Top: Relative proportions of Httex1p97QP-expressing cells with cytoplasmic (left) and nuclear (right) inclusions in the absence or presence of PML (mean + standard deviation, n = 3). Bottom: Representative fluorescent images of transfected cells immunostained with anti-Htt antibody.Arrowheads indicate Httex1p97QP aggregates. (Fig. 1J and 1K) Levels of HA-Httex1p97QP and HA-Httex1p97QP(KR) (Fig. 1J) and GFP-TDP-43 (Fig. 1K) in cells with and without PML overexpression. Virtually all Htt aggregates were in the SR fraction. (Fig. 1L) Stability of nFucDM-GFP in control and PML-depleted cells treated with CHX and analyzed by WB. [Figure 1H]Figure 1, including Figures 1A to 1L, shows the results of example experiments demonstrating that PML promotes the degradation of Atxn1 82Q and other misfolded nuclear proteins. (Figure 1A) HeLa cells transfected with Atxn1 82Q-GFP were stained with anti-PML antibody (red) and DAPI (blue). Individual and merged images are shown. Scale bar, 10 μm. (Figure 1B) Atxn1 82Q-GFP was expressed in HeLa cells alone or together with PML. Left: Fluorescence images of representative cells. Scale bar, 20 μm. Right: Quantification of cells based on the size of Atxn1 82Q-GFP inclusions. (Figure 1C) Atxn1 82Q-GFP was expressed in HeLa cells alone or together with PML (left), or in HeLa cells pretreated with control (-) or PML siRNA. Cell lysate fractions (where indicated) and whole cell lysates (WCL) were analyzed by filter phase contrast assay (for the SR fraction) or Western blot (WB; for the remainder). Molecular weight standards (in kDa) and the relative ratios of SS or SR Atxn1 to actin are shown. (Figure 1D) Steady-state levels of FLAG-Atxn1 82Q or 30Q analyzed by WB when expressed alone or together with PML in HeLa cells (left), or when expressed alone in HeLa cells treated with control or PML siRNA (right). (Figure 1E) Effect of PML on the stability of total FLAG-Atxn1 82Q protein analyzed by pulse-chase assay and autoradiography. The relative amounts of 35S-labeled Atxn1 82Q are shown. (Figure 1F and Figure 1G) Effect of PML overexpression (Figure 1F) and knockdown (Figure 1G) on the stability of Atxn1 82Q-GFP analyzed by treatment with CHX and WB. (Figure 1H) Effect of PML on Atxn1 82Q-GFP levels in the absence or presence of MG132. (Figure 1I) Top: Relative proportions of Httex1p97QP-expressing cells with cytoplasmic (left) and nuclear (right) inclusions in the absence or presence of PML (mean + standard deviation, n = 3). Bottom: Representative fluorescent images of transfected cells immunostained with anti-Htt antibody.Arrowheads indicate Httex1p97QP aggregates. (Fig. 1J and 1K) Levels of HA-Httex1p97QP and HA-Httex1p97QP(KR) (Fig. 1J) and GFP-TDP-43 (Fig. 1K) in cells with and without PML overexpression. Virtually all Htt aggregates were in the SR fraction. (Fig. 1L) Stability of nFucDM-GFP in control and PML-depleted cells treated with CHX and analyzed by WB. [Figure 1I]Figure 1, including Figures 1A to 1L, shows the results of example experiments demonstrating that PML promotes the degradation of Atxn1 82Q and other misfolded nuclear proteins. (Figure 1A) HeLa cells transfected with Atxn1 82Q-GFP were stained with anti-PML antibody (red) and DAPI (blue). Individual and merged images are shown. Scale bar, 10 μm. (Figure 1B) Atxn1 82Q-GFP was expressed in HeLa cells alone or together with PML. Left: Fluorescence images of representative cells. Scale bar, 20 μm. Right: Quantification of cells based on the size of Atxn1 82Q-GFP inclusions. (Figure 1C) Atxn1 82Q-GFP was expressed in HeLa cells alone or together with PML (left), or in HeLa cells pretreated with control (-) or PML siRNA. Cell lysate fractions (where indicated) and whole cell lysates (WCL) were analyzed by filter phase contrast assay (for the SR fraction) or Western blot (WB; for the remainder). Molecular weight standards (in kDa) and the relative ratios of SS or SR Atxn1 to actin are shown. (Figure 1D) Steady-state levels of FLAG-Atxn1 82Q or 30Q analyzed by WB when expressed alone or together with PML in HeLa cells (left), or when expressed alone in HeLa cells treated with control or PML siRNA (right). (Figure 1E) Effect of PML on the stability of total FLAG-Atxn1 82Q protein analyzed by pulse-chase assay and autoradiography. The relative amounts of 35S-labeled Atxn1 82Q are shown. (Figure 1F and Figure 1G) Effect of PML overexpression (Figure 1F) and knockdown (Figure 1G) on the stability of Atxn1 82Q-GFP analyzed by treatment with CHX and WB. (Figure 1H) Effect of PML on Atxn1 82Q-GFP levels in the absence or presence of MG132. (Figure 1I) Top: Relative proportions of Httex1p97QP-expressing cells with cytoplasmic (left) and nuclear (right) inclusions in the absence or presence of PML (mean + standard deviation, n = 3). Bottom: Representative fluorescent images of transfected cells immunostained with anti-Htt antibody.Arrowheads indicate Httex1p97QP aggregates. (Fig. 1J and 1K) Levels of HA-Httex1p97QP and HA-Httex1p97QP(KR) (Fig. 1J) and GFP-TDP-43 (Fig. 1K) in cells with and without PML overexpression. Virtually all Htt aggregates were in the SR fraction. (Fig. 1L) Stability of nFucDM-GFP in control and PML-depleted cells treated with CHX and analyzed by WB. [Figure 1J]Figure 1, including Figures 1A to 1L, shows the results of example experiments demonstrating that PML promotes the degradation of Atxn1 82Q and other misfolded nuclear proteins. (Figure 1A) HeLa cells transfected with Atxn1 82Q-GFP were stained with anti-PML antibody (red) and DAPI (blue). Individual and merged images are shown. Scale bar, 10 μm. (Figure 1B) Atxn1 82Q-GFP was expressed in HeLa cells alone or together with PML. Left: Fluorescence images of representative cells. Scale bar, 20 μm. Right: Quantification of cells based on the size of Atxn1 82Q-GFP inclusions. (Figure 1C) Atxn1 82Q-GFP was expressed in HeLa cells alone or together with PML (left), or in HeLa cells pretreated with control (-) or PML siRNA. Cell lysate fractions (where indicated) and whole cell lysates (WCL) were analyzed by filter phase contrast assay (for the SR fraction) or Western blot (WB; for the remainder). Molecular weight standards (in kDa) and the relative ratios of SS or SR Atxn1 to actin are shown. (Figure 1D) Steady-state levels of FLAG-Atxn1 82Q or 30Q analyzed by WB when expressed alone or together with PML in HeLa cells (left), or when expressed alone in HeLa cells treated with control or PML siRNA (right). (Figure 1E) Effect of PML on the stability of total FLAG-Atxn1 82Q protein analyzed by pulse-chase assay and autoradiography. The relative amounts of 35S-labeled Atxn1 82Q are shown. (Figure 1F and Figure 1G) Effect of PML overexpression (Figure 1F) and knockdown (Figure 1G) on the stability of Atxn1 82Q-GFP analyzed by treatment with CHX and WB. (Figure 1H) Effect of PML on Atxn1 82Q-GFP levels in the absence or presence of MG132. (Figure 1I) Top: Relative proportions of Httex1p97QP-expressing cells with cytoplasmic (left) and nuclear (right) inclusions in the absence or presence of PML (mean + standard deviation, n = 3). Bottom: Representative fluorescent images of transfected cells immunostained with anti-Htt antibody.Arrowheads indicate Httex1p97QP aggregates. (Fig. 1J and 1K) Levels of HA-Httex1p97QP and HA-Httex1p97QP(KR) (Fig. 1J) and GFP-TDP-43 (Fig. 1K) in cells with and without PML overexpression. Virtually all Htt aggregates were in the SR fraction. (Fig. 1L) Stability of nFucDM-GFP in control and PML-depleted cells treated with CHX and analyzed by WB. [Figure 1K]Figure 1, including Figures 1A to 1L, shows the results of example experiments demonstrating that PML promotes the degradation of Atxn1 82Q and other misfolded nuclear proteins. (Figure 1A) HeLa cells transfected with Atxn1 82Q-GFP were stained with anti-PML antibody (red) and DAPI (blue). Individual and merged images are shown. Scale bar, 10 μm. (Figure 1B) Atxn1 82Q-GFP was expressed in HeLa cells alone or together with PML. Left: Fluorescence images of representative cells. Scale bar, 20 μm. Right: Quantification of cells based on the size of Atxn1 82Q-GFP inclusions. (Figure 1C) Atxn1 82Q-GFP was expressed in HeLa cells alone or together with PML (left), or in HeLa cells pretreated with control (-) or PML siRNA. Cell lysate fractions (where indicated) and whole cell lysates (WCL) were analyzed by filter phase contrast assay (for the SR fraction) or Western blot (WB; for the remainder). Molecular weight standards (in kDa) and the relative ratios of SS or SR Atxn1 to actin are shown. (Figure 1D) Steady-state levels of FLAG-Atxn1 82Q or 30Q analyzed by WB when expressed alone or together with PML in HeLa cells (left), or when expressed alone in HeLa cells treated with control or PML siRNA (right). (Figure 1E) Effect of PML on the stability of total FLAG-Atxn1 82Q protein analyzed by pulse-chase assay and autoradiography. The relative amounts of 35S-labeled Atxn1 82Q are shown. (Figure 1F and Figure 1G) Effect of PML overexpression (Figure 1F) and knockdown (Figure 1G) on the stability of Atxn1 82Q-GFP analyzed by treatment with CHX and WB. (Figure 1H) Effect of PML on Atxn1 82Q-GFP levels in the absence or presence of MG132. (Figure 1I) Top: Relative proportions of Httex1p97QP-expressing cells with cytoplasmic (left) and nuclear (right) inclusions in the absence or presence of PML (mean + standard deviation, n = 3). Bottom: Representative fluorescent images of transfected cells immunostained with anti-Htt antibody.Arrowheads indicate Httex1p97QP aggregates. (Fig. 1J and 1K) Levels of HA-Httex1p97QP and HA-Httex1p97QP(KR) (Fig. 1J) and GFP-TDP-43 (Fig. 1K) in cells with and without PML overexpression. Virtually all Htt aggregates were in the SR fraction. (Fig. 1L) Stability of nFucDM-GFP in control and PML-depleted cells treated with CHX and analyzed by WB. [Figure 1L]Figure 1, including Figures 1A to 1L, shows the results of example experiments demonstrating that PML promotes the degradation of Atxn1 82Q and other misfolded nuclear proteins. (Figure 1A) HeLa cells transfected with Atxn1 82Q-GFP were stained with anti-PML antibody (red) and DAPI (blue). Individual and merged images are shown. Scale bar, 10 μm. (Figure 1B) Atxn1 82Q-GFP was expressed in HeLa cells alone or together with PML. Left: Fluorescence images of representative cells. Scale bar, 20 μm. Right: Quantification of cells based on the size of Atxn1 82Q-GFP inclusions. (Figure 1C) Atxn1 82Q-GFP was expressed in HeLa cells alone or together with PML (left), or in HeLa cells pretreated with control (-) or PML siRNA. Cell lysate fractions (where indicated) and whole cell lysates (WCL) were analyzed by filter phase contrast assay (for the SR fraction) or Western blot (WB; for the remainder). Molecular weight standards (in kDa) and the relative ratios of SS or SR Atxn1 to actin are shown. (Figure 1D) Steady-state levels of FLAG-Atxn1 82Q or 30Q analyzed by WB when expressed alone or together with PML in HeLa cells (left), or when expressed alone in HeLa cells treated with control or PML siRNA (right). (Figure 1E) Effect of PML on the stability of total FLAG-Atxn1 82Q protein analyzed by pulse-chase assay and autoradiography. The relative amounts of 35S-labeled Atxn1 82Q are shown. (Figure 1F and Figure 1G) Effect of PML overexpression (Figure 1F) and knockdown (Figure 1G) on the stability of Atxn1 82Q-GFP analyzed by treatment with CHX and WB. (Figure 1H) Effect of PML on Atxn1 82Q-GFP levels in the absence or presence of MG132. (Figure 1I) Top: Relative proportions of Httex1p97QP-expressing cells with cytoplasmic (left) and nuclear (right) inclusions in the absence or presence of PML (mean + standard deviation, n = 3). Bottom: Representative fluorescent images of transfected cells immunostained with anti-Htt antibody.Arrowheads indicate Httex1p97QP aggregates. (Fig. 1J and 1K) Levels of HA-Httex1p97QP and HA-Httex1p97QP(KR) (Fig. 1J) and GFP-TDP-43 (Fig. 1K) in cells with and without PML overexpression. Virtually all Htt aggregates were in the SR fraction. (Fig. 1L) Stability of nFucDM-GFP in control and PML-depleted cells treated with CHX and analyzed by WB. [Figure 2A] Figure 2, including Figures 2A to 2E, shows the results of example experiments demonstrating the recognition of misfolded proteins by PML. (Figure 2A) Binding of GST-Htt25Q and GST-Htt103Q to immobilized FLAG-PML and FLAG-GFP (negative control) analyzed by in vitro pull-down assay, followed by WB (top and bottom) and Ponceau S staining (center). *IgG heavy chain. (Figure 2B) Binding of GST-PML (shown on the right) and control GST proteins to native (N) and urea-denatured (D) luciferase (luc) immobilized on Ni-NTA beads analyzed as in (Figure 2A). *Nonspecific protein derived from BL21 bacterial lysate bound to control beads. (Figure 2C) Binding of the indicated GST-Htt fusions to FLAG-PML CC conjugated to anti-FlagM2 beads or control beads analyzed by WB (top and center) and Coomassie staining (bottom). (Fig. 2D) Binding of PML F12 / SRS2 (shown on the right) to a luciferase-derived peptide library. The N-terminal amino acid of the first peptide spotted in each row and the number of the last peptide are shown. (Fig. 2E) The abundance of each amino acid in PML SRS2-binding peptides compared to its abundance in the luciferase peptide array (set at 100%). [Figure 2B]Figure 2, including Figures 2A to 2E, shows the results of example experiments demonstrating the recognition of misfolded proteins by PML. (Figure 2A) Binding of GST-Htt25Q and GST-Htt103Q to immobilized FLAG-PML and FLAG-GFP (negative control) analyzed by in vitro pull-down assay, followed by WB (top and bottom) and Ponceau S staining (center). *IgG heavy chain. (Figure 2B) Binding of GST-PML (shown on the right) and control GST proteins to native (N) and urea-denatured (D) luciferase (luc) immobilized on Ni-NTA beads analyzed as in (Figure 2A). *Nonspecific protein derived from BL21 bacterial lysate bound to control beads. (Figure 2C) Binding of the indicated GST-Htt fusions to FLAG-PML CC conjugated to anti-FlagM2 beads or control beads analyzed by WB (top and center) and Coomassie staining (bottom). (Fig. 2D) Binding of PML F12 / SRS2 (shown on the right) to a luciferase-derived peptide library. The N-terminal amino acid of the first peptide spotted in each row and the number of the last peptide are shown. (Fig. 2E) The abundance of each amino acid in PML SRS2-binding peptides compared to its abundance in the luciferase peptide array (set at 100%). [Figure 2C]Figure 2, including Figures 2A to 2E, shows the results of example experiments demonstrating the recognition of misfolded proteins by PML. (Figure 2A) Binding of GST-Htt25Q and GST-Htt103Q to immobilized FLAG-PML and FLAG-GFP (negative control) analyzed by in vitro pull-down assay, followed by WB (top and bottom) and Ponceau S staining (center). *IgG heavy chain. (Figure 2B) Binding of GST-PML (shown on the right) and control GST proteins to native (N) and urea-denatured (D) luciferase (luc) immobilized on Ni-NTA beads analyzed as in (Figure 2A). *Nonspecific protein derived from BL21 bacterial lysate bound to control beads. (Figure 2C) Binding of the indicated GST-Htt fusions to FLAG-PML CC conjugated to anti-FlagM2 beads or control beads analyzed by WB (top and center) and Coomassie staining (bottom). (Fig. 2D) Binding of PML F12 / SRS2 (shown on the right) to a luciferase-derived peptide library. The N-terminal amino acid of the first peptide spotted in each row and the number of the last peptide are shown. (Fig. 2E) The abundance of each amino acid in PML SRS2-binding peptides compared to its abundance in the luciferase peptide array (set at 100%). [Figure 2D]Figure 2, including Figures 2A to 2E, shows the results of example experiments demonstrating the recognition of misfolded proteins by PML. (Figure 2A) Binding of GST-Htt25Q and GST-Htt103Q to immobilized FLAG-PML and FLAG-GFP (negative control) analyzed by in vitro pull-down assay, followed by WB (top and bottom) and Ponceau S staining (center). *IgG heavy chain. (Figure 2B) Binding of GST-PML (shown on the right) and control GST proteins to native (N) and urea-denatured (D) luciferase (luc) immobilized on Ni-NTA beads analyzed as in (Figure 2A). *Nonspecific protein derived from BL21 bacterial lysate bound to control beads. (Figure 2C) Binding of the indicated GST-Htt fusions to FLAG-PML CC conjugated to anti-FlagM2 beads or control beads analyzed by WB (top and center) and Coomassie staining (bottom). (Fig. 2D) Binding of PML F12 / SRS2 (shown on the right) to a luciferase-derived peptide library. The N-terminal amino acid of the first peptide spotted in each row and the number of the last peptide are shown. (Fig. 2E) The abundance of each amino acid in PML SRS2-binding peptides compared to its abundance in the luciferase peptide array (set at 100%). [Figure 2E]Figure 2, including Figures 2A to 2E, shows the results of example experiments demonstrating the recognition of misfolded proteins by PML. (Figure 2A) Binding of GST-Htt25Q and GST-Htt103Q to immobilized FLAG-PML and FLAG-GFP (negative control) analyzed by in vitro pull-down assay, followed by WB (top and bottom) and Ponceau S staining (center). *IgG heavy chain. (Figure 2B) Binding of GST-PML (shown on the right) and control GST proteins to native (N) and urea-denatured (D) luciferase (luc) immobilized on Ni-NTA beads analyzed as in (Figure 2A). *Nonspecific protein derived from BL21 bacterial lysate bound to control beads. (Figure 2C) Binding of the indicated GST-Htt fusions to FLAG-PML CC conjugated to anti-FlagM2 beads or control beads analyzed by WB (top and center) and Coomassie staining (bottom). (Fig. 2D) Binding of PML F12 / SRS2 (shown on the right) to a luciferase-derived peptide library. The N-terminal amino acid of the first peptide spotted in each row and the number of the last peptide are shown. (Fig. 2E) The abundance of each amino acid in PML SRS2-binding peptides compared to its abundance in the luciferase peptide array (set at 100%). [Figure 3A]Figure 3, including Figures 3A to 3F, shows the results of example experiments demonstrating that SUMO2 / 3 are involved in the ubiquitination and PML-mediated degradation of Atxn1 82Q. (Figure 3A) Modification of Atxn1 82Q by SUMO1 and SUMO2 / 3 in HeLa cells treated without or with MG132. To better compare modified Atxn1 82Q, denatured immunoprecipitation (d-IP) products containing similar levels of unmodified Atxn1 82Q were analyzed by WB. *Nonspecific band. (Figure 3B) Localization of Atxn1 82Q (detected by anti-FLAG antibody, red) in GFP-SUMO2- or GFP-SUMO3-expressing U2OS cells treated with or without MG132. Scale bar, 10 μm. (Figure 3C) Modification of Atxn1 82Q and 30Q by SUMO2 / 3 in HeLa cells analyzed by d-IP followed by WB (top) and Ponry S staining (bottom). (Figure 3D) Atxn1 82Q was expressed alone or together with SUMO1 or HA-SUMO2 KR in HeLa cells pre-transfected with the indicated siRNAs or untransfected (-). Cells were treated with or without MG132. SUMOylation and ubiquitination of FLAG-Atxn1 82Q were analyzed by d-IP and WB. (Figure 3E) Levels of Atxn1 82Q-GFP expressed alone or together with increasing amounts of PML in HeLa cells pre-treated with the indicated siRNAs. (Figure 3F) Effect of PML on Atxn1 82Q-GFP levels in the presence or absence of SUMO1 or SUMO2 KR. [Figure 3B]Figure 3, including Figures 3A to 3F, shows the results of example experiments demonstrating that SUMO2 / 3 are involved in the ubiquitination and PML-mediated degradation of Atxn1 82Q. (Figure 3A) Modification of Atxn1 82Q by SUMO1 and SUMO2 / 3 in HeLa cells treated without or with MG132. To better compare modified Atxn1 82Q, denatured immunoprecipitation (d-IP) products containing similar levels of unmodified Atxn1 82Q were analyzed by WB. *Nonspecific band. (Figure 3B) Localization of Atxn1 82Q (detected by anti-FLAG antibody, red) in GFP-SUMO2- or GFP-SUMO3-expressing U2OS cells treated with or without MG132. Scale bar, 10 μm. (Figure 3C) Modification of Atxn1 82Q and 30Q by SUMO2 / 3 in HeLa cells analyzed by d-IP followed by WB (top) and Ponry S staining (bottom). (Figure 3D) Atxn1 82Q was expressed alone or together with SUMO1 or HA-SUMO2 KR in HeLa cells pre-transfected with the indicated siRNAs or untransfected (-). Cells were treated with or without MG132. SUMOylation and ubiquitination of FLAG-Atxn1 82Q were analyzed by d-IP and WB. (Figure 3E) Levels of Atxn1 82Q-GFP expressed alone or together with increasing amounts of PML in HeLa cells pre-treated with the indicated siRNAs. (Figure 3F) Effect of PML on Atxn1 82Q-GFP levels in the presence or absence of SUMO1 or SUMO2 KR. [Figure 3C]Figure 3, including Figures 3A to 3F, shows the results of example experiments demonstrating that SUMO2 / 3 are involved in the ubiquitination and PML-mediated degradation of Atxn1 82Q. (Figure 3A) Modification of Atxn1 82Q by SUMO1 and SUMO2 / 3 in HeLa cells treated without or with MG132. To better compare modified Atxn1 82Q, denatured immunoprecipitation (d-IP) products containing similar levels of unmodified Atxn1 82Q were analyzed by WB. *Nonspecific band. (Figure 3B) Localization of Atxn1 82Q (detected by anti-FLAG antibody, red) in GFP-SUMO2- or GFP-SUMO3-expressing U2OS cells treated with or without MG132. Scale bar, 10 μm. (Figure 3C) Modification of Atxn1 82Q and 30Q by SUMO2 / 3 in HeLa cells analyzed by d-IP followed by WB (top) and Ponry S staining (bottom). (Figure 3D) Atxn1 82Q was expressed alone or together with SUMO1 or HA-SUMO2 KR in HeLa cells pre-transfected with the indicated siRNAs or untransfected (-). Cells were treated with or without MG132. SUMOylation and ubiquitination of FLAG-Atxn1 82Q were analyzed by d-IP and WB. (Figure 3E) Levels of Atxn1 82Q-GFP expressed alone or together with increasing amounts of PML in HeLa cells pre-treated with the indicated siRNAs. (Figure 3F) Effect of PML on Atxn1 82Q-GFP levels in the presence or absence of SUMO1 or SUMO2 KR. [Figure 3D]Figure 3, including Figures 3A to 3F, shows the results of example experiments demonstrating that SUMO2 / 3 are involved in the ubiquitination and PML-mediated degradation of Atxn1 82Q. (Figure 3A) Modification of Atxn1 82Q by SUMO1 and SUMO2 / 3 in HeLa cells treated without or with MG132. To better compare modified Atxn1 82Q, denatured immunoprecipitation (d-IP) products containing similar levels of unmodified Atxn1 82Q were analyzed by WB. *Nonspecific band. (Figure 3B) Localization of Atxn1 82Q (detected by anti-FLAG antibody, red) in GFP-SUMO2- or GFP-SUMO3-expressing U2OS cells treated with or without MG132. Scale bar, 10 μm. (Figure 3C) Modification of Atxn1 82Q and 30Q by SUMO2 / 3 in HeLa cells analyzed by d-IP followed by WB (top) and Ponry S staining (bottom). (Figure 3D) Atxn1 82Q was expressed alone or together with SUMO1 or HA-SUMO2 KR in HeLa cells pre-transfected with the indicated siRNAs or untransfected (-). Cells were treated with or without MG132. SUMOylation and ubiquitination of FLAG-Atxn1 82Q were analyzed by d-IP and WB. (Figure 3E) Levels of Atxn1 82Q-GFP expressed alone or together with increasing amounts of PML in HeLa cells pre-treated with the indicated siRNAs. (Figure 3F) Effect of PML on Atxn1 82Q-GFP levels in the presence or absence of SUMO1 or SUMO2 KR. [Figure 3E]Figure 3, including Figures 3A to 3F, shows the results of example experiments demonstrating that SUMO2 / 3 are involved in the ubiquitination and PML-mediated degradation of Atxn1 82Q. (Figure 3A) Modification of Atxn1 82Q by SUMO1 and SUMO2 / 3 in HeLa cells treated without or with MG132. To better compare modified Atxn1 82Q, denatured immunoprecipitation (d-IP) products containing similar levels of unmodified Atxn1 82Q were analyzed by WB. *Nonspecific band. (Figure 3B) Localization of Atxn1 82Q (detected by anti-FLAG antibody, red) in GFP-SUMO2- or GFP-SUMO3-expressing U2OS cells treated with or without MG132. Scale bar, 10 μm. (Figure 3C) Modification of Atxn1 82Q and 30Q by SUMO2 / 3 in HeLa cells analyzed by d-IP followed by WB (top) and Ponry S staining (bottom). (Figure 3D) Atxn1 82Q was expressed alone or together with SUMO1 or HA-SUMO2 KR in HeLa cells pre-transfected with the indicated siRNAs or untransfected (-). Cells were treated with or without MG132. SUMOylation and ubiquitination of FLAG-Atxn1 82Q were analyzed by d-IP and WB. (Figure 3E) Levels of Atxn1 82Q-GFP expressed alone or together with increasing amounts of PML in HeLa cells pre-treated with the indicated siRNAs. (Figure 3F) Effect of PML on Atxn1 82Q-GFP levels in the presence or absence of SUMO1 or SUMO2 KR. [Figure 3F]Figure 3, including Figures 3A to 3F, shows the results of example experiments demonstrating that SUMO2 / 3 are involved in the ubiquitination and PML-mediated degradation of Atxn1 82Q. (Figure 3A) Modification of Atxn1 82Q by SUMO1 and SUMO2 / 3 in HeLa cells treated without or with MG132. To better compare modified Atxn1 82Q, denatured immunoprecipitation (d-IP) products containing similar levels of unmodified Atxn1 82Q were analyzed by WB. *Nonspecific band. (Figure 3B) Localization of Atxn1 82Q (detected by anti-FLAG antibody, red) in GFP-SUMO2- or GFP-SUMO3-expressing U2OS cells treated with or without MG132. Scale bar, 10 μm. (Figure 3C) Modification of Atxn1 82Q and 30Q by SUMO2 / 3 in HeLa cells analyzed by d-IP followed by WB (top) and Ponry S staining (bottom). (Figure 3D) Atxn1 82Q was expressed alone or together with SUMO1 or HA-SUMO2 KR in HeLa cells pre-transfected with the indicated siRNAs or untransfected (-). Cells were treated with or without MG132. SUMOylation and ubiquitination of FLAG-Atxn1 82Q were analyzed by d-IP and WB. (Figure 3E) Levels of Atxn1 82Q-GFP expressed alone or together with increasing amounts of PML in HeLa cells pre-treated with the indicated siRNAs. (Figure 3F) Effect of PML on Atxn1 82Q-GFP levels in the presence or absence of SUMO1 or SUMO2 KR. [Figure 4A]Figure 4, including Figures 4A to 4F, shows the results of example experiments demonstrating that PML promotes the sumoylation of Atxn1 82Q. (Figure 4A) SUMOylation of FLAG-Atxn1 82Q in HeLa cells in the absence or presence of HA-PML cells and without or with treatment with MG132. The amount of Atxn1 82Q DNA used for transfection was adjusted to yield comparable levels of unmodified protein. (Figures 4B and 4C) SUMOylation of FLAG-Atxn1 82Q (Figure 4B) and FLAG-nFlucDM-GFP (Figure 4C) in control cells treated without or with MG132 and HeLa cells transfected with PML siRNA. (Figures 4D and 4E) SUMOylation of purified HA-Atxn1 82Q-FLAG was performed in the presence of recombinant FLAG-PML, FLAG-PML M6, and SUMO2 as indicated. In (Figure 4D), the amounts of various d-IP products were adjusted to yield similar levels of unmodified Atxn1 82Q (center). (Figure 4F) Levels of Atxn1 82Q-GFP in HeLa cells in the absence or presence of increasing amounts of PML or PML M6. [Figure 4B]Figure 4, including Figures 4A to 4F, shows the results of example experiments demonstrating that PML promotes the sumoylation of Atxn1 82Q. (Figure 4A) SUMOylation of FLAG-Atxn1 82Q in HeLa cells in the absence or presence of HA-PML cells and without or with treatment with MG132. The amount of Atxn1 82Q DNA used for transfection was adjusted to yield comparable levels of unmodified protein. (Figures 4B and 4C) SUMOylation of FLAG-Atxn1 82Q (Figure 4B) and FLAG-nFlucDM-GFP (Figure 4C) in control cells treated without or with MG132 and HeLa cells transfected with PML siRNA. (Figures 4D and 4E) SUMOylation of purified HA-Atxn1 82Q-FLAG was performed in the presence of recombinant FLAG-PML, FLAG-PML M6, and SUMO2 as indicated. In (Figure 4D), the amounts of various d-IP products were adjusted to yield similar levels of unmodified Atxn1 82Q (center). (Figure 4F) Levels of Atxn1 82Q-GFP in HeLa cells in the absence or presence of increasing amounts of PML or PML M6. [Figure 4C]Figure 4, including Figures 4A to 4F, shows the results of example experiments demonstrating that PML promotes the sumoylation of Atxn1 82Q. (Figure 4A) SUMOylation of FLAG-Atxn1 82Q in HeLa cells in the absence or presence of HA-PML cells and without or with treatment with MG132. The amount of Atxn1 82Q DNA used for transfection was adjusted to yield comparable levels of unmodified protein. (Figures 4B and 4C) SUMOylation of FLAG-Atxn1 82Q (Figure 4B) and FLAG-nFlucDM-GFP (Figure 4C) in control cells treated without or with MG132 and HeLa cells transfected with PML siRNA. (Figures 4D and 4E) SUMOylation of purified HA-Atxn1 82Q-FLAG was performed in the presence of recombinant FLAG-PML, FLAG-PML M6, and SUMO2 as indicated. In (Figure 4D), the amounts of various d-IP products were adjusted to yield similar levels of unmodified Atxn1 82Q (center). (Figure 4F) Levels of Atxn1 82Q-GFP in HeLa cells in the absence or presence of increasing amounts of PML or PML M6. [Figure 4D]Figure 4, including Figures 4A to 4F, shows the results of example experiments demonstrating that PML promotes the sumoylation of Atxn1 82Q. (Figure 4A) SUMOylation of FLAG-Atxn1 82Q in HeLa cells in the absence or presence of HA-PML cells and without or with treatment with MG132. The amount of Atxn1 82Q DNA used for transfection was adjusted to yield comparable levels of unmodified protein. (Figures 4B and 4C) SUMOylation of FLAG-Atxn1 82Q (Figure 4B) and FLAG-nFlucDM-GFP (Figure 4C) in control cells treated without or with MG132 and HeLa cells transfected with PML siRNA. (Figures 4D and 4E) SUMOylation of purified HA-Atxn1 82Q-FLAG was performed in the presence of recombinant FLAG-PML, FLAG-PML M6, and SUMO2 as indicated. In (Figure 4D), the amounts of various d-IP products were adjusted to yield similar levels of unmodified Atxn1 82Q (center). (Figure 4F) Levels of Atxn1 82Q-GFP in HeLa cells in the absence or presence of increasing amounts of PML or PML M6. [Figure 4E]Figure 4, including Figures 4A to 4F, shows the results of example experiments demonstrating that PML promotes the sumoylation of Atxn1 82Q. (Figure 4A) SUMOylation of FLAG-Atxn1 82Q in HeLa cells in the absence or presence of HA-PML cells and without or with treatment with MG132. The amount of Atxn1 82Q DNA used for transfection was adjusted to yield comparable levels of unmodified protein. (Figures 4B and 4C) SUMOylation of FLAG-Atxn1 82Q (Figure 4B) and FLAG-nFlucDM-GFP (Figure 4C) in control cells treated without or with MG132 and HeLa cells transfected with PML siRNA. (Figures 4D and 4E) SUMOylation of purified HA-Atxn1 82Q-FLAG was performed in the presence of recombinant FLAG-PML, FLAG-PML M6, and SUMO2 as indicated. In (Figure 4D), the amounts of various d-IP products were adjusted to yield similar levels of unmodified Atxn1 82Q (center). (Figure 4F) Levels of Atxn1 82Q-GFP in HeLa cells in the absence or presence of increasing amounts of PML or PML M6. [Figure 4F]Figure 4, including Figures 4A to 4F, shows the results of example experiments demonstrating that PML promotes the sumoylation of Atxn1 82Q. (Figure 4A) SUMOylation of FLAG-Atxn1 82Q in HeLa cells in the absence or presence of HA-PML cells and without or with treatment with MG132. The amount of Atxn1 82Q DNA used for transfection was adjusted to yield comparable levels of unmodified protein. (Figures 4B and 4C) SUMOylation of FLAG-Atxn1 82Q (Figure 4B) and FLAG-nFlucDM-GFP (Figure 4C) in control cells treated without or with MG132 and HeLa cells transfected with PML siRNA. (Figures 4D and 4E) SUMOylation of purified HA-Atxn1 82Q-FLAG was performed in the presence of recombinant FLAG-PML, FLAG-PML M6, and SUMO2 as indicated. In (Figure 4D), the amounts of various d-IP products were adjusted to yield similar levels of unmodified Atxn1 82Q (center). (Figure 4F) Levels of Atxn1 82Q-GFP in HeLa cells in the absence or presence of increasing amounts of PML or PML M6. [Figure 5A]Figure 5, including Figures 5A to 5I, shows the results of example experiments demonstrating the role of RNF4 in the degradation of Atxn1 82Q. (Figure 5A) Levels of Atxn1 82Q-GFP in HeLa cells without and with RNF4 overexpression. (Figures 5B and 5C) Effect of RNF4 overexpression on Atxn1 82Q-GFP stability in control and PML-depleted HeLa cells treated with CHX and analyzed by WB. The relative ratio of SS Atxn1 82Q / actin is shown in (Figure 5C). (Figure 5D) Levels of FLAG-Atxn1 82Q in HeLa cells pretreated with control siRNA (-) or a combination of three RNF4 siRNAs. (Figure 5E) Representative fluorescence images of Atxn1 82Q-GFP in control and RNF4-knockdown HeLa cells. Scale bar, 20 μm. (Figure 5F) Localization of Atxn1 82Q-GFP and endogenous RNF4 in HeLa cells treated with vehicle (DMSO) or MG132. Scale bar, 10 μm. (Figures 5G and 5H) Levels of FLAG-Atxn1 82Q and FLAG-Atxn1 30Q (Figure 5G) or HA-Httex1p 97QP and HA-Httex1p 97QP(KR) (Figure 5H) in HeLa cells without and with RNF4 overexpression. (Figure 5I) Stability of nFlucDM-GFP in HeLa cells stably expressing shCtrl and shRNF4 (left) and levels of RNF4 in these cells (right). [Figure 5B]Figure 5, including Figures 5A to 5I, shows the results of example experiments demonstrating the role of RNF4 in the degradation of Atxn1 82Q. (Figure 5A) Levels of Atxn1 82Q-GFP in HeLa cells without and with RNF4 overexpression. (Figures 5B and 5C) Effect of RNF4 overexpression on Atxn1 82Q-GFP stability in control and PML-depleted HeLa cells treated with CHX and analyzed by WB. The relative ratio of SS Atxn1 82Q / actin is shown in (Figure 5C). (Figure 5D) Levels of FLAG-Atxn1 82Q in HeLa cells pretreated with control siRNA (-) or a combination of three RNF4 siRNAs. (Figure 5E) Representative fluorescence images of Atxn1 82Q-GFP in control and RNF4-knockdown HeLa cells. Scale bar, 20 μm. (Figure 5F) Localization of Atxn1 82Q-GFP and endogenous RNF4 in HeLa cells treated with vehicle (DMSO) or MG132. Scale bar, 10 μm. (Figures 5G and 5H) Levels of FLAG-Atxn1 82Q and FLAG-Atxn1 30Q (Figure 5G) or HA-Httex1p 97QP and HA-Httex1p 97QP(KR) (Figure 5H) in HeLa cells without and with RNF4 overexpression. (Figure 5I) Stability of nFlucDM-GFP in HeLa cells stably expressing shCtrl and shRNF4 (left) and levels of RNF4 in these cells (right). [Figure 5C]Figure 5, including Figures 5A to 5I, shows the results of example experiments demonstrating the role of RNF4 in the degradation of Atxn1 82Q. (Figure 5A) Levels of Atxn1 82Q-GFP in HeLa cells without and with RNF4 overexpression. (Figures 5B and 5C) Effect of RNF4 overexpression on Atxn1 82Q-GFP stability in control and PML-depleted HeLa cells treated with CHX and analyzed by WB. The relative ratio of SS Atxn1 82Q / actin is shown in (Figure 5C). (Figure 5D) Levels of FLAG-Atxn1 82Q in HeLa cells pretreated with control siRNA (-) or a combination of three RNF4 siRNAs. (Figure 5E) Representative fluorescence images of Atxn1 82Q-GFP in control and RNF4-knockdown HeLa cells. Scale bar, 20 μm. (Figure 5F) Localization of Atxn1 82Q-GFP and endogenous RNF4 in HeLa cells treated with vehicle (DMSO) or MG132. Scale bar, 10 μm. (Figures 5G and 5H) Levels of FLAG-Atxn1 82Q and FLAG-Atxn1 30Q (Figure 5G) or HA-Httex1p 97QP and HA-Httex1p 97QP(KR) (Figure 5H) in HeLa cells without and with RNF4 overexpression. (Figure 5I) Stability of nFlucDM-GFP in HeLa cells stably expressing shCtrl and shRNF4 (left) and levels of RNF4 in these cells (right). [Figure 5D]Figure 5, including Figures 5A to 5I, shows the results of example experiments demonstrating the role of RNF4 in the degradation of Atxn1 82Q. (Figure 5A) Levels of Atxn1 82Q-GFP in HeLa cells without and with RNF4 overexpression. (Figures 5B and 5C) Effect of RNF4 overexpression on Atxn1 82Q-GFP stability in control and PML-depleted HeLa cells treated with CHX and analyzed by WB. The relative ratio of SS Atxn1 82Q / actin is shown in (Figure 5C). (Figure 5D) Levels of FLAG-Atxn1 82Q in HeLa cells pretreated with control siRNA (-) or a combination of three RNF4 siRNAs. (Figure 5E) Representative fluorescence images of Atxn1 82Q-GFP in control and RNF4-knockdown HeLa cells. Scale bar, 20 μm. (Figure 5F) Localization of Atxn1 82Q-GFP and endogenous RNF4 in HeLa cells treated with vehicle (DMSO) or MG132. Scale bar, 10 μm. (Figures 5G and 5H) Levels of FLAG-Atxn1 82Q and FLAG-Atxn1 30Q (Figure 5G) or HA-Httex1p 97QP and HA-Httex1p 97QP(KR) (Figure 5H) in HeLa cells without and with RNF4 overexpression. (Figure 5I) Stability of nFlucDM-GFP in HeLa cells stably expressing shCtrl and shRNF4 (left) and levels of RNF4 in these cells (right). [Figure 5E]Figure 5, including Figures 5A to 5I, shows the results of example experiments demonstrating the role of RNF4 in the degradation of Atxn1 82Q. (Figure 5A) Levels of Atxn1 82Q-GFP in HeLa cells without and with RNF4 overexpression. (Figures 5B and 5C) Effect of RNF4 overexpression on Atxn1 82Q-GFP stability in control and PML-depleted HeLa cells treated with CHX and analyzed by WB. The relative ratio of SS Atxn1 82Q / actin is shown in (Figure 5C). (Figure 5D) Levels of FLAG-Atxn1 82Q in HeLa cells pretreated with control siRNA (-) or a combination of three RNF4 siRNAs. (Figure 5E) Representative fluorescence images of Atxn1 82Q-GFP in control and RNF4-knockdown HeLa cells. Scale bar, 20 μm. (Figure 5F) Localization of Atxn1 82Q-GFP and endogenous RNF4 in HeLa cells treated with vehicle (DMSO) or MG132. Scale bar, 10 μm. (Figures 5G and 5H) Levels of FLAG-Atxn1 82Q and FLAG-Atxn1 30Q (Figure 5G) or HA-Httex1p 97QP and HA-Httex1p 97QP(KR) (Figure 5H) in HeLa cells without and with RNF4 overexpression. (Figure 5I) Stability of nFlucDM-GFP in HeLa cells stably expressing shCtrl and shRNF4 (left) and levels of RNF4 in these cells (right). [Figure 5F]Figure 5, including Figures 5A to 5I, shows the results of example experiments demonstrating the role of RNF4 in the degradation of Atxn1 82Q. (Figure 5A) Levels of Atxn1 82Q-GFP in HeLa cells without and with RNF4 overexpression. (Figures 5B and 5C) Effect of RNF4 overexpression on Atxn1 82Q-GFP stability in control and PML-depleted HeLa cells treated with CHX and analyzed by WB. The relative ratio of SS Atxn1 82Q / actin is shown in (Figure 5C). (Figure 5D) Levels of FLAG-Atxn1 82Q in HeLa cells pretreated with control siRNA (-) or a combination of three RNF4 siRNAs. (Figure 5E) Representative fluorescence images of Atxn1 82Q-GFP in control and RNF4-knockdown HeLa cells. Scale bar, 20 μm. (Figure 5F) Localization of Atxn1 82Q-GFP and endogenous RNF4 in HeLa cells treated with vehicle (DMSO) or MG132. Scale bar, 10 μm. (Figures 5G and 5H) Levels of FLAG-Atxn1 82Q and FLAG-Atxn1 30Q (Figure 5G) or HA-Httex1p 97QP and HA-Httex1p 97QP(KR) (Figure 5H) in HeLa cells without and with RNF4 overexpression. (Figure 5I) Stability of nFlucDM-GFP in HeLa cells stably expressing shCtrl and shRNF4 (left) and levels of RNF4 in these cells (right). [Figure 5G]Figure 5, including Figures 5A to 5I, shows the results of example experiments demonstrating the role of RNF4 in the degradation of Atxn1 82Q. (Figure 5A) Levels of Atxn1 82Q-GFP in HeLa cells without and with RNF4 overexpression. (Figures 5B and 5C) Effect of RNF4 overexpression on Atxn1 82Q-GFP stability in control and PML-depleted HeLa cells treated with CHX and analyzed by WB. The relative ratio of SS Atxn1 82Q / actin is shown in (Figure 5C). (Figure 5D) Levels of FLAG-Atxn1 82Q in HeLa cells pretreated with control siRNA (-) or a combination of three RNF4 siRNAs. (Figure 5E) Representative fluorescence images of Atxn1 82Q-GFP in control and RNF4-knockdown HeLa cells. Scale bar, 20 μm. (Figure 5F) Localization of Atxn1 82Q-GFP and endogenous RNF4 in HeLa cells treated with vehicle (DMSO) or MG132. Scale bar, 10 μm. (Figures 5G and 5H) Levels of FLAG-Atxn1 82Q and FLAG-Atxn1 30Q (Figure 5G) or HA-Httex1p 97QP and HA-Httex1p 97QP(KR) (Figure 5H) in HeLa cells without and with RNF4 overexpression. (Figure 5I) Stability of nFlucDM-GFP in HeLa cells stably expressing shCtrl and shRNF4 (left) and levels of RNF4 in these cells (right). [Figure 5H]Figure 5, including Figures 5A to 5I, shows the results of example experiments demonstrating the role of RNF4 in the degradation of Atxn1 82Q. (Figure 5A) Levels of Atxn1 82Q-GFP in HeLa cells without and with RNF4 overexpression. (Figures 5B and 5C) Effect of RNF4 overexpression on Atxn1 82Q-GFP stability in control and PML-depleted HeLa cells treated with CHX and analyzed by WB. The relative ratio of SS Atxn1 82Q / actin is shown in (Figure 5C). (Figure 5D) Levels of FLAG-Atxn1 82Q in HeLa cells pretreated with control siRNA (-) or a combination of three RNF4 siRNAs. (Figure 5E) Representative fluorescence images of Atxn1 82Q-GFP in control and RNF4-knockdown HeLa cells. Scale bar, 20 μm. (Figure 5F) Localization of Atxn1 82Q-GFP and endogenous RNF4 in HeLa cells treated with vehicle (DMSO) or MG132. Scale bar, 10 μm. (Figures 5G and 5H) Levels of FLAG-Atxn1 82Q and FLAG-Atxn1 30Q (Figure 5G) or HA-Httex1p 97QP and HA-Httex1p 97QP(KR) (Figure 5H) in HeLa cells without and with RNF4 overexpression. (Figure 5I) Stability of nFlucDM-GFP in HeLa cells stably expressing shCtrl and shRNF4 (left) and levels of RNF4 in these cells (right). [Figure 5I]Figure 5, including Figures 5A to 5I, shows the results of example experiments demonstrating the role of RNF4 in the degradation of Atxn1 82Q. (Figure 5A) Levels of Atxn1 82Q-GFP in HeLa cells without and with RNF4 overexpression. (Figures 5B and 5C) Effect of RNF4 overexpression on Atxn1 82Q-GFP stability in control and PML-depleted HeLa cells treated with CHX and analyzed by WB. The relative ratio of SS Atxn1 82Q / actin is shown in (Figure 5C). (Figure 5D) Levels of FLAG-Atxn1 82Q in HeLa cells pretreated with control siRNA (-) or a combination of three RNF4 siRNAs. (Figure 5E) Representative fluorescence images of Atxn1 82Q-GFP in control and RNF4-knockdown HeLa cells. Scale bar, 20 μm. (Figure 5F) Localization of Atxn1 82Q-GFP and endogenous RNF4 in HeLa cells treated with vehicle (DMSO) or MG132. Scale bar, 10 μm. (Figures 5G and 5H) Levels of FLAG-Atxn1 82Q and FLAG-Atxn1 30Q (Figure 5G) or HA-Httex1p 97QP and HA-Httex1p 97QP(KR) (Figure 5H) in HeLa cells without and with RNF4 overexpression. (Figure 5I) Stability of nFlucDM-GFP in HeLa cells stably expressing shCtrl and shRNF4 (left) and levels of RNF4 in these cells (right). [Figure 6A]Figure 6, including Figures 6A to 6I, shows the results of an example experiment demonstrating that RNF4 promotes the ubiquitination and degradation of SUMO2 / 3-modified Atxn1 82Q. (Figures 6A and 6B) Levels of SUMOylated FLAG-Atxn1 82Q (Figure 6A) and FLAG-nFlucDM-GFP (Figure 6B) in HeLa cells treated with or without MG132 in the absence or presence of RNF4. d-IP products and WCLs with similar levels of unmodified protein were analyzed. (Figure 6C) Levels of SUMOylated FLAG-Atxn1 82Q in HeLa cells pretreated with a control siRNA or RNF4 siRNA combination, analyzed as in (Figure 6A). (Figures 6D and 6E) Unmodified and SUMO2-modified FLAG-Atxn1 82Q proteins conjugated to M2 beads (+) or control M2 beads (-) were incubated with the ubiquitination reaction mixture in the absence or presence of GST-RNF4. (Figure 6D) Schematic of the experimental design. (Figure 6E) WB analysis of FLAG-Atxn1 82Q (left) and GST-RNF4 (right). (Figures 6F and 6G) Localization of Atxn1 82Q-GFP and RNF4 proteins in HeLa cells (detected by anti-FLAG antibody). Scale bar, 10 μm. (Figure 6H) Effect of the indicated RNF4 proteins on Atxn1 82Q-GFP levels in HeLa cells. (Figure 6I) Effect of PML overexpression on Atxn1 82Q-GFP levels in HeLa cells pretreated with control or RNF4 siRNA. [Figure 6B]Figure 6, including Figures 6A to 6I, shows the results of an example experiment demonstrating that RNF4 promotes the ubiquitination and degradation of SUMO2 / 3-modified Atxn1 82Q. (Figures 6A and 6B) Levels of SUMOylated FLAG-Atxn1 82Q (Figure 6A) and FLAG-nFlucDM-GFP (Figure 6B) in HeLa cells treated with or without MG132 in the absence or presence of RNF4. d-IP products and WCLs with similar levels of unmodified protein were analyzed. (Figure 6C) Levels of SUMOylated FLAG-Atxn1 82Q in HeLa cells pretreated with a control siRNA or RNF4 siRNA combination, analyzed as in (Figure 6A). (Figures 6D and 6E) Unmodified and SUMO2-modified FLAG-Atxn1 82Q proteins conjugated to M2 beads (+) or control M2 beads (-) were incubated with the ubiquitination reaction mixture in the absence or presence of GST-RNF4. (Figure 6D) Schematic of the experimental design. (Figure 6E) WB analysis of FLAG-Atxn1 82Q (left) and GST-RNF4 (right). (Figures 6F and 6G) Localization of Atxn1 82Q-GFP and RNF4 proteins in HeLa cells (detected by anti-FLAG antibody). Scale bar, 10 μm. (Figure 6H) Effect of the indicated RNF4 proteins on Atxn1 82Q-GFP levels in HeLa cells. (Figure 6I) Effect of PML overexpression on Atxn1 82Q-GFP levels in HeLa cells pretreated with control or RNF4 siRNA. [Figure 6C]Figure 6, including Figures 6A to 6I, shows the results of an example experiment demonstrating that RNF4 promotes the ubiquitination and degradation of SUMO2 / 3-modified Atxn1 82Q. (Figures 6A and 6B) Levels of SUMOylated FLAG-Atxn1 82Q (Figure 6A) and FLAG-nFlucDM-GFP (Figure 6B) in HeLa cells treated with or without MG132 in the absence or presence of RNF4. d-IP products and WCLs with similar levels of unmodified protein were analyzed. (Figure 6C) Levels of SUMOylated FLAG-Atxn1 82Q in HeLa cells pretreated with a control siRNA or RNF4 siRNA combination, analyzed as in (Figure 6A). (Figures 6D and 6E) Unmodified and SUMO2-modified FLAG-Atxn1 82Q proteins conjugated to M2 beads (+) or control M2 beads (-) were incubated with the ubiquitination reaction mixture in the absence or presence of GST-RNF4. (Figure 6D) Schematic of the experimental design. (Figure 6E) WB analysis of FLAG-Atxn1 82Q (left) and GST-RNF4 (right). (Figures 6F and 6G) Localization of Atxn1 82Q-GFP and RNF4 proteins in HeLa cells (detected by anti-FLAG antibody). Scale bar, 10 μm. (Figure 6H) Effect of the indicated RNF4 proteins on Atxn1 82Q-GFP levels in HeLa cells. (Figure 6I) Effect of PML overexpression on Atxn1 82Q-GFP levels in HeLa cells pretreated with control or RNF4 siRNA. [Figure 6D]Figure 6, including Figures 6A to 6I, shows the results of an example experiment demonstrating that RNF4 promotes the ubiquitination and degradation of SUMO2 / 3-modified Atxn1 82Q. (Figures 6A and 6B) Levels of SUMOylated FLAG-Atxn1 82Q (Figure 6A) and FLAG-nFlucDM-GFP (Figure 6B) in HeLa cells treated with or without MG132 in the absence or presence of RNF4. d-IP products and WCLs with similar levels of unmodified protein were analyzed. (Figure 6C) Levels of SUMOylated FLAG-Atxn1 82Q in HeLa cells pretreated with a control siRNA or RNF4 siRNA combination, analyzed as in (Figure 6A). (Figures 6D and 6E) Unmodified and SUMO2-modified FLAG-Atxn1 82Q proteins conjugated to M2 beads (+) or control M2 beads (-) were incubated with the ubiquitination reaction mixture in the absence or presence of GST-RNF4. (Figure 6D) Schematic of the experimental design. (Figure 6E) WB analysis of FLAG-Atxn1 82Q (left) and GST-RNF4 (right). (Figures 6F and 6G) Localization of Atxn1 82Q-GFP and RNF4 proteins in HeLa cells (detected by anti-FLAG antibody). Scale bar, 10 μm. (Figure 6H) Effect of the indicated RNF4 proteins on Atxn1 82Q-GFP levels in HeLa cells. (Figure 6I) Effect of PML overexpression on Atxn1 82Q-GFP levels in HeLa cells pretreated with control or RNF4 siRNA. [Figure 6E]Figure 6, including Figures 6A to 6I, shows the results of an example experiment demonstrating that RNF4 promotes the ubiquitination and degradation of SUMO2 / 3-modified Atxn1 82Q. (Figures 6A and 6B) Levels of SUMOylated FLAG-Atxn1 82Q (Figure 6A) and FLAG-nFlucDM-GFP (Figure 6B) in HeLa cells treated with or without MG132 in the absence or presence of RNF4. d-IP products and WCLs with similar levels of unmodified protein were analyzed. (Figure 6C) Levels of SUMOylated FLAG-Atxn1 82Q in HeLa cells pretreated with a control siRNA or RNF4 siRNA combination, analyzed as in (Figure 6A). (Figures 6D and 6E) Unmodified and SUMO2-modified FLAG-Atxn1 82Q proteins conjugated to M2 beads (+) or control M2 beads (-) were incubated with the ubiquitination reaction mixture in the absence or presence of GST-RNF4. (Figure 6D) Schematic of the experimental design. (Figure 6E) WB analysis of FLAG-Atxn1 82Q (left) and GST-RNF4 (right). (Figures 6F and 6G) Localization of Atxn1 82Q-GFP and RNF4 proteins in HeLa cells (detected by anti-FLAG antibody). Scale bar, 10 μm. (Figure 6H) Effect of the indicated RNF4 proteins on Atxn1 82Q-GFP levels in HeLa cells. (Figure 6I) Effect of PML overexpression on Atxn1 82Q-GFP levels in HeLa cells pretreated with control or RNF4 siRNA. [Figure 6F]Figure 6, including Figures 6A to 6I, shows the results of an example experiment demonstrating that RNF4 promotes the ubiquitination and degradation of SUMO2 / 3-modified Atxn1 82Q. (Figures 6A and 6B) Levels of SUMOylated FLAG-Atxn1 82Q (Figure 6A) and FLAG-nFlucDM-GFP (Figure 6B) in HeLa cells treated with or without MG132 in the absence or presence of RNF4. d-IP products and WCLs with similar levels of unmodified protein were analyzed. (Figure 6C) Levels of SUMOylated FLAG-Atxn1 82Q in HeLa cells pretreated with a control siRNA or RNF4 siRNA combination, analyzed as in (Figure 6A). (Figures 6D and 6E) Unmodified and SUMO2-modified FLAG-Atxn1 82Q proteins conjugated to M2 beads (+) or control M2 beads (-) were incubated with the ubiquitination reaction mixture in the absence or presence of GST-RNF4. (Figure 6D) Schematic of the experimental design. (Figure 6E) WB analysis of FLAG-Atxn1 82Q (left) and GST-RNF4 (right). (Figures 6F and 6G) Localization of Atxn1 82Q-GFP and RNF4 proteins in HeLa cells (detected by anti-FLAG antibody). Scale bar, 10 μm. (Figure 6H) Effect of the indicated RNF4 proteins on Atxn1 82Q-GFP levels in HeLa cells. (Figure 6I) Effect of PML overexpression on Atxn1 82Q-GFP levels in HeLa cells pretreated with control or RNF4 siRNA. [Figure 6G]Figure 6, including Figures 6A to 6I, shows the results of an example experiment demonstrating that RNF4 promotes the ubiquitination and degradation of SUMO2 / 3-modified Atxn1 82Q. (Figures 6A and 6B) Levels of SUMOylated FLAG-Atxn1 82Q (Figure 6A) and FLAG-nFlucDM-GFP (Figure 6B) in HeLa cells treated with or without MG132 in the absence or presence of RNF4. d-IP products and WCLs with similar levels of unmodified protein were analyzed. (Figure 6C) Levels of SUMOylated FLAG-Atxn1 82Q in HeLa cells pretreated with a control siRNA or RNF4 siRNA combination, analyzed as in (Figure 6A). (Figures 6D and 6E) Unmodified and SUMO2-modified FLAG-Atxn1 82Q proteins conjugated to M2 beads (+) or control M2 beads (-) were incubated with the ubiquitination reaction mixture in the absence or presence of GST-RNF4. (Figure 6D) Schematic of the experimental design. (Figure 6E) WB analysis of FLAG-Atxn1 82Q (left) and GST-RNF4 (right). (Figures 6F and 6G) Localization of Atxn1 82Q-GFP and RNF4 proteins in HeLa cells (detected by anti-FLAG antibody). Scale bar, 10 μm. (Figure 6H) Effect of the indicated RNF4 proteins on Atxn1 82Q-GFP levels in HeLa cells. (Figure 6I) Effect of PML overexpression on Atxn1 82Q-GFP levels in HeLa cells pretreated with control or RNF4 siRNA. [Figure 6H]Figure 6, including Figures 6A to 6I, shows the results of an example experiment demonstrating that RNF4 promotes the ubiquitination and degradation of SUMO2 / 3-modified Atxn1 82Q. (Figures 6A and 6B) Levels of SUMOylated FLAG-Atxn1 82Q (Figure 6A) and FLAG-nFlucDM-GFP (Figure 6B) in HeLa cells treated with or without MG132 in the absence or presence of RNF4. d-IP products and WCLs with similar levels of unmodified protein were analyzed. (Figure 6C) Levels of SUMOylated FLAG-Atxn1 82Q in HeLa cells pretreated with a control siRNA or RNF4 siRNA combination, analyzed as in (Figure 6A). (Figures 6D and 6E) Unmodified and SUMO2-modified FLAG-Atxn1 82Q proteins conjugated to M2 beads (+) or control M2 beads (-) were incubated with the ubiquitination reaction mixture in the absence or presence of GST-RNF4. (Figure 6D) Schematic of the experimental design. (Figure 6E) WB analysis of FLAG-Atxn1 82Q (left) and GST-RNF4 (right). (Figures 6F and 6G) Localization of Atxn1 82Q-GFP and RNF4 proteins in HeLa cells (detected by anti-FLAG antibody). Scale bar, 10 μm. (Figure 6H) Effect of the indicated RNF4 proteins on Atxn1 82Q-GFP levels in HeLa cells. (Figure 6I) Effect of PML overexpression on Atxn1 82Q-GFP levels in HeLa cells pretreated with control or RNF4 siRNA. [Figure 6I]Figure 6, including Figures 6A to 6I, shows the results of an example experiment demonstrating that RNF4 promotes the ubiquitination and degradation of SUMO2 / 3-modified Atxn1 82Q. (Figures 6A and 6B) Levels of SUMOylated FLAG-Atxn1 82Q (Figure 6A) and FLAG-nFlucDM-GFP (Figure 6B) in HeLa cells treated with or without MG132 in the absence or presence of RNF4. d-IP products and WCLs with similar levels of unmodified protein were analyzed. (Figure 6C) Levels of SUMOylated FLAG-Atxn1 82Q in HeLa cells pretreated with a control siRNA or RNF4 siRNA combination, analyzed as in (Figure 6A). (Figures 6D and 6E) Unmodified and SUMO2-modified FLAG-Atxn1 82Q proteins conjugated to M2 beads (+) or control M2 beads (-) were incubated with the ubiquitination reaction mixture in the absence or presence of GST-RNF4. (Figure 6D) Schematic of the experimental design. (Figure 6E) WB analysis of FLAG-Atxn1 82Q (left) and GST-RNF4 (right). (Figures 6F and 6G) Localization of Atxn1 82Q-GFP and RNF4 proteins in HeLa cells (detected by anti-FLAG antibody). Scale bar, 10 μm. (Figure 6H) Effect of the indicated RNF4 proteins on Atxn1 82Q-GFP levels in HeLa cells. (Figure 6I) Effect of PML overexpression on Atxn1 82Q-GFP levels in HeLa cells pretreated with control or RNF4 siRNA. [Figure 7A]Figure 7, including Figures 7A to 7I, shows the results of an example experiment demonstrating that PML deficiency exacerbates behavioral and pathological phenotypes in an SCA1 mouse model. (Figures 7A and 7B) Retention times (mean ± standard error) on an accelerating rotarod at 7 weeks of age (Figure 7A) and 11 weeks of age (Figure 7B). Animal numbers are shown in parentheses. (Figures 7C and 7D) Cerebellar sections from 12-week-old animals were stained with hematoxylin. (Figure 7C) Quantification of molecular layer thickness (mean ± standard error, 3 mice per genotype). (Figure 7D) Representative stained image. Scale bar, 200 μm. (Figures 7E and 7F) Cerebellar sections from 1-year-old animals were stained with anti-calbindin antibody. (E) Quantification of Purkinje cells graphed as the average number of cell bodies per mm of length (mean ± standard error, 4 mice per genotype). (F) Representative stained image. Scale bar, 200 μm. (Figures 7G and 7H) Cerebellar cortex sections from 12-week-old mice were stained with anti-ubiquitin antibody and counterstained with hematoxylin. (Figure 7G) Percentage of aggregate-containing Purkinje cells (mean ± standard error, 3 mice per genotype). (Figure 7H) Representative immunohistochemical staining images. Arrowheads indicate ubiquitin-positive aggregates within Purkinje cell bodies. Scale bar, 50 μm. No ubiquitin-positive aggregates were observed in Purkinje cells from Atxn1tg / - mice (see Figure 14D). (Figure 7I) A model of PQC via the PML-RNF4 system. PML recognizes misfolded proteins through SRS and conjugates them with poly-SUMO2 / 3 chains through its SUMO E3 ligase activity (a). RNF4 ubiquitinates SUMOylated misfolded proteins (b) and targets them for degradation by the proteasome (c). [Figure 7B]Figure 7, including Figures 7A to 7I, shows the results of an example experiment demonstrating that PML deficiency exacerbates behavioral and pathological phenotypes in an SCA1 mouse model. (Figures 7A and 7B) Retention times (mean ± standard error) on an accelerating rotarod at 7 weeks of age (Figure 7A) and 11 weeks of age (Figure 7B). Animal numbers are shown in parentheses. (Figures 7C and 7D) Cerebellar sections from 12-week-old animals were stained with hematoxylin. (Figure 7C) Quantification of molecular layer thickness (mean ± standard error, 3 mice per genotype). (Figure 7D) Representative stained image. Scale bar, 200 μm. (Figures 7E and 7F) Cerebellar sections from 1-year-old animals were stained with anti-calbindin antibody. (E) Quantification of Purkinje cells graphed as the average number of cell bodies per mm of length (mean ± standard error, 4 mice per genotype). (F) Representative stained image. Scale bar, 200 μm. (Figures 7G and 7H) Cerebellar cortex sections from 12-week-old mice were stained with anti-ubiquitin antibody and counterstained with hematoxylin. (Figure 7G) Percentage of aggregate-containing Purkinje cells (mean ± standard error, 3 mice per genotype). (Figure 7H) Representative immunohistochemical staining images. Arrowheads indicate ubiquitin-positive aggregates within Purkinje cell bodies. Scale bar, 50 μm. No ubiquitin-positive aggregates were observed in Purkinje cells from Atxn1tg / - mice (see Figure 14D). (Figure 7I) A model of PQC via the PML-RNF4 system. PML recognizes misfolded proteins through SRS and conjugates them with poly-SUMO2 / 3 chains through its SUMO E3 ligase activity (a). RNF4 ubiquitinates SUMOylated misfolded proteins (b) and targets them for degradation by the proteasome (c). [Figure 7C]Figure 7, including Figures 7A to 7I, shows the results of an example experiment demonstrating that PML deficiency exacerbates behavioral and pathological phenotypes in an SCA1 mouse model. (Figures 7A and 7B) Retention times (mean ± standard error) on an accelerating rotarod at 7 weeks of age (Figure 7A) and 11 weeks of age (Figure 7B). Animal numbers are shown in parentheses. (Figures 7C and 7D) Cerebellar sections from 12-week-old animals were stained with hematoxylin. (Figure 7C) Quantification of molecular layer thickness (mean ± standard error, 3 mice per genotype). (Figure 7D) Representative stained image. Scale bar, 200 μm. (Figures 7E and 7F) Cerebellar sections from 1-year-old animals were stained with anti-calbindin antibody. (E) Quantification of Purkinje cells graphed as the average number of cell bodies per mm of length (mean ± standard error, 4 mice per genotype). (F) Representative stained image. Scale bar, 200 μm. (Figures 7G and 7H) Cerebellar cortex sections from 12-week-old mice were stained with anti-ubiquitin antibody and counterstained with hematoxylin. (Figure 7G) Percentage of aggregate-containing Purkinje cells (mean ± standard error, 3 mice per genotype). (Figure 7H) Representative immunohistochemical staining images. Arrowheads indicate ubiquitin-positive aggregates within Purkinje cell bodies. Scale bar, 50 μm. No ubiquitin-positive aggregates were observed in Purkinje cells from Atxn1tg / - mice (see Figure 14D). (Figure 7I) A model of PQC via the PML-RNF4 system. PML recognizes misfolded proteins through SRS and conjugates them with poly-SUMO2 / 3 chains through its SUMO E3 ligase activity (a). RNF4 ubiquitinates SUMOylated misfolded proteins (b) and targets them for degradation by the proteasome (c). [Figure 7D]Figure 7, including Figures 7A to 7I, shows the results of an example experiment demonstrating that PML deficiency exacerbates behavioral and pathological phenotypes in an SCA1 mouse model. (Figures 7A and 7B) Retention times (mean ± standard error) on an accelerating rotarod at 7 weeks of age (Figure 7A) and 11 weeks of age (Figure 7B). Animal numbers are shown in parentheses. (Figures 7C and 7D) Cerebellar sections from 12-week-old animals were stained with hematoxylin. (Figure 7C) Quantification of molecular layer thickness (mean ± standard error, 3 mice per genotype). (Figure 7D) Representative stained image. Scale bar, 200 μm. (Figures 7E and 7F) Cerebellar sections from 1-year-old animals were stained with anti-calbindin antibody. (E) Quantification of Purkinje cells graphed as the average number of cell bodies per mm of length (mean ± standard error, 4 mice per genotype). (F) Representative stained image. Scale bar, 200 μm. (Figures 7G and 7H) Cerebellar cortex sections from 12-week-old mice were stained with anti-ubiquitin antibody and counterstained with hematoxylin. (Figure 7G) Percentage of aggregate-containing Purkinje cells (mean ± standard error, 3 mice per genotype). (Figure 7H) Representative immunohistochemical staining images. Arrowheads indicate ubiquitin-positive aggregates within Purkinje cell bodies. Scale bar, 50 μm. No ubiquitin-positive aggregates were observed in Purkinje cells from Atxn1tg / - mice (see Figure 14D). (Figure 7I) A model of PQC via the PML-RNF4 system. PML recognizes misfolded proteins through SRS and conjugates them with poly-SUMO2 / 3 chains through its SUMO E3 ligase activity (a). RNF4 ubiquitinates SUMOylated misfolded proteins (b) and targets them for degradation by the proteasome (c). [Figure 7E]Figure 7, including Figures 7A to 7I, shows the results of an example experiment demonstrating that PML deficiency exacerbates behavioral and pathological phenotypes in an SCA1 mouse model. (Figures 7A and 7B) Retention times (mean ± standard error) on an accelerating rotarod at 7 weeks of age (Figure 7A) and 11 weeks of age (Figure 7B). Animal numbers are shown in parentheses. (Figures 7C and 7D) Cerebellar sections from 12-week-old animals were stained with hematoxylin. (Figure 7C) Quantification of molecular layer thickness (mean ± standard error, 3 mice per genotype). (Figure 7D) Representative stained image. Scale bar, 200 μm. (Figures 7E and 7F) Cerebellar sections from 1-year-old animals were stained with anti-calbindin antibody. (E) Quantification of Purkinje cells graphed as the average number of cell bodies per mm of length (mean ± standard error, 4 mice per genotype). (F) Representative stained image. Scale bar, 200 μm. (Figures 7G and 7H) Cerebellar cortex sections from 12-week-old mice were stained with anti-ubiquitin antibody and counterstained with hematoxylin. (Figure 7G) Percentage of aggregate-containing Purkinje cells (mean ± standard error, 3 mice per genotype). (Figure 7H) Representative immunohistochemical staining images. Arrowheads indicate ubiquitin-positive aggregates within Purkinje cell bodies. Scale bar, 50 μm. No ubiquitin-positive aggregates were observed in Purkinje cells from Atxn1tg / - mice (see Figure 14D). (Figure 7I) A model of PQC via the PML-RNF4 system. PML recognizes misfolded proteins through SRS and conjugates them with poly-SUMO2 / 3 chains through its SUMO E3 ligase activity (a). RNF4 ubiquitinates SUMOylated misfolded proteins (b) and targets them for degradation by the proteasome (c). [Figure 7F]Figure 7, including Figures 7A to 7I, shows the results of an example experiment demonstrating that PML deficiency exacerbates behavioral and pathological phenotypes in an SCA1 mouse model. (Figures 7A and 7B) Retention times (mean ± standard error) on an accelerating rotarod at 7 weeks of age (Figure 7A) and 11 weeks of age (Figure 7B). Animal numbers are shown in parentheses. (Figures 7C and 7D) Cerebellar sections from 12-week-old animals were stained with hematoxylin. (Figure 7C) Quantification of molecular layer thickness (mean ± standard error, 3 mice per genotype). (Figure 7D) Representative stained image. Scale bar, 200 μm. (Figures 7E and 7F) Cerebellar sections from 1-year-old animals were stained with anti-calbindin antibody. (E) Quantification of Purkinje cells graphed as the average number of cell bodies per mm of length (mean ± standard error, 4 mice per genotype). (F) Representative stained image. Scale bar, 200 μm. (Figures 7G and 7H) Cerebellar cortex sections from 12-week-old mice were stained with anti-ubiquitin antibody and counterstained with hematoxylin. (Figure 7G) Percentage of aggregate-containing Purkinje cells (mean ± standard error, 3 mice per genotype). (Figure 7H) Representative immunohistochemical staining images. Arrowheads indicate ubiquitin-positive aggregates within Purkinje cell bodies. Scale bar, 50 μm. No ubiquitin-positive aggregates were observed in Purkinje cells from Atxn1tg / - mice (see Figure 14D). (Figure 7I) A model of PQC via the PML-RNF4 system. PML recognizes misfolded proteins through SRS and conjugates them with poly-SUMO2 / 3 chains through its SUMO E3 ligase activity (a). RNF4 ubiquitinates SUMOylated misfolded proteins (b) and targets them for degradation by the proteasome (c). [Figure 7G]Figure 7, including Figures 7A to 7I, shows the results of an example experiment demonstrating that PML deficiency exacerbates behavioral and pathological phenotypes in an SCA1 mouse model. (Figures 7A and 7B) Retention times (mean ± standard error) on an accelerating rotarod at 7 weeks of age (Figure 7A) and 11 weeks of age (Figure 7B). Animal numbers are shown in parentheses. (Figures 7C and 7D) Cerebellar sections from 12-week-old animals were stained with hematoxylin. (Figure 7C) Quantification of molecular layer thickness (mean ± standard error, 3 mice per genotype). (Figure 7D) Representative stained image. Scale bar, 200 μm. (Figures 7E and 7F) Cerebellar sections from 1-year-old animals were stained with anti-calbindin antibody. (E) Quantification of Purkinje cells graphed as the average number of cell bodies per mm of length (mean ± standard error, 4 mice per genotype). (F) Representative stained image. Scale bar, 200 μm. (Figures 7G and 7H) Cerebellar cortex sections from 12-week-old mice were stained with anti-ubiquitin antibody and counterstained with hematoxylin. (Figure 7G) Percentage of aggregate-containing Purkinje cells (mean ± standard error, 3 mice per genotype). (Figure 7H) Representative immunohistochemical staining images. Arrowheads indicate ubiquitin-positive aggregates within Purkinje cell bodies. Scale bar, 50 μm. No ubiquitin-positive aggregates were observed in Purkinje cells from Atxn1tg / - mice (see Figure 14D). (Figure 7I) A model of PQC via the PML-RNF4 system. PML recognizes misfolded proteins through SRS and conjugates them with poly-SUMO2 / 3 chains through its SUMO E3 ligase activity (a). RNF4 ubiquitinates SUMOylated misfolded proteins (b) and targets them for degradation by the proteasome (c). [Figure 7H]Figure 7, including Figures 7A to 7I, shows the results of an example experiment demonstrating that PML deficiency exacerbates behavioral and pathological phenotypes in an SCA1 mouse model. (Figures 7A and 7B) Retention times (mean ± standard error) on an accelerating rotarod at 7 weeks of age (Figure 7A) and 11 weeks of age (Figure 7B). Animal numbers are shown in parentheses. (Figures 7C and 7D) Cerebellar sections from 12-week-old animals were stained with hematoxylin. (Figure 7C) Quantification of molecular layer thickness (mean ± standard error, 3 mice per genotype). (Figure 7D) Representative stained image. Scale bar, 200 μm. (Figures 7E and 7F) Cerebellar sections from 1-year-old animals were stained with anti-calbindin antibody. (E) Quantification of Purkinje cells graphed as the average number of cell bodies per mm of length (mean ± standard error, 4 mice per genotype). (F) Representative stained image. Scale bar, 200 μm. (Figures 7G and 7H) Cerebellar cortex sections from 12-week-old mice were stained with anti-ubiquitin antibody and counterstained with hematoxylin. (Figure 7G) Percentage of aggregate-containing Purkinje cells (mean ± standard error, 3 mice per genotype). (Figure 7H) Representative immunohistochemical staining images. Arrowheads indicate ubiquitin-positive aggregates within Purkinje cell bodies. Scale bar, 50 μm. No ubiquitin-positive aggregates were observed in Purkinje cells from Atxn1tg / - mice (see Figure 14D). (Figure 7I) A model of PQC via the PML-RNF4 system. PML recognizes misfolded proteins through SRS and conjugates them with poly-SUMO2 / 3 chains through its SUMO E3 ligase activity (a). RNF4 ubiquitinates SUMOylated misfolded proteins (b) and targets them for degradation by the proteasome (c). [Figure 7I]Figure 7, including Figures 7A to 7I, shows the results of an example experiment demonstrating that PML deficiency exacerbates behavioral and pathological phenotypes in an SCA1 mouse model. (Figures 7A and 7B) Retention times (mean ± standard error) on an accelerating rotarod at 7 weeks of age (Figure 7A) and 11 weeks of age (Figure 7B). Animal numbers are shown in parentheses. (Figures 7C and 7D) Cerebellar sections from 12-week-old animals were stained with hematoxylin. (Figure 7C) Quantification of molecular layer thickness (mean ± standard error, 3 mice per genotype). (Figure 7D) Representative stained image. Scale bar, 200 μm. (Figures 7E and 7F) Cerebellar sections from 1-year-old animals were stained with anti-calbindin antibody. (E) Quantification of Purkinje cells graphed as the average number of cell bodies per mm of length (mean ± standard error, 4 mice per genotype). (F) Representative stained image. Scale bar, 200 μm. (Figures 7G and 7H) Cerebellar cortex sections from 12-week-old mice were stained with anti-ubiquitin antibody and counterstained with hematoxylin. (Figure 7G) Percentage of aggregate-containing Purkinje cells (mean ± standard error, 3 mice per genotype). (Figure 7H) Representative immunohistochemical staining images. Arrowheads indicate ubiquitin-positive aggregates within Purkinje cell bodies. Scale bar, 50 μm. No ubiquitin-positive aggregates were observed in Purkinje cells from Atxn1tg / - mice (see Figure 14D). (Figure 7I) A model of PQC via the PML-RNF4 system. PML recognizes misfolded proteins through SRS and conjugates them with poly-SUMO2 / 3 chains through its SUMO E3 ligase activity (a). RNF4 ubiquitinates SUMOylated misfolded proteins (b) and targets them for degradation by the proteasome (c). [Figure 8A]Figure 8, including Figures 8A to 8G, shows the results of an example experiment demonstrating that PML colocalizes with Atxn1 82Q aggregates and reduces insoluble Atxn1 82Q. (Figure 8A) Atxn1 82Q-GFP was expressed in PML-deficient (PML- / -) mouse embryonic fibroblasts (MEFs) together with each of the indicated PML isoforms. Cells were stained with anti-PML antibody (red) and DAPI (blue). (Figure 8B) Levels of FLAG-Atxn1 82Q in HeLa cells treated with control siRNA (-), PML siRNA #4, or PML siRNA #9. Cell lysates were analyzed by Western blot and filter phase contrast assay. The ratio of Atxn1 82Q in the SS fraction to actin, normalized to the control, is shown. (Figure 8C) HeLa cells were transfected with control siRNA, PML siRNA#4 (targeting the 5'UTR of PML mRNA), or PML siRNA#4 plus a plasmid expressing the PML open reading frame (thus resistant to siRNA). The levels of Atxn1 82Q-GFP in various fractions were analyzed. (Figure 8D) HeLa cells were treated with control siRNA, PML siRNA#4, and PML siRNA#9 and then transfected with FLAG-Atxn1 82Q. FLAG-Atxn1 82Q transcript levels were determined by quantitative RT-PCR normalized to 18S rRNA levels. (Figure 8E) Atxn1 30Q-GFP was expressed in HeLa cells in the absence or presence of PML. The cells were then treated with CHX for the indicated times. (Figure 8F) HeLa cells were transfected with nFlucDM-GFP and the corresponding wild-type luciferase (WT) protein. Endogenous PML was detected with an anti-PML antibody (red), and DNA was detected with DAPI (blue). Scale bar: 10 μm. (Figure 8G) PML knockdown leads to the accumulation of insoluble mutant luciferase. HeLa cells were transfected with control or PML siRNA and then with nFluc-GFP or nFlucDM-GFP.The SR fraction contained very little nFlucDM-GFP. [Figure 8B]Figure 8, including Figures 8A to 8G, shows the results of an example experiment demonstrating that PML colocalizes with Atxn1 82Q aggregates and reduces insoluble Atxn1 82Q. (Figure 8A) Atxn1 82Q-GFP was expressed in PML-deficient (PML- / -) mouse embryonic fibroblasts (MEFs) together with each of the indicated PML isoforms. Cells were stained with anti-PML antibody (red) and DAPI (blue). (Figure 8B) Levels of FLAG-Atxn1 82Q in HeLa cells treated with control siRNA (-), PML siRNA #4, or PML siRNA #9. Cell lysates were analyzed by Western blot and filter phase contrast assay. The ratio of Atxn1 82Q in the SS fraction to actin, normalized to the control, is shown. (Figure 8C) HeLa cells were transfected with control siRNA, PML siRNA#4 (targeting the 5'UTR of PML mRNA), or PML siRNA#4 plus a plasmid expressing the PML open reading frame (thus resistant to siRNA). The levels of Atxn1 82Q-GFP in various fractions were analyzed. (Figure 8D) HeLa cells were treated with control siRNA, PML siRNA#4, and PML siRNA#9 and then transfected with FLAG-Atxn1 82Q. FLAG-Atxn1 82Q transcript levels were determined by quantitative RT-PCR normalized to 18S rRNA levels. (Figure 8E) Atxn1 30Q-GFP was expressed in HeLa cells in the absence or presence of PML. The cells were then treated with CHX for the indicated times. (Figure 8F) HeLa cells were transfected with nFlucDM-GFP and the corresponding wild-type luciferase (WT) protein. Endogenous PML was detected with an anti-PML antibody (red), and DNA was detected with DAPI (blue). Scale bar: 10 μm. (Figure 8G) PML knockdown leads to the accumulation of insoluble mutant luciferase. HeLa cells were transfected with control or PML siRNA and then with nFluc-GFP or nFlucDM-GFP.The SR fraction contained very little nFlucDM-GFP. [Figure 8C]Figure 8, including Figures 8A to 8G, shows the results of an example experiment demonstrating that PML colocalizes with Atxn1 82Q aggregates and reduces insoluble Atxn1 82Q. (Figure 8A) Atxn1 82Q-GFP was expressed in PML-deficient (PML- / -) mouse embryonic fibroblasts (MEFs) together with each of the indicated PML isoforms. Cells were stained with anti-PML antibody (red) and DAPI (blue). (Figure 8B) Levels of FLAG-Atxn1 82Q in HeLa cells treated with control siRNA (-), PML siRNA #4, or PML siRNA #9. Cell lysates were analyzed by Western blot and filter phase contrast assay. The ratio of Atxn1 82Q in the SS fraction to actin, normalized to the control, is shown. (Figure 8C) HeLa cells were transfected with control siRNA, PML siRNA#4 (targeting the 5'UTR of PML mRNA), or PML siRNA#4 plus a plasmid expressing the PML open reading frame (thus resistant to siRNA). The levels of Atxn1 82Q-GFP in various fractions were analyzed. (Figure 8D) HeLa cells were treated with control siRNA, PML siRNA#4, and PML siRNA#9 and then transfected with FLAG-Atxn1 82Q. FLAG-Atxn1 82Q transcript levels were determined by quantitative RT-PCR normalized to 18S rRNA levels. (Figure 8E) Atxn1 30Q-GFP was expressed in HeLa cells in the absence or presence of PML. The cells were then treated with CHX for the indicated times. (Figure 8F) HeLa cells were transfected with nFlucDM-GFP and the corresponding wild-type luciferase (WT) protein. Endogenous PML was detected with an anti-PML antibody (red), and DNA was detected with DAPI (blue). Scale bar: 10 μm. (Figure 8G) PML knockdown leads to the accumulation of insoluble mutant luciferase. HeLa cells were transfected with control or PML siRNA and then with nFluc-GFP or nFlucDM-GFP.The SR fraction contained very little nFlucDM-GFP. [Figure 8D]Figure 8, including Figures 8A to 8G, shows the results of an example experiment demonstrating that PML colocalizes with Atxn1 82Q aggregates and reduces insoluble Atxn1 82Q. (Figure 8A) Atxn1 82Q-GFP was expressed in PML-deficient (PML- / -) mouse embryonic fibroblasts (MEFs) together with each of the indicated PML isoforms. Cells were stained with anti-PML antibody (red) and DAPI (blue). (Figure 8B) Levels of FLAG-Atxn1 82Q in HeLa cells treated with control siRNA (-), PML siRNA #4, or PML siRNA #9. Cell lysates were analyzed by Western blot and filter phase contrast assay. The ratio of Atxn1 82Q in the SS fraction to actin, normalized to the control, is shown. (Figure 8C) HeLa cells were transfected with control siRNA, PML siRNA#4 (targeting the 5'UTR of PML mRNA), or PML siRNA#4 plus a plasmid expressing the PML open reading frame (thus resistant to siRNA). The levels of Atxn1 82Q-GFP in various fractions were analyzed. (Figure 8D) HeLa cells were treated with control siRNA, PML siRNA#4, and PML siRNA#9 and then transfected with FLAG-Atxn1 82Q. FLAG-Atxn1 82Q transcript levels were determined by quantitative RT-PCR normalized to 18S rRNA levels. (Figure 8E) Atxn1 30Q-GFP was expressed in HeLa cells in the absence or presence of PML. The cells were then treated with CHX for the indicated times. (Figure 8F) HeLa cells were transfected with nFlucDM-GFP and the corresponding wild-type luciferase (WT) protein. Endogenous PML was detected with an anti-PML antibody (red), and DNA was detected with DAPI (blue). Scale bar: 10 μm. (Figure 8G) PML knockdown leads to the accumulation of insoluble mutant luciferase. HeLa cells were transfected with control or PML siRNA and then with nFluc-GFP or nFlucDM-GFP.The SR fraction contained very little nFlucDM-GFP. [Figure 8E]Figure 8, including Figures 8A to 8G, shows the results of an example experiment demonstrating that PML colocalizes with Atxn1 82Q aggregates and reduces insoluble Atxn1 82Q. (Figure 8A) Atxn1 82Q-GFP was expressed in PML-deficient (PML- / -) mouse embryonic fibroblasts (MEFs) together with each of the indicated PML isoforms. Cells were stained with anti-PML antibody (red) and DAPI (blue). (Figure 8B) Levels of FLAG-Atxn1 82Q in HeLa cells treated with control siRNA (-), PML siRNA #4, or PML siRNA #9. Cell lysates were analyzed by Western blot and filter phase contrast assay. The ratio of Atxn1 82Q in the SS fraction to actin, normalized to the control, is shown. (Figure 8C) HeLa cells were transfected with control siRNA, PML siRNA#4 (targeting the 5'UTR of PML mRNA), or PML siRNA#4 plus a plasmid expressing the PML open reading frame (thus resistant to siRNA). The levels of Atxn1 82Q-GFP in various fractions were analyzed. (Figure 8D) HeLa cells were treated with control siRNA, PML siRNA#4, and PML siRNA#9 and then transfected with FLAG-Atxn1 82Q. FLAG-Atxn1 82Q transcript levels were determined by quantitative RT-PCR normalized to 18S rRNA levels. (Figure 8E) Atxn1 30Q-GFP was expressed in HeLa cells in the absence or presence of PML. The cells were then treated with CHX for the indicated times. (Figure 8F) HeLa cells were transfected with nFlucDM-GFP and the corresponding wild-type luciferase (WT) protein. Endogenous PML was detected with an anti-PML antibody (red), and DNA was detected with DAPI (blue). Scale bar: 10 μm. (Figure 8G) PML knockdown leads to the accumulation of insoluble mutant luciferase. HeLa cells were transfected with control or PML siRNA and then with nFluc-GFP or nFlucDM-GFP.The SR fraction contained very little nFlucDM-GFP. [Figure 8F]Figure 8, including Figures 8A to 8G, shows the results of an example experiment demonstrating that PML colocalizes with Atxn1 82Q aggregates and reduces insoluble Atxn1 82Q. (Figure 8A) Atxn1 82Q-GFP was expressed in PML-deficient (PML- / -) mouse embryonic fibroblasts (MEFs) together with each of the indicated PML isoforms. Cells were stained with anti-PML antibody (red) and DAPI (blue). (Figure 8B) Levels of FLAG-Atxn1 82Q in HeLa cells treated with control siRNA (-), PML siRNA #4, or PML siRNA #9. Cell lysates were analyzed by Western blot and filter phase contrast assay. The ratio of Atxn1 82Q in the SS fraction to actin, normalized to the control, is shown. (Figure 8C) HeLa cells were transfected with control siRNA, PML siRNA#4 (targeting the 5'UTR of PML mRNA), or PML siRNA#4 plus a plasmid expressing the PML open reading frame (thus resistant to siRNA). The levels of Atxn1 82Q-GFP in various fractions were analyzed. (Figure 8D) HeLa cells were treated with control siRNA, PML siRNA#4, and PML siRNA#9 and then transfected with FLAG-Atxn1 82Q. FLAG-Atxn1 82Q transcript levels were determined by quantitative RT-PCR normalized to 18S rRNA levels. (Figure 8E) Atxn1 30Q-GFP was expressed in HeLa cells in the absence or presence of PML. The cells were then treated with CHX for the indicated times. (Figure 8F) HeLa cells were transfected with nFlucDM-GFP and the corresponding wild-type luciferase (WT) protein. Endogenous PML was detected with an anti-PML antibody (red), and DNA was detected with DAPI (blue). Scale bar: 10 μm. (Figure 8G) PML knockdown leads to the accumulation of insoluble mutant luciferase. HeLa cells were transfected with control or PML siRNA and then with nFluc-GFP or nFlucDM-GFP.The SR fraction contained very little nFlucDM-GFP. [Figure 8G]Figure 8, including Figures 8A to 8G, shows the results of an example experiment demonstrating that PML colocalizes with Atxn1 82Q aggregates and reduces insoluble Atxn1 82Q. (Figure 8A) Atxn1 82Q-GFP was expressed in PML-deficient (PML- / -) mouse embryonic fibroblasts (MEFs) together with each of the indicated PML isoforms. Cells were stained with anti-PML antibody (red) and DAPI (blue). (Figure 8B) Levels of FLAG-Atxn1 82Q in HeLa cells treated with control siRNA (-), PML siRNA #4, or PML siRNA #9. Cell lysates were analyzed by Western blot and filter phase contrast assay. The ratio of Atxn1 82Q in the SS fraction to actin, normalized to the control, is shown. (Figure 8C) HeLa cells were transfected with control siRNA, PML siRNA#4 (targeting the 5'UTR of PML mRNA), or PML siRNA#4 plus a plasmid expressing the PML open reading frame (thus resistant to siRNA). The levels of Atxn1 82Q-GFP in various fractions were analyzed. (Figure 8D) HeLa cells were treated with control siRNA, PML siRNA#4, and PML siRNA#9 and then transfected with FLAG-Atxn1 82Q. FLAG-Atxn1 82Q transcript levels were determined by quantitative RT-PCR normalized to 18S rRNA levels. (Figure 8E) Atxn1 30Q-GFP was expressed in HeLa cells in the absence or presence of PML. The cells were then treated with CHX for the indicated times. (Figure 8F) HeLa cells were transfected with nFlucDM-GFP and the corresponding wild-type luciferase (WT) protein. Endogenous PML was detected with an anti-PML antibody (red), and DNA was detected with DAPI (blue). Scale bar: 10 μm. (Figure 8G) PML knockdown leads to the accumulation of insoluble mutant luciferase. HeLa cells were transfected with control or PML siRNA and then with nFluc-GFP or nFlucDM-GFP.The SR fraction contained very little nFlucDM-GFP. [Figure 9A] Figure 9, including Figures 9A to 9E, shows the results of an example experiment demonstrating the interaction between PML and pathogenic Htt proteins. (Figure 9A) PML preferentially interacts with pathogenic Htt. Lysates of 293T cells expressing FLAG-GFP or FLAG-PML were incubated with GST-Htt25Q or GST-Htt103Q immobilized on glutathione beads (lanes 1–3 and 5–7) or with control glutathione beads (lanes 4 and 8). Input and pull-down fractions were analyzed by Western blot. (Figure 9B) Schematic representation of wild-type PML isoform IV (amino acids 1–633) (referred to as PML in this study) and various deletion fragments (F1–F10). The RING domain (R), B1 box, B2 box, and coiled-coil region (CC) are labeled. The substrate recognition sites SRS1 and SRS2 are indicated by lines. The interaction of PML with pathogenic Htt proteins (Htt103Q or 52Q) and denatured luciferase is shown. ND: Not performed. (Figure 9C) Interaction of Htt with full-length PML and PML deletion mutants. PML protein was produced by coupled in vitro transcription / translation in the presence of [35S]Met and incubated with purified GST-Htt103Q, GST-Htt25Q, or GST immobilized on glutathione beads. [35S]Met-labeled proteins in the input and pull-down samples were analyzed by autoradiography, and GST proteins in the pull-down samples were analyzed by Coomassie staining. Three sets of pull-down samples were analyzed simultaneously and in the same manner (including sample amount and autoradiographic exposure time). The input sample was exposed for a shorter time. (Figure 9D) Sequences of Htt52Q and CC-destabilizing (cc-) mutants. The amino acids in Htt52Q that were changed to Pro in Htt52Qcc- are shown in red. (Figure 9E) The interaction of purified PML CC region (shown on the right) with cellulose-bound luciferase peptide scan was assayed as in Figure 2D. *TEV protease. [Figure 9B] Figure 9, including Figures 9A to 9E, shows the results of an example experiment demonstrating the interaction between PML and pathogenic Htt proteins. (Figure 9A) PML preferentially interacts with pathogenic Htt. Lysates of 293T cells expressing FLAG-GFP or FLAG-PML were incubated with GST-Htt25Q or GST-Htt103Q immobilized on glutathione beads (lanes 1–3 and 5–7) or with control glutathione beads (lanes 4 and 8). Input and pull-down fractions were analyzed by Western blot. (Figure 9B) Schematic representation of wild-type PML isoform IV (amino acids 1–633) (referred to as PML in this study) and various deletion fragments (F1–F10). The RING domain (R), B1 box, B2 box, and coiled-coil region (CC) are labeled. The substrate recognition sites SRS1 and SRS2 are indicated by lines. The interaction of PML with pathogenic Htt proteins (Htt103Q or 52Q) and denatured luciferase is shown. ND: Not performed. (Figure 9C) Interaction of Htt with full-length PML and PML deletion mutants. PML protein was produced by coupled in vitro transcription / translation in the presence of [35S]Met and incubated with purified GST-Htt103Q, GST-Htt25Q, or GST immobilized on glutathione beads. [35S]Met-labeled proteins in the input and pull-down samples were analyzed by autoradiography, and GST proteins in the pull-down samples were analyzed by Coomassie staining. Three sets of pull-down samples were analyzed simultaneously and in the same manner (including sample amount and autoradiographic exposure time). The input sample was exposed for a shorter time. (Figure 9D) Sequences of Htt52Q and CC-destabilizing (cc-) mutants. The amino acids in Htt52Q that were changed to Pro in Htt52Qcc- are shown in red. (Figure 9E) The interaction of purified PML CC region (shown on the right) with cellulose-bound luciferase peptide scan was assayed as in Figure 2D. *TEV protease. [Figure 9C]Figure 9, including Figures 9A to 9E, shows the results of an example experiment demonstrating the interaction between PML and pathogenic Htt proteins. (Figure 9A) PML preferentially interacts with pathogenic Htt. Lysates of 293T cells expressing FLAG-GFP or FLAG-PML were incubated with GST-Htt25Q or GST-Htt103Q immobilized on glutathione beads (lanes 1–3 and 5–7) or with control glutathione beads (lanes 4 and 8). Input and pull-down fractions were analyzed by Western blot. (Figure 9B) Schematic representation of wild-type PML isoform IV (amino acids 1–633) (referred to as PML in this study) and various deletion fragments (F1–F10). The RING domain (R), B1 box, B2 box, and coiled-coil region (CC) are labeled. The substrate recognition sites SRS1 and SRS2 are indicated by lines. The interaction of PML with pathogenic Htt proteins (Htt103Q or 52Q) and denatured luciferase is shown. ND: Not performed. (Figure 9C) Interaction of Htt with full-length PML and PML deletion mutants. PML protein was produced by coupled in vitro transcription / translation in the presence of [35S]Met and incubated with purified GST-Htt103Q, GST-Htt25Q, or GST immobilized on glutathione beads. [35S]Met-labeled proteins in the input and pull-down samples were analyzed by autoradiography, and GST proteins in the pull-down samples were analyzed by Coomassie staining. Three sets of pull-down samples were analyzed simultaneously and in the same manner (including sample amount and autoradiographic exposure time). The input sample was exposed for a shorter time. (Figure 9D) Sequences of Htt52Q and CC-destabilizing (cc-) mutants. The amino acids in Htt52Q that were changed to Pro in Htt52Qcc- are shown in red. (Figure 9E) The interaction of purified PML CC region (shown on the right) with cellulose-bound luciferase peptide scan was assayed as in Figure 2D. *TEV protease. [Figure 9D]Figure 9, including Figures 9A to 9E, shows the results of an example experiment demonstrating the interaction between PML and pathogenic Htt proteins. (Figure 9A) PML preferentially interacts with pathogenic Htt. Lysates of 293T cells expressing FLAG-GFP or FLAG-PML were incubated with GST-Htt25Q or GST-Htt103Q immobilized on glutathione beads (lanes 1–3 and 5–7) or with control glutathione beads (lanes 4 and 8). Input and pull-down fractions were analyzed by Western blot. (Figure 9B) Schematic representation of wild-type PML isoform IV (amino acids 1–633) (referred to as PML in this study) and various deletion fragments (F1–F10). The RING domain (R), B1 box, B2 box, and coiled-coil region (CC) are labeled. The substrate recognition sites SRS1 and SRS2 are indicated by lines. The interaction of PML with pathogenic Htt proteins (Htt103Q or 52Q) and denatured luciferase is shown. ND: Not performed. (Figure 9C) Interaction of Htt with full-length PML and PML deletion mutants. PML protein was produced by coupled in vitro transcription / translation in the presence of [35S]Met and incubated with purified GST-Htt103Q, GST-Htt25Q, or GST immobilized on glutathione beads. [35S]Met-labeled proteins in the input and pull-down samples were analyzed by autoradiography, and GST proteins in the pull-down samples were analyzed by Coomassie staining. Three sets of pull-down samples were analyzed simultaneously and in the same manner (including sample amount and autoradiographic exposure time). The input sample was exposed for a shorter time. (Figure 9D) Sequences of Htt52Q and CC-destabilizing (cc-) mutants. The amino acids in Htt52Q that were changed to Pro in Htt52Qcc- are shown in red. (Figure 9E) The interaction of purified PML CC region (shown on the right) with cellulose-bound luciferase peptide scan was assayed as in Figure 2D. *TEV protease. [Figure 9E]Figure 9, including Figures 9A to 9E, shows the results of an example experiment demonstrating the interaction between PML and pathogenic Htt proteins. (Figure 9A) PML preferentially interacts with pathogenic Htt. Lysates of 293T cells expressing FLAG-GFP or FLAG-PML were incubated with GST-Htt25Q or GST-Htt103Q immobilized on glutathione beads (lanes 1–3 and 5–7) or with control glutathione beads (lanes 4 and 8). Input and pull-down fractions were analyzed by Western blot. (Figure 9B) Schematic representation of wild-type PML isoform IV (amino acids 1–633) (referred to as PML in this study) and various deletion fragments (F1–F10). The RING domain (R), B1 box, B2 box, and coiled-coil region (CC) are labeled. The substrate recognition sites SRS1 and SRS2 are indicated by lines. The interaction of PML with pathogenic Htt proteins (Htt103Q or 52Q) and denatured luciferase is shown. ND: Not performed. (Figure 9C) Interaction of Htt with full-length PML and PML deletion mutants. PML protein was produced by coupled in vitro transcription / translation in the presence of [35S]Met and incubated with purified GST-Htt103Q, GST-Htt25Q, or GST immobilized on glutathione beads. [35S]Met-labeled proteins in the input and pull-down samples were analyzed by autoradiography, and GST proteins in the pull-down samples were analyzed by Coomassie staining. Three sets of pull-down samples were analyzed simultaneously and in the same manner (including sample amount and autoradiographic exposure time). The input sample was exposed for a shorter time. (Figure 9D) Sequences of Htt52Q and CC-destabilizing (cc-) mutants. The amino acids in Htt52Q that were changed to Pro in Htt52Qcc- are shown in red. (Figure 9E) The interaction of purified PML CC region (shown on the right) with cellulose-bound luciferase peptide scan was assayed as in Figure 2D. *TEV protease. [Figure 10A]Figure 10, including Figures 10A to 10C, shows the results of an example experiment demonstrating the interaction of PML with denatured luciferase. (Figure 10A) Interaction of PML fragments with denatured luciferase. In vitro-translated and [35S]-labeled full-length FLAG-PML and FLAG-PML deletion mutants were incubated with native or denatured luciferase immobilized on beads or control beads. Input and bead-bound PML proteins were analyzed by autoradiography, and luciferase was analyzed by Coomassie blue staining. *, nonspecific band. Three pulldown sample sets were analyzed simultaneously and in the same manner (including sample amount and autoradiographic exposure time). The input sample was exposed for a shorter time. (Figures 10B and 10C) Identification of a second substrate recognition site (SRS2) on PML. (Figure 10B) Summary of PML deletion mutants incorporating amino acids at the C-terminus and their interaction with denatured luciferase. (FIG. 10C) In vitro translated and [ 35 S]-labeled GST fusions of PML fragments or GST were tested for interaction with luciferase as described in (FIG. 10A). [Figure 10B]Figure 10, including Figures 10A to 10C, shows the results of an example experiment demonstrating the interaction of PML with denatured luciferase. (Figure 10A) Interaction of PML fragments with denatured luciferase. In vitro-translated and [35S]-labeled full-length FLAG-PML and FLAG-PML deletion mutants were incubated with native or denatured luciferase immobilized on beads or control beads. Input and bead-bound PML proteins were analyzed by autoradiography, and luciferase was analyzed by Coomassie blue staining. *, nonspecific band. Three pulldown sample sets were analyzed simultaneously and in the same manner (including sample amount and autoradiographic exposure time). The input sample was exposed for a shorter time. (Figures 10B and 10C) Identification of a second substrate recognition site (SRS2) on PML. (Figure 10B) Summary of PML deletion mutants incorporating amino acids at the C-terminus and their interaction with denatured luciferase. (FIG. 10C) In vitro translated and [ 35 S]-labeled GST fusions of PML fragments or GST were tested for interaction with luciferase as described in (FIG. 10A). [Figure 10C]Figure 10, including Figures 10A to 10C, shows the results of an example experiment demonstrating the interaction of PML with denatured luciferase. (Figure 10A) Interaction of PML fragments with denatured luciferase. In vitro-translated and [35S]-labeled full-length FLAG-PML and FLAG-PML deletion mutants were incubated with native or denatured luciferase immobilized on beads or control beads. Input and bead-bound PML proteins were analyzed by autoradiography, and luciferase was analyzed by Coomassie blue staining. *, nonspecific band. Three pulldown sample sets were analyzed simultaneously and in the same manner (including sample amount and autoradiographic exposure time). The input sample was exposed for a shorter time. (Figures 10B and 10C) Identification of a second substrate recognition site (SRS2) on PML. (Figure 10B) Summary of PML deletion mutants incorporating amino acids at the C-terminus and their interaction with denatured luciferase. (FIG. 10C) In vitro translated and [ 35 S]-labeled GST fusions of PML fragments or GST were tested for interaction with luciferase as described in (FIG. 10A). [Figure 11A]Figure 11, including Figures 11A to 11G, shows the results of example experiments demonstrating the modification of misfolded proteins by SUMO2 / 3. (Figure 11A) HeLa cells were transfected with FLAG-Atxn1 82Q or FLAG-Atxn1 82Q(5KR) and treated with or without MG132. FLAG-Atxn1 82Q and FLAG-Atxn1 82Q(5KR) were isolated by d-IP, and their SUMO2 / 3 modification was analyzed by Western blot. (Figure 11B) HeLa cells were transfected without or with GFP-TDP-43 and treated with vehicle (DMSO) (-) or MG132 (+). d-IP was performed using an anti-GFP antibody or a control antibody. d-IP products were analyzed by Western blot. (Figure 11C) HeLa cells were transfected with nFluc-GFP, nFlucSM-GFP, and nFlucSM-GFP (each also N-terminally tagged with a FLAG epitope) and treated with or without MG132. nFluc protein was isolated by d-IP. Whole cell lysates (WCLs) and IP products were analyzed by Western blot. Note that the difference between SUMO2 / 3 modification of WT luciferase versus SM / DM luciferase (top, lanes 1–3) was not due to changes in overall SUMO2 / 3 conjugation in WCLs (bottom). (Figure 11D) Atxn1 82Q-GFP was expressed in HeLa cells pretreated with control (Ctrl), SUMO2 / 3, or SUMO1 siRNA. Cell lysates were analyzed by Western blot. (Figures 11E and 11F) HeLa cells were treated with control (Ctrl) siRNA, SUMO2 / 3 siRNA, or SUMO1 siRNA (Figure 11E), or these siRNAs and then transfected with GFP (Figure 11F). Cell lysates were analyzed by Western blot. (Figure 11G) PML and PML M6 proteins were used for in vitro sumoylation assays.FLAG-PML and FLAG-PML M6 were expressed in 293T cells and purified with anti-FLAG (M2) beads. Proteins were analyzed by Coomassie staining (left) and Western blot (right) with BSA standards. Two additional bands (arrowheads) present in both the PML and PML M6 lanes (left) were determined to be PML fragments based on both Western blot (right) and mass spectrometry. A diagram of the M6 mutants is shown below. *: Point mutations are described elsewhere herein. [Figure 11B]Figure 11, including Figures 11A to 11G, shows the results of example experiments demonstrating the modification of misfolded proteins by SUMO2 / 3. (Figure 11A) HeLa cells were transfected with FLAG-Atxn1 82Q or FLAG-Atxn1 82Q(5KR) and treated with or without MG132. FLAG-Atxn1 82Q and FLAG-Atxn1 82Q(5KR) were isolated by d-IP, and their SUMO2 / 3 modification was analyzed by Western blot. (Figure 11B) HeLa cells were transfected without or with GFP-TDP-43 and treated with vehicle (DMSO) (-) or MG132 (+). d-IP was performed using an anti-GFP antibody or a control antibody. d-IP products were analyzed by Western blot. (Figure 11C) HeLa cells were transfected with nFluc-GFP, nFlucSM-GFP, and nFlucSM-GFP (each also N-terminally tagged with a FLAG epitope) and treated with or without MG132. nFluc protein was isolated by d-IP. Whole cell lysates (WCLs) and IP products were analyzed by Western blot. Note that the difference between SUMO2 / 3 modification of WT luciferase versus SM / DM luciferase (top, lanes 1–3) was not due to changes in overall SUMO2 / 3 conjugation in WCLs (bottom). (Figure 11D) Atxn1 82Q-GFP was expressed in HeLa cells pretreated with control (Ctrl), SUMO2 / 3, or SUMO1 siRNA. Cell lysates were analyzed by Western blot. (Figures 11E and 11F) HeLa cells were treated with control (Ctrl) siRNA, SUMO2 / 3 siRNA, or SUMO1 siRNA (Figure 11E), or these siRNAs and then transfected with GFP (Figure 11F). Cell lysates were analyzed by Western blot. (Figure 11G) PML and PML M6 proteins were used for in vitro sumoylation assays.FLAG-PML and FLAG-PML M6 were expressed in 293T cells and purified with anti-FLAG (M2) beads. Proteins were analyzed by Coomassie staining (left) and Western blot (right) with BSA standards. Two additional bands (arrowheads) present in both the PML and PML M6 lanes (left) were determined to be PML fragments based on both Western blot (right) and mass spectrometry. A diagram of the M6 mutants is shown below. *: Point mutations are described elsewhere herein. [Figure 11C]Figure 11, including Figures 11A to 11G, shows the results of example experiments demonstrating the modification of misfolded proteins by SUMO2 / 3. (Figure 11A) HeLa cells were transfected with FLAG-Atxn1 82Q or FLAG-Atxn1 82Q(5KR) and treated with or without MG132. FLAG-Atxn1 82Q and FLAG-Atxn1 82Q(5KR) were isolated by d-IP, and their SUMO2 / 3 modification was analyzed by Western blot. (Figure 11B) HeLa cells were transfected without or with GFP-TDP-43 and treated with vehicle (DMSO) (-) or MG132 (+). d-IP was performed using an anti-GFP antibody or a control antibody. d-IP products were analyzed by Western blot. (Figure 11C) HeLa cells were transfected with nFluc-GFP, nFlucSM-GFP, and nFlucSM-GFP (each also N-terminally tagged with a FLAG epitope) and treated with or without MG132. nFluc protein was isolated by d-IP. Whole cell lysates (WCLs) and IP products were analyzed by Western blot. Note that the difference between SUMO2 / 3 modification of WT luciferase versus SM / DM luciferase (top, lanes 1–3) was not due to changes in overall SUMO2 / 3 conjugation in WCLs (bottom). (Figure 11D) Atxn1 82Q-GFP was expressed in HeLa cells pretreated with control (Ctrl), SUMO2 / 3, or SUMO1 siRNA. Cell lysates were analyzed by Western blot. (Figures 11E and 11F) HeLa cells were treated with control (Ctrl) siRNA, SUMO2 / 3 siRNA, or SUMO1 siRNA (Figure 11E), or these siRNAs and then transfected with GFP (Figure 11F). Cell lysates were analyzed by Western blot. (Figure 11G) PML and PML M6 proteins were used for in vitro sumoylation assays.FLAG-PML and FLAG-PML M6 were expressed in 293T cells and purified with anti-FLAG (M2) beads. Proteins were analyzed by Coomassie staining (left) and Western blot (right) with BSA standards. Two additional bands (arrowheads) present in both the PML and PML M6 lanes (left) were determined to be PML fragments based on both Western blot (right) and mass spectrometry. A diagram of the M6 mutants is shown below. *: Point mutations are described elsewhere herein. [Figure 11D]Figure 11, including Figures 11A to 11G, shows the results of example experiments demonstrating the modification of misfolded proteins by SUMO2 / 3. (Figure 11A) HeLa cells were transfected with FLAG-Atxn1 82Q or FLAG-Atxn1 82Q(5KR) and treated with or without MG132. FLAG-Atxn1 82Q and FLAG-Atxn1 82Q(5KR) were isolated by d-IP, and their SUMO2 / 3 modification was analyzed by Western blot. (Figure 11B) HeLa cells were transfected without or with GFP-TDP-43 and treated with vehicle (DMSO) (-) or MG132 (+). d-IP was performed using an anti-GFP antibody or a control antibody. d-IP products were analyzed by Western blot. (Figure 11C) HeLa cells were transfected with nFluc-GFP, nFlucSM-GFP, and nFlucSM-GFP (each also N-terminally tagged with a FLAG epitope) and treated with or without MG132. nFluc protein was isolated by d-IP. Whole cell lysates (WCLs) and IP products were analyzed by Western blot. Note that the difference between SUMO2 / 3 modification of WT luciferase versus SM / DM luciferase (top, lanes 1–3) was not due to changes in overall SUMO2 / 3 conjugation in WCLs (bottom). (Figure 11D) Atxn1 82Q-GFP was expressed in HeLa cells pretreated with control (Ctrl), SUMO2 / 3, or SUMO1 siRNA. Cell lysates were analyzed by Western blot. (Figures 11E and 11F) HeLa cells were treated with control (Ctrl) siRNA, SUMO2 / 3 siRNA, or SUMO1 siRNA (Figure 11E), or these siRNAs and then transfected with GFP (Figure 11F). Cell lysates were analyzed by Western blot. (Figure 11G) PML and PML M6 proteins were used for in vitro sumoylation assays.FLAG-PML and FLAG-PML M6 were expressed in 293T cells and purified with anti-FLAG (M2) beads. Proteins were analyzed by Coomassie staining (left) and Western blot (right) with BSA standards. Two additional bands (arrowheads) present in both the PML and PML M6 lanes (left) were determined to be PML fragments based on both Western blot (right) and mass spectrometry. A diagram of the M6 mutants is shown below. *: Point mutations are described elsewhere herein. [Figure 11E]Figure 11, including Figures 11A to 11G, shows the results of example experiments demonstrating the modification of misfolded proteins by SUMO2 / 3. (Figure 11A) HeLa cells were transfected with FLAG-Atxn1 82Q or FLAG-Atxn1 82Q(5KR) and treated with or without MG132. FLAG-Atxn1 82Q and FLAG-Atxn1 82Q(5KR) were isolated by d-IP, and their SUMO2 / 3 modification was analyzed by Western blot. (Figure 11B) HeLa cells were transfected without or with GFP-TDP-43 and treated with vehicle (DMSO) (-) or MG132 (+). d-IP was performed using an anti-GFP antibody or a control antibody. d-IP products were analyzed by Western blot. (Figure 11C) HeLa cells were transfected with nFluc-GFP, nFlucSM-GFP, and nFlucSM-GFP (each also N-terminally tagged with a FLAG epitope) and treated with or without MG132. nFluc protein was isolated by d-IP. Whole cell lysates (WCLs) and IP products were analyzed by Western blot. Note that the difference between SUMO2 / 3 modification of WT luciferase versus SM / DM luciferase (top, lanes 1–3) was not due to changes in overall SUMO2 / 3 conjugation in WCLs (bottom). (Figure 11D) Atxn1 82Q-GFP was expressed in HeLa cells pretreated with control (Ctrl), SUMO2 / 3, or SUMO1 siRNA. Cell lysates were analyzed by Western blot. (Figures 11E and 11F) HeLa cells were treated with control (Ctrl) siRNA, SUMO2 / 3 siRNA, or SUMO1 siRNA (Figure 11E), or these siRNAs and then transfected with GFP (Figure 11F). Cell lysates were analyzed by Western blot. (Figure 11G) PML and PML M6 proteins were used for in vitro sumoylation assays.FLAG-PML and FLAG-PML M6 were expressed in 293T cells and purified with anti-FLAG (M2) beads. Proteins were analyzed by Coomassie staining (left) and Western blot (right) with BSA standards. Two additional bands (arrowheads) present in both the PML and PML M6 lanes (left) were determined to be PML fragments based on both Western blot (right) and mass spectrometry. A diagram of the M6 mutants is shown below. *: Point mutations are described elsewhere herein. [Figure 11F]Figure 11, including Figures 11A to 11G, shows the results of example experiments demonstrating the modification of misfolded proteins by SUMO2 / 3. (Figure 11A) HeLa cells were transfected with FLAG-Atxn1 82Q or FLAG-Atxn1 82Q(5KR) and treated with or without MG132. FLAG-Atxn1 82Q and FLAG-Atxn1 82Q(5KR) were isolated by d-IP, and their SUMO2 / 3 modification was analyzed by Western blot. (Figure 11B) HeLa cells were transfected without or with GFP-TDP-43 and treated with vehicle (DMSO) (-) or MG132 (+). d-IP was performed using an anti-GFP antibody or a control antibody. d-IP products were analyzed by Western blot. (Figure 11C) HeLa cells were transfected with nFluc-GFP, nFlucSM-GFP, and nFlucSM-GFP (each also N-terminally tagged with a FLAG epitope) and treated with or without MG132. nFluc protein was isolated by d-IP. Whole cell lysates (WCLs) and IP products were analyzed by Western blot. Note that the difference between SUMO2 / 3 modification of WT luciferase versus SM / DM luciferase (top, lanes 1–3) was not due to changes in overall SUMO2 / 3 conjugation in WCLs (bottom). (Figure 11D) Atxn1 82Q-GFP was expressed in HeLa cells pretreated with control (Ctrl), SUMO2 / 3, or SUMO1 siRNA. Cell lysates were analyzed by Western blot. (Figures 11E and 11F) HeLa cells were treated with control (Ctrl) siRNA, SUMO2 / 3 siRNA, or SUMO1 siRNA (Figure 11E), or these siRNAs and then transfected with GFP (Figure 11F). Cell lysates were analyzed by Western blot. (Figure 11G) PML and PML M6 proteins were used for in vitro sumoylation assays.FLAG-PML and FLAG-PML M6 were expressed in 293T cells and purified with anti-FLAG (M2) beads. Proteins were analyzed by Coomassie staining (left) and Western blot (right) with BSA standards. Two additional bands (arrowheads) present in both the PML and PML M6 lanes (left) were determined to be PML fragments based on both Western blot (right) and mass spectrometry. A diagram of the M6 mutants is shown below. *: Point mutations are described elsewhere herein. [Figure 11G]Figure 11, including Figures 11A to 11G, shows the results of example experiments demonstrating the modification of misfolded proteins by SUMO2 / 3. (Figure 11A) HeLa cells were transfected with FLAG-Atxn1 82Q or FLAG-Atxn1 82Q(5KR) and treated with or without MG132. FLAG-Atxn1 82Q and FLAG-Atxn1 82Q(5KR) were isolated by d-IP, and their SUMO2 / 3 modification was analyzed by Western blot. (Figure 11B) HeLa cells were transfected without or with GFP-TDP-43 and treated with vehicle (DMSO) (-) or MG132 (+). d-IP was performed using an anti-GFP antibody or a control antibody. d-IP products were analyzed by Western blot. (Figure 11C) HeLa cells were transfected with nFluc-GFP, nFlucSM-GFP, and nFlucSM-GFP (each also N-terminally tagged with a FLAG epitope) and treated with or without MG132. nFluc protein was isolated by d-IP. Whole cell lysates (WCLs) and IP products were analyzed by Western blot. Note that the difference between SUMO2 / 3 modification of WT luciferase versus SM / DM luciferase (top, lanes 1–3) was not due to changes in overall SUMO2 / 3 conjugation in WCLs (bottom). (Figure 11D) Atxn1 82Q-GFP was expressed in HeLa cells pretreated with control (Ctrl), SUMO2 / 3, or SUMO1 siRNA. Cell lysates were analyzed by Western blot. (Figures 11E and 11F) HeLa cells were treated with control (Ctrl) siRNA, SUMO2 / 3 siRNA, or SUMO1 siRNA (Figure 11E), or these siRNAs and then transfected with GFP (Figure 11F). Cell lysates were analyzed by Western blot. (Figure 11G) PML and PML M6 proteins were used for in vitro sumoylation assays.FLAG-PML and FLAG-PML M6 were expressed in 293T cells and purified with anti-FLAG (M2) beads. Proteins were analyzed by Coomassie staining (left) and Western blot (right) with BSA standards. Two additional bands (arrowheads) present in both the PML and PML M6 lanes (left) were determined to be PML fragments based on both Western blot (right) and mass spectrometry. A diagram of the M6 mutants is shown below. *: Point mutations are described elsewhere herein. [Figure 12A]Figure 12, including Figures 12A to 12I, shows the results of example experiments demonstrating that RNF4 promotes the degradation of misfolded proteins. (Figure 12A) Representative fluorescence images of HeLa cells expressing Atxn 82Q-GFP alone or together with RNF4. Scale bar: 20 μm. Images are from the same experiment as shown in Figure 1B. (Figure 12B) Half-life of Atxn 82Q-GFP in HeLa cells with and without RNF4 overexpression. Samples are from the same experiment as shown in Figure 1F. (Figure 12C) HeLa cells were transfected with control siRNA (-), RNF4 siRNA alone, or RNF4 siRNA and siRNA-resistant RNF4. Cell lysates were analyzed by Western blot. (Figure 12D) FLAG-Atxn1 82Q was expressed in HeLa cells pretreated with control siRNA and the indicated RNF4 siRNA. FLAG-Atxn1 82Q was isolated by d-IP using anti-FLAG M2 beads. WCL and IP products were analyzed by Western blot using the indicated antibodies. (Figure 12E) HeLa cells expressing both Atxn 82Q-GFP and FLAG-RNF4 were treated with vehicle (DMSO) or MG132. Exogenous (Exo) RNF4 was detected using an anti-FLAG antibody. In control cells treated with DMSO, exogenous RNF4 showed partial colocalization with Atxn1 82Q-GFP aggregates. Upon treatment with MG132, complete colocalization of exogenous RNF4 and Atxn1 82Q aggregates was observed in 100% of cells. Scale bar: 10 μm. (Figure 12F) Western blot analysis of HeLa cells transfected with GFP-TDP-43 alone or together with increasing amounts of RNF4. (Figure 12G) GFP-TDP-43 was expressed in cells pretreated with control siRNA (-) or the indicated RNF4 siRNA. Five hundred cells were counted in each experiment. The percentage of cells with GFP-TDP-43 foci is shown. (Figure 12H) HeLa cells treated with RNF4 siRNA were transfected with GFP-TDP-43.Cells were stained with anti-RNF4 antibody (red) and DAPI (blue). Note that TDP-43 formed aggregates in cells where RNF4 was knocked down (filled arrowheads) but was diffuse in control cells (open arrowheads) (Figure 12I). HeLa cells were transfected with GFP-TDP-43 and treated with MG132. Endogenous RNF4 was stained with anti-RNF4 antibody (red). Note that RNF4 also formed nuclear foci in cells that lacked any TDP-43 (Figures 12E–H). [Figure 12B]Figure 12, including Figures 12A to 12I, shows the results of example experiments demonstrating that RNF4 promotes the degradation of misfolded proteins. (Figure 12A) Representative fluorescence images of HeLa cells expressing Atxn 82Q-GFP alone or together with RNF4. Scale bar: 20 μm. Images are from the same experiment as shown in Figure 1B. (Figure 12B) Half-life of Atxn 82Q-GFP in HeLa cells with and without RNF4 overexpression. Samples are from the same experiment as shown in Figure 1F. (Figure 12C) HeLa cells were transfected with control siRNA (-), RNF4 siRNA alone, or RNF4 siRNA and siRNA-resistant RNF4. Cell lysates were analyzed by Western blot. (Figure 12D) FLAG-Atxn1 82Q was expressed in HeLa cells pretreated with control siRNA and the indicated RNF4 siRNA. FLAG-Atxn1 82Q was isolated by d-IP using anti-FLAG M2 beads. WCL and IP products were analyzed by Western blot using the indicated antibodies. (Figure 12E) HeLa cells expressing both Atxn 82Q-GFP and FLAG-RNF4 were treated with vehicle (DMSO) or MG132. Exogenous (Exo) RNF4 was detected using an anti-FLAG antibody. In control cells treated with DMSO, exogenous RNF4 showed partial colocalization with Atxn1 82Q-GFP aggregates. Upon treatment with MG132, complete colocalization of exogenous RNF4 and Atxn1 82Q aggregates was observed in 100% of cells. Scale bar: 10 μm. (Figure 12F) Western blot analysis of HeLa cells transfected with GFP-TDP-43 alone or together with increasing amounts of RNF4. (Figure 12G) GFP-TDP-43 was expressed in cells pretreated with control siRNA (-) or the indicated RNF4 siRNA. Five hundred cells were counted in each experiment. The percentage of cells with GFP-TDP-43 foci is shown. (Figure 12H) HeLa cells treated with RNF4 siRNA were transfected with GFP-TDP-43.Cells were stained with anti-RNF4 antibody (red) and DAPI (blue). Note that TDP-43 formed aggregates in cells where RNF4 was knocked down (filled arrowheads) but was diffuse in control cells (open arrowheads) (Figure 12I). HeLa cells were transfected with GFP-TDP-43 and treated with MG132. Endogenous RNF4 was stained with anti-RNF4 antibody (red). Note that RNF4 also formed nuclear foci in cells that lacked any TDP-43 (Figures 12E–H). [Figure 12C]Figure 12, including Figures 12A to 12I, shows the results of example experiments demonstrating that RNF4 promotes the degradation of misfolded proteins. (Figure 12A) Representative fluorescence images of HeLa cells expressing Atxn 82Q-GFP alone or together with RNF4. Scale bar: 20 μm. Images are from the same experiment as shown in Figure 1B. (Figure 12B) Half-life of Atxn 82Q-GFP in HeLa cells with and without RNF4 overexpression. Samples are from the same experiment as shown in Figure 1F. (Figure 12C) HeLa cells were transfected with control siRNA (-), RNF4 siRNA alone, or RNF4 siRNA and siRNA-resistant RNF4. Cell lysates were analyzed by Western blot. (Figure 12D) FLAG-Atxn1 82Q was expressed in HeLa cells pretreated with control siRNA and the indicated RNF4 siRNA. FLAG-Atxn1 82Q was isolated by d-IP using anti-FLAG M2 beads. WCL and IP products were analyzed by Western blot using the indicated antibodies. (Figure 12E) HeLa cells expressing both Atxn 82Q-GFP and FLAG-RNF4 were treated with vehicle (DMSO) or MG132. Exogenous (Exo) RNF4 was detected using an anti-FLAG antibody. In control cells treated with DMSO, exogenous RNF4 showed partial colocalization with Atxn1 82Q-GFP aggregates. Upon treatment with MG132, complete colocalization of exogenous RNF4 and Atxn1 82Q aggregates was observed in 100% of cells. Scale bar: 10 μm. (Figure 12F) Western blot analysis of HeLa cells transfected with GFP-TDP-43 alone or together with increasing amounts of RNF4. (Figure 12G) GFP-TDP-43 was expressed in cells pretreated with control siRNA (-) or the indicated RNF4 siRNA. Five hundred cells were counted in each experiment. The percentage of cells with GFP-TDP-43 foci is shown. (Figure 12H) HeLa cells treated with RNF4 siRNA were transfected with GFP-TDP-43.Cells were stained with anti-RNF4 antibody (red) and DAPI (blue). Note that TDP-43 formed aggregates in cells where RNF4 was knocked down (filled arrowheads) but was diffuse in control cells (open arrowheads) (Figure 12I). HeLa cells were transfected with GFP-TDP-43 and treated with MG132. Endogenous RNF4 was stained with anti-RNF4 antibody (red). Note that RNF4 also formed nuclear foci in cells that lacked any TDP-43 (Figures 12E–H). [Figure 12D]Figure 12, including Figures 12A to 12I, shows the results of example experiments demonstrating that RNF4 promotes the degradation of misfolded proteins. (Figure 12A) Representative fluorescence images of HeLa cells expressing Atxn 82Q-GFP alone or together with RNF4. Scale bar: 20 μm. Images are from the same experiment as shown in Figure 1B. (Figure 12B) Half-life of Atxn 82Q-GFP in HeLa cells with and without RNF4 overexpression. Samples are from the same experiment as shown in Figure 1F. (Figure 12C) HeLa cells were transfected with control siRNA (-), RNF4 siRNA alone, or RNF4 siRNA and siRNA-resistant RNF4. Cell lysates were analyzed by Western blot. (Figure 12D) FLAG-Atxn1 82Q was expressed in HeLa cells pretreated with control siRNA and the indicated RNF4 siRNA. FLAG-Atxn1 82Q was isolated by d-IP using anti-FLAG M2 beads. WCL and IP products were analyzed by Western blot using the indicated antibodies. (Figure 12E) HeLa cells expressing both Atxn 82Q-GFP and FLAG-RNF4 were treated with vehicle (DMSO) or MG132. Exogenous (Exo) RNF4 was detected using an anti-FLAG antibody. In control cells treated with DMSO, exogenous RNF4 showed partial colocalization with Atxn1 82Q-GFP aggregates. Upon treatment with MG132, complete colocalization of exogenous RNF4 and Atxn1 82Q aggregates was observed in 100% of cells. Scale bar: 10 μm. (Figure 12F) Western blot analysis of HeLa cells transfected with GFP-TDP-43 alone or together with increasing amounts of RNF4. (Figure 12G) GFP-TDP-43 was expressed in cells pretreated with control siRNA (-) or the indicated RNF4 siRNA. Five hundred cells were counted in each experiment. The percentage of cells with GFP-TDP-43 foci is shown. (Figure 12H) HeLa cells treated with RNF4 siRNA were transfected with GFP-TDP-43.Cells were stained with anti-RNF4 antibody (red) and DAPI (blue). Note that TDP-43 formed aggregates in cells where RNF4 was knocked down (filled arrowheads) but was diffuse in control cells (open arrowheads) (Figure 12I). HeLa cells were transfected with GFP-TDP-43 and treated with MG132. Endogenous RNF4 was stained with anti-RNF4 antibody (red). Note that RNF4 also formed nuclear foci in cells that lacked any TDP-43 (Figures 12E–H). [Figure 12E]Figure 12, including Figures 12A to 12I, shows the results of example experiments demonstrating that RNF4 promotes the degradation of misfolded proteins. (Figure 12A) Representative fluorescence images of HeLa cells expressing Atxn 82Q-GFP alone or together with RNF4. Scale bar: 20 μm. Images are from the same experiment as shown in Figure 1B. (Figure 12B) Half-life of Atxn 82Q-GFP in HeLa cells with and without RNF4 overexpression. Samples are from the same experiment as shown in Figure 1F. (Figure 12C) HeLa cells were transfected with control siRNA (-), RNF4 siRNA alone, or RNF4 siRNA and siRNA-resistant RNF4. Cell lysates were analyzed by Western blot. (Figure 12D) FLAG-Atxn1 82Q was expressed in HeLa cells pretreated with control siRNA and the indicated RNF4 siRNA. FLAG-Atxn1 82Q was isolated by d-IP using anti-FLAG M2 beads. WCL and IP products were analyzed by Western blot using the indicated antibodies. (Figure 12E) HeLa cells expressing both Atxn 82Q-GFP and FLAG-RNF4 were treated with vehicle (DMSO) or MG132. Exogenous (Exo) RNF4 was detected using an anti-FLAG antibody. In control cells treated with DMSO, exogenous RNF4 showed partial colocalization with Atxn1 82Q-GFP aggregates. Upon treatment with MG132, complete colocalization of exogenous RNF4 and Atxn1 82Q aggregates was observed in 100% of cells. Scale bar: 10 μm. (Figure 12F) Western blot analysis of HeLa cells transfected with GFP-TDP-43 alone or together with increasing amounts of RNF4. (Figure 12G) GFP-TDP-43 was expressed in cells pretreated with control siRNA (-) or the indicated RNF4 siRNA. Five hundred cells were counted in each experiment. The percentage of cells with GFP-TDP-43 foci is shown. (Figure 12H) HeLa cells treated with RNF4 siRNA were transfected with GFP-TDP-43.Cells were stained with anti-RNF4 antibody (red) and DAPI (blue). Note that TDP-43 formed aggregates in cells where RNF4 was knocked down (filled arrowheads) but was diffuse in control cells (open arrowheads) (Figure 12I). HeLa cells were transfected with GFP-TDP-43 and treated with MG132. Endogenous RNF4 was stained with anti-RNF4 antibody (red). Note that RNF4 also formed nuclear foci in cells that lacked any TDP-43 (Figures 12E–H). [Figure 12F]Figure 12, including Figures 12A to 12I, shows the results of example experiments demonstrating that RNF4 promotes the degradation of misfolded proteins. (Figure 12A) Representative fluorescence images of HeLa cells expressing Atxn 82Q-GFP alone or together with RNF4. Scale bar: 20 μm. Images are from the same experiment as shown in Figure 1B. (Figure 12B) Half-life of Atxn 82Q-GFP in HeLa cells with and without RNF4 overexpression. Samples are from the same experiment as shown in Figure 1F. (Figure 12C) HeLa cells were transfected with control siRNA (-), RNF4 siRNA alone, or RNF4 siRNA and siRNA-resistant RNF4. Cell lysates were analyzed by Western blot. (Figure 12D) FLAG-Atxn1 82Q was expressed in HeLa cells pretreated with control siRNA and the indicated RNF4 siRNA. FLAG-Atxn1 82Q was isolated by d-IP using anti-FLAG M2 beads. WCL and IP products were analyzed by Western blot using the indicated antibodies. (Figure 12E) HeLa cells expressing both Atxn 82Q-GFP and FLAG-RNF4 were treated with vehicle (DMSO) or MG132. Exogenous (Exo) RNF4 was detected using an anti-FLAG antibody. In control cells treated with DMSO, exogenous RNF4 showed partial colocalization with Atxn1 82Q-GFP aggregates. Upon treatment with MG132, complete colocalization of exogenous RNF4 and Atxn1 82Q aggregates was observed in 100% of cells. Scale bar: 10 μm. (Figure 12F) Western blot analysis of HeLa cells transfected with GFP-TDP-43 alone or together with increasing amounts of RNF4. (Figure 12G) GFP-TDP-43 was expressed in cells pretreated with control siRNA (-) or the indicated RNF4 siRNA. Five hundred cells were counted in each experiment. The percentage of cells with GFP-TDP-43 foci is shown. (Figure 12H) HeLa cells treated with RNF4 siRNA were transfected with GFP-TDP-43.Cells were stained with anti-RNF4 antibody (red) and DAPI (blue). Note that TDP-43 formed aggregates in cells where RNF4 was knocked down (filled arrowheads) but was diffuse in control cells (open arrowheads) (Figure 12I). HeLa cells were transfected with GFP-TDP-43 and treated with MG132. Endogenous RNF4 was stained with anti-RNF4 antibody (red). Note that RNF4 also formed nuclear foci in cells that lacked any TDP-43 (Figures 12E–H). [Figure 12G]Figure 12, including Figures 12A to 12I, shows the results of example experiments demonstrating that RNF4 promotes the degradation of misfolded proteins. (Figure 12A) Representative fluorescence images of HeLa cells expressing Atxn 82Q-GFP alone or together with RNF4. Scale bar: 20 μm. Images are from the same experiment as shown in Figure 1B. (Figure 12B) Half-life of Atxn 82Q-GFP in HeLa cells with and without RNF4 overexpression. Samples are from the same experiment as shown in Figure 1F. (Figure 12C) HeLa cells were transfected with control siRNA (-), RNF4 siRNA alone, or RNF4 siRNA and siRNA-resistant RNF4. Cell lysates were analyzed by Western blot. (Figure 12D) FLAG-Atxn1 82Q was expressed in HeLa cells pretreated with control siRNA and the indicated RNF4 siRNA. FLAG-Atxn1 82Q was isolated by d-IP using anti-FLAG M2 beads. WCL and IP products were analyzed by Western blot using the indicated antibodies. (Figure 12E) HeLa cells expressing both Atxn 82Q-GFP and FLAG-RNF4 were treated with vehicle (DMSO) or MG132. Exogenous (Exo) RNF4 was detected using an anti-FLAG antibody. In control cells treated with DMSO, exogenous RNF4 showed partial colocalization with Atxn1 82Q-GFP aggregates. Upon treatment with MG132, complete colocalization of exogenous RNF4 and Atxn1 82Q aggregates was observed in 100% of cells. Scale bar: 10 μm. (Figure 12F) Western blot analysis of HeLa cells transfected with GFP-TDP-43 alone or together with increasing amounts of RNF4. (Figure 12G) GFP-TDP-43 was expressed in cells pretreated with control siRNA (-) or the indicated RNF4 siRNA. Five hundred cells were counted in each experiment. The percentage of cells with GFP-TDP-43 foci is shown. (Figure 12H) HeLa cells treated with RNF4 siRNA were transfected with GFP-TDP-43.Cells were stained with anti-RNF4 antibody (red) and DAPI (blue). Note that TDP-43 formed aggregates in cells where RNF4 was knocked down (filled arrowheads) but was diffuse in control cells (open arrowheads) (Figure 12I). HeLa cells were transfected with GFP-TDP-43 and treated with MG132. Endogenous RNF4 was stained with anti-RNF4 antibody (red). Note that RNF4 also formed nuclear foci in cells that lacked any TDP-43 (Figures 12E–H). [Figure 12H]Figure 12, including Figures 12A to 12I, shows the results of example experiments demonstrating that RNF4 promotes the degradation of misfolded proteins. (Figure 12A) Representative fluorescence images of HeLa cells expressing Atxn 82Q-GFP alone or together with RNF4. Scale bar: 20 μm. Images are from the same experiment as shown in Figure 1B. (Figure 12B) Half-life of Atxn 82Q-GFP in HeLa cells with and without RNF4 overexpression. Samples are from the same experiment as shown in Figure 1F. (Figure 12C) HeLa cells were transfected with control siRNA (-), RNF4 siRNA alone, or RNF4 siRNA and siRNA-resistant RNF4. Cell lysates were analyzed by Western blot. (Figure 12D) FLAG-Atxn1 82Q was expressed in HeLa cells pretreated with control siRNA and the indicated RNF4 siRNA. FLAG-Atxn1 82Q was isolated by d-IP using anti-FLAG M2 beads. WCL and IP products were analyzed by Western blot using the indicated antibodies. (Figure 12E) HeLa cells expressing both Atxn 82Q-GFP and FLAG-RNF4 were treated with vehicle (DMSO) or MG132. Exogenous (Exo) RNF4 was detected using an anti-FLAG antibody. In control cells treated with DMSO, exogenous RNF4 showed partial colocalization with Atxn1 82Q-GFP aggregates. Upon treatment with MG132, complete colocalization of exogenous RNF4 and Atxn1 82Q aggregates was observed in 100% of cells. Scale bar: 10 μm. (Figure 12F) Western blot analysis of HeLa cells transfected with GFP-TDP-43 alone or together with increasing amounts of RNF4. (Figure 12G) GFP-TDP-43 was expressed in cells pretreated with control siRNA (-) or the indicated RNF4 siRNA. Five hundred cells were counted in each experiment. The percentage of cells with GFP-TDP-43 foci is shown. (Figure 12H) HeLa cells treated with RNF4 siRNA were transfected with GFP-TDP-43.Cells were stained with anti-RNF4 antibody (red) and DAPI (blue). Note that TDP-43 formed aggregates in cells where RNF4 was knocked down (filled arrowheads) but was diffuse in control cells (open arrowheads) (Figure 12I). HeLa cells were transfected with GFP-TDP-43 and treated with MG132. Endogenous RNF4 was stained with anti-RNF4 antibody (red). Note that RNF4 also formed nuclear foci in cells that lacked any TDP-43 (Figures 12E–H). [Figure 12I]Figure 12, including Figures 12A to 12I, shows the results of example experiments demonstrating that RNF4 promotes the degradation of misfolded proteins. (Figure 12A) Representative fluorescence images of HeLa cells expressing Atxn 82Q-GFP alone or together with RNF4. Scale bar: 20 μm. Images are from the same experiment as shown in Figure 1B. (Figure 12B) Half-life of Atxn 82Q-GFP in HeLa cells with and without RNF4 overexpression. Samples are from the same experiment as shown in Figure 1F. (Figure 12C) HeLa cells were transfected with control siRNA (-), RNF4 siRNA alone, or RNF4 siRNA and siRNA-resistant RNF4. Cell lysates were analyzed by Western blot. (Figure 12D) FLAG-Atxn1 82Q was expressed in HeLa cells pretreated with control siRNA and the indicated RNF4 siRNA. FLAG-Atxn1 82Q was isolated by d-IP using anti-FLAG M2 beads. WCL and IP products were analyzed by Western blot using the indicated antibodies. (Figure 12E) HeLa cells expressing both Atxn 82Q-GFP and FLAG-RNF4 were treated with vehicle (DMSO) or MG132. Exogenous (Exo) RNF4 was detected using an anti-FLAG antibody. In control cells treated with DMSO, exogenous RNF4 showed partial colocalization with Atxn1 82Q-GFP aggregates. Upon treatment with MG132, complete colocalization of exogenous RNF4 and Atxn1 82Q aggregates was observed in 100% of cells. Scale bar: 10 μm. (Figure 12F) Western blot analysis of HeLa cells transfected with GFP-TDP-43 alone or together with increasing amounts of RNF4. (Figure 12G) GFP-TDP-43 was expressed in cells pretreated with control siRNA (-) or the indicated RNF4 siRNA. Five hundred cells were counted in each experiment. The percentage of cells with GFP-TDP-43 foci is shown. (Figure 12H) HeLa cells treated with RNF4 siRNA were transfected with GFP-TDP-43.Cells were stained with anti-RNF4 antibody (red) and DAPI (blue). Note that TDP-43 formed aggregates in cells where RNF4 was knocked down (filled arrowheads) but was diffuse in control cells (open arrowheads) (Figure 12I). HeLa cells were transfected with GFP-TDP-43 and treated with MG132. Endogenous RNF4 was stained with anti-RNF4 antibody (red). Note that RNF4 also formed nuclear foci in cells that lacked any TDP-43 (Figures 12E–H). [Figure 13A]Figure 13, including Figures 13A to 13F, shows the results of an example experiment demonstrating that SUMO2 / 3 is involved in RNF4-mediated degradation of Atxn1 82Q. (Figure 13A) Atxn1 82Q-GFP and / or RNF4 were expressed in HeLa cells pretreated with control siRNA, SUMO2 / 3 siRNA, and SUMO1 siRNA. Cell lysates were analyzed by Western blot. (Figure 13B) U2OS cells stably expressing GFP-SUMO2 were first transfected with the indicated RNF4 siRNA or control siRNA (-), followed by FLAG-Atxn1 82Q. The percentage of transfected cells containing GFP-SUMO2-positive Atxn1 82Q aggregates is shown (mean + standard deviation, n = 3). 200 cells were counted in each experiment. Representative images of transfected cells are shown on the right. GFP-SUMO2 does not form aggregated structures in cells without Atxn1 82Q expression. (Figure 13C) Diagram of wild-type and mutant RNF4 proteins. SUMO-interacting motifs (SIM) 1-4 and the RING domain are indicated. *: Point mutations are described elsewhere herein. (Figures 13D and 13E) Purified recombinant GST fusions of rat (r) RNF4 and RNF4 CS1 (Figure 13D) or human RNF4 and RNF4 SIMm (Figure 13E) were incubated with ubiquitin E1, E2 (UbcH5a), and ubiquitin (Ub) and Mg2+-ATP as indicated. The reaction mixtures were analyzed by Western blot using an anti-GST antibody. (Figure 13F) Expression of Atxn1 82Q-GFP in cells treated with the indicated combinations of control, PML, and RNF4 siRNA as indicated. Cell lysates were analyzed by Western blot. [Figure 13B]Figure 13, including Figures 13A to 13F, shows the results of an example experiment demonstrating that SUMO2 / 3 is involved in RNF4-mediated degradation of Atxn1 82Q. (Figure 13A) Atxn1 82Q-GFP and / or RNF4 were expressed in HeLa cells pretreated with control siRNA, SUMO2 / 3 siRNA, and SUMO1 siRNA. Cell lysates were analyzed by Western blot. (Figure 13B) U2OS cells stably expressing GFP-SUMO2 were first transfected with the indicated RNF4 siRNA or control siRNA (-), followed by FLAG-Atxn1 82Q. The percentage of transfected cells containing GFP-SUMO2-positive Atxn1 82Q aggregates is shown (mean + standard deviation, n = 3). 200 cells were counted in each experiment. Representative images of transfected cells are shown on the right. GFP-SUMO2 does not form aggregated structures in cells without Atxn1 82Q expression. (Figure 13C) Diagram of wild-type and mutant RNF4 proteins. SUMO-interacting motifs (SIM) 1-4 and the RING domain are indicated. *: Point mutations are described elsewhere herein. (Figures 13D and 13E) Purified recombinant GST fusions of rat (r) RNF4 and RNF4 CS1 (Figure 13D) or human RNF4 and RNF4 SIMm (Figure 13E) were incubated with ubiquitin E1, E2 (UbcH5a), and ubiquitin (Ub) and Mg2+-ATP as indicated. The reaction mixtures were analyzed by Western blot using an anti-GST antibody. (Figure 13F) Expression of Atxn1 82Q-GFP in cells treated with the indicated combinations of control, PML, and RNF4 siRNA as indicated. Cell lysates were analyzed by Western blot. [Figure 13C]Figure 13, including Figures 13A to 13F, shows the results of an example experiment demonstrating that SUMO2 / 3 is involved in RNF4-mediated degradation of Atxn1 82Q. (Figure 13A) Atxn1 82Q-GFP and / or RNF4 were expressed in HeLa cells pretreated with control siRNA, SUMO2 / 3 siRNA, and SUMO1 siRNA. Cell lysates were analyzed by Western blot. (Figure 13B) U2OS cells stably expressing GFP-SUMO2 were first transfected with the indicated RNF4 siRNA or control siRNA (-), followed by FLAG-Atxn1 82Q. The percentage of transfected cells containing GFP-SUMO2-positive Atxn1 82Q aggregates is shown (mean + standard deviation, n = 3). 200 cells were counted in each experiment. Representative images of transfected cells are shown on the right. GFP-SUMO2 does not form aggregated structures in cells without Atxn1 82Q expression. (Figure 13C) Diagram of wild-type and mutant RNF4 proteins. SUMO-interacting motifs (SIM) 1-4 and the RING domain are indicated. *: Point mutations are described elsewhere herein. (Figures 13D and 13E) Purified recombinant GST fusions of rat (r) RNF4 and RNF4 CS1 (Figure 13D) or human RNF4 and RNF4 SIMm (Figure 13E) were incubated with ubiquitin E1, E2 (UbcH5a), and ubiquitin (Ub) and Mg2+-ATP as indicated. The reaction mixtures were analyzed by Western blot using an anti-GST antibody. (Figure 13F) Expression of Atxn1 82Q-GFP in cells treated with the indicated combinations of control, PML, and RNF4 siRNA as indicated. Cell lysates were analyzed by Western blot. [Figure 13D]Figure 13, including Figures 13A to 13F, shows the results of an example experiment demonstrating that SUMO2 / 3 is involved in RNF4-mediated degradation of Atxn1 82Q. (Figure 13A) Atxn1 82Q-GFP and / or RNF4 were expressed in HeLa cells pretreated with control siRNA, SUMO2 / 3 siRNA, and SUMO1 siRNA. Cell lysates were analyzed by Western blot. (Figure 13B) U2OS cells stably expressing GFP-SUMO2 were first transfected with the indicated RNF4 siRNA or control siRNA (-), followed by FLAG-Atxn1 82Q. The percentage of transfected cells containing GFP-SUMO2-positive Atxn1 82Q aggregates is shown (mean + standard deviation, n = 3). 200 cells were counted in each experiment. Representative images of transfected cells are shown on the right. GFP-SUMO2 does not form aggregated structures in cells without Atxn1 82Q expression. (Figure 13C) Diagram of wild-type and mutant RNF4 proteins. SUMO-interacting motifs (SIM) 1-4 and the RING domain are indicated. *: Point mutations are described elsewhere herein. (Figures 13D and 13E) Purified recombinant GST fusions of rat (r) RNF4 and RNF4 CS1 (Figure 13D) or human RNF4 and RNF4 SIMm (Figure 13E) were incubated with ubiquitin E1, E2 (UbcH5a), and ubiquitin (Ub) and Mg2+-ATP as indicated. The reaction mixtures were analyzed by Western blot using an anti-GST antibody. (Figure 13F) Expression of Atxn1 82Q-GFP in cells treated with the indicated combinations of control, PML, and RNF4 siRNA as indicated. Cell lysates were analyzed by Western blot. [Figure 13E]Figure 13, including Figures 13A to 13F, shows the results of an example experiment demonstrating that SUMO2 / 3 is involved in RNF4-mediated degradation of Atxn1 82Q. (Figure 13A) Atxn1 82Q-GFP and / or RNF4 were expressed in HeLa cells pretreated with control siRNA, SUMO2 / 3 siRNA, and SUMO1 siRNA. Cell lysates were analyzed by Western blot. (Figure 13B) U2OS cells stably expressing GFP-SUMO2 were first transfected with the indicated RNF4 siRNA or control siRNA (-), followed by FLAG-Atxn1 82Q. The percentage of transfected cells containing GFP-SUMO2-positive Atxn1 82Q aggregates is shown (mean + standard deviation, n = 3). 200 cells were counted in each experiment. Representative images of transfected cells are shown on the right. GFP-SUMO2 does not form aggregated structures in cells without Atxn1 82Q expression. (Figure 13C) Diagram of wild-type and mutant RNF4 proteins. SUMO-interacting motifs (SIM) 1-4 and the RING domain are indicated. *: Point mutations are described elsewhere herein. (Figures 13D and 13E) Purified recombinant GST fusions of rat (r) RNF4 and RNF4 CS1 (Figure 13D) or human RNF4 and RNF4 SIMm (Figure 13E) were incubated with ubiquitin E1, E2 (UbcH5a), and ubiquitin (Ub) and Mg2+-ATP as indicated. The reaction mixtures were analyzed by Western blot using an anti-GST antibody. (Figure 13F) Expression of Atxn1 82Q-GFP in cells treated with the indicated combinations of control, PML, and RNF4 siRNA as indicated. Cell lysates were analyzed by Western blot. [Figure 13F]Figure 13, including Figures 13A to 13F, shows the results of an example experiment demonstrating that SUMO2 / 3 is involved in RNF4-mediated degradation of Atxn1 82Q. (Figure 13A) Atxn1 82Q-GFP and / or RNF4 were expressed in HeLa cells pretreated with control siRNA, SUMO2 / 3 siRNA, and SUMO1 siRNA. Cell lysates were analyzed by Western blot. (Figure 13B) U2OS cells stably expressing GFP-SUMO2 were first transfected with the indicated RNF4 siRNA or control siRNA (-), followed by FLAG-Atxn1 82Q. The percentage of transfected cells containing GFP-SUMO2-positive Atxn1 82Q aggregates is shown (mean + standard deviation, n = 3). 200 cells were counted in each experiment. Representative images of transfected cells are shown on the right. GFP-SUMO2 does not form aggregated structures in cells without Atxn1 82Q expression. (Figure 13C) Diagram of wild-type and mutant RNF4 proteins. SUMO-interacting motifs (SIM) 1-4 and the RING domain are indicated. *: Point mutations are described elsewhere herein. (Figures 13D and 13E) Purified recombinant GST fusions of rat (r) RNF4 and RNF4 CS1 (Figure 13D) or human RNF4 and RNF4 SIMm (Figure 13E) were incubated with ubiquitin E1, E2 (UbcH5a), and ubiquitin (Ub) and Mg2+-ATP as indicated. The reaction mixtures were analyzed by Western blot using an anti-GST antibody. (Figure 13F) Expression of Atxn1 82Q-GFP in cells treated with the indicated combinations of control, PML, and RNF4 siRNA as indicated. Cell lysates were analyzed by Western blot. [Figure 14A]Figure 14, including Figures 14A to 14D, shows the results of experiments demonstrating that PML deficiency reduces Purkinje cell dendritic branching but does not result in intracellular aggregation in Purkinje cells. (Figure 14A) Midsagittal cerebellar sections from 12-week-old mice were stained with an antibody against the Purkinje cell-specific protein calbindin. Fluorescence intensity of a rectangular area from the premountal fissure was plotted (n = 2 mice for PML+ / +, n = 3 mice for all other genotypes). PML- / - mice showed significantly reduced dendritic branching compared with PML+ / + mice (ANOVA, p = 0.031). (Figure 14B) Representative calbindin immunofluorescence confocal image. Scale bar: 100 μm. (Fig. 14C) Quantification of Purkinje cell density in 12-week-old PML+ / +, PML+ / -, and PML- / - mice with and without Atxn1tg / -, graphed as the average number of somata per mm of length (mean + standard error, 3 mice per genotype). (Fig. 14D) Immunohistochemical staining of cerebellar cortex sections from 12-week-old PML+ / + and PML- / - mice without Atxn1tg / -. Sections were stained with an anti-ubiquitin antibody and counterstained with hematoxylin. Scale bar: 50 μm. Note that no ubiquitin-positive aggregates were detected in these sections. Stained sections from PML+ / +:Atxn1tg / - and PML- / -:Atxn1tg / - mice are shown in Fig. 7G. [Figure 14B]Figure 14, including Figures 14A to 14D, shows the results of experiments demonstrating that PML deficiency reduces Purkinje cell dendritic branching but does not result in intracellular aggregation in Purkinje cells. (Figure 14A) Midsagittal cerebellar sections from 12-week-old mice were stained with an antibody against the Purkinje cell-specific protein calbindin. Fluorescence intensity of a rectangular area from the premountal fissure was plotted (n = 2 mice for PML+ / +, n = 3 mice for all other genotypes). PML- / - mice showed significantly reduced dendritic branching compared with PML+ / + mice (ANOVA, p = 0.031). (Figure 14B) Representative calbindin immunofluorescence confocal image. Scale bar: 100 μm. (Fig. 14C) Quantification of Purkinje cell density in 12-week-old PML+ / +, PML+ / -, and PML- / - mice with and without Atxn1tg / -, graphed as the average number of somata per mm of length (mean + standard error, 3 mice per genotype). (Fig. 14D) Immunohistochemical staining of cerebellar cortex sections from 12-week-old PML+ / + and PML- / - mice without Atxn1tg / -. Sections were stained with an anti-ubiquitin antibody and counterstained with hematoxylin. Scale bar: 50 μm. Note that no ubiquitin-positive aggregates were detected in these sections. Stained sections from PML+ / +:Atxn1tg / - and PML- / -:Atxn1tg / - mice are shown in Fig. 7G. [Figure 14C]Figure 14, including Figures 14A to 14D, shows the results of experiments demonstrating that PML deficiency reduces Purkinje cell dendritic branching but does not result in intracellular aggregation in Purkinje cells. (Figure 14A) Midsagittal cerebellar sections from 12-week-old mice were stained with an antibody against the Purkinje cell-specific protein calbindin. Fluorescence intensity of a rectangular area from the premountal fissure was plotted (n = 2 mice for PML+ / +, n = 3 mice for all other genotypes). PML- / - mice showed significantly reduced dendritic branching compared with PML+ / + mice (ANOVA, p = 0.031). (Figure 14B) Representative calbindin immunofluorescence confocal image. Scale bar: 100 μm. (Fig. 14C) Quantification of Purkinje cell density in 12-week-old PML+ / +, PML+ / -, and PML- / - mice with and without Atxn1tg / -, graphed as the average number of somata per mm of length (mean + standard error, 3 mice per genotype). (Fig. 14D) Immunohistochemical staining of cerebellar cortex sections from 12-week-old PML+ / + and PML- / - mice without Atxn1tg / -. Sections were stained with an anti-ubiquitin antibody and counterstained with hematoxylin. Scale bar: 50 μm. Note that no ubiquitin-positive aggregates were detected in these sections. Stained sections from PML+ / +:Atxn1tg / - and PML- / -:Atxn1tg / - mice are shown in Fig. 7G. [Figure 14D]Figure 14, including Figures 14A to 14D, shows the results of experiments demonstrating that PML deficiency reduces Purkinje cell dendritic branching but does not result in intracellular aggregation in Purkinje cells. (Figure 14A) Midsagittal cerebellar sections from 12-week-old mice were stained with an antibody against the Purkinje cell-specific protein calbindin. Fluorescence intensity of a rectangular area from the premountal fissure was plotted (n = 2 mice for PML+ / +, n = 3 mice for all other genotypes). PML- / - mice showed significantly reduced dendritic branching compared with PML+ / + mice (ANOVA, p = 0.031). (Figure 14B) Representative calbindin immunofluorescence confocal image. Scale bar: 100 μm. (Fig. 14C) Quantification of Purkinje cell density in 12-week-old PML+ / +, PML+ / -, and PML- / - mice with and without Atxn1tg / -, graphed as the average number of somata per mm of length (mean + standard error, 3 mice per genotype). (Fig. 14D) Immunohistochemical staining of cerebellar cortex sections from 12-week-old PML+ / + and PML- / - mice without Atxn1tg / -. Sections were stained with an anti-ubiquitin antibody and counterstained with hematoxylin. Scale bar: 50 μm. Note that no ubiquitin-positive aggregates were detected in these sections. Stained sections from PML+ / +:Atxn1tg / - and PML- / -:Atxn1tg / - mice are shown in Fig. 7G. [Figure 15A]Figure 15, including Figures 15A to 15D, shows the results of example experiments demonstrating colocalization of TRIM27, TRIM32, and TRIM5δ with EGFP-Atxn1 82Q and Httex1p 97QP. (Figure 15A) Atxn1 82Q-GFP was expressed in HeLa cells together with the indicated FLAG-tagged TRIM proteins. Cells were stained with anti-FLAG antibody (red) and DAPI (blue). Scale bar: 10 μm. (Figures 15B and 15C) Httex1p 97QP was expressed in HeLa cells together with FLAG-tagged TRIM5δ, TRIM27 (Figure 15B), and TRIM32 (Figure 15C). Cells were immunostained with anti-huntingtin antibody (green) and anti-FLAG antibody (red). Note that TRIM32 colocalized with Httex1p 97QP, despite the subcellular localization of Httex1p 97QP. (FIG. 15D) HeLa cells were transfected with Atxn1 82QP-GFP. Endogenous TRIM27 was detected with an anti-TRIM27 antibody (red). Arrowheads indicate endogenous TRIM27 structures that colocalized with Atxn1 82Q aggregates. Scale bar: 10 μm. [Figure 15B]Figure 15, including Figures 15A to 15D, shows the results of example experiments demonstrating colocalization of TRIM27, TRIM32, and TRIM5δ with EGFP-Atxn1 82Q and Httex1p 97QP. (Figure 15A) Atxn1 82Q-GFP was expressed in HeLa cells together with the indicated FLAG-tagged TRIM proteins. Cells were stained with anti-FLAG antibody (red) and DAPI (blue). Scale bar: 10 μm. (Figures 15B and 15C) Httex1p 97QP was expressed in HeLa cells together with FLAG-tagged TRIM5δ, TRIM27 (Figure 15B), and TRIM32 (Figure 15C). Cells were immunostained with anti-huntingtin antibody (green) and anti-FLAG antibody (red). Note that TRIM32 colocalized with Httex1p 97QP, despite the subcellular localization of Httex1p 97QP. (FIG. 15D) HeLa cells were transfected with Atxn1 82QP-GFP. Endogenous TRIM27 was detected with an anti-TRIM27 antibody (red). Arrowheads indicate endogenous TRIM27 structures that colocalized with Atxn1 82Q aggregates. Scale bar: 10 μm. [Figure 15C]Figure 15, including Figures 15A to 15D, shows the results of example experiments demonstrating colocalization of TRIM27, TRIM32, and TRIM5δ with EGFP-Atxn1 82Q and Httex1p 97QP. (Figure 15A) Atxn1 82Q-GFP was expressed in HeLa cells together with the indicated FLAG-tagged TRIM proteins. Cells were stained with anti-FLAG antibody (red) and DAPI (blue). Scale bar: 10 μm. (Figures 15B and 15C) Httex1p 97QP was expressed in HeLa cells together with FLAG-tagged TRIM5δ, TRIM27 (Figure 15B), and TRIM32 (Figure 15C). Cells were immunostained with anti-huntingtin antibody (green) and anti-FLAG antibody (red). Note that TRIM32 colocalized with Httex1p 97QP, despite the subcellular localization of Httex1p 97QP. (FIG. 15D) HeLa cells were transfected with Atxn1 82QP-GFP. Endogenous TRIM27 was detected with an anti-TRIM27 antibody (red). Arrowheads indicate endogenous TRIM27 structures that colocalized with Atxn1 82Q aggregates. Scale bar: 10 μm. [Figure 15D]Figure 15, including Figures 15A to 15D, shows the results of example experiments demonstrating colocalization of TRIM27, TRIM32, and TRIM5δ with EGFP-Atxn1 82Q and Httex1p 97QP. (Figure 15A) Atxn1 82Q-GFP was expressed in HeLa cells together with the indicated FLAG-tagged TRIM proteins. Cells were stained with anti-FLAG antibody (red) and DAPI (blue). Scale bar: 10 μm. (Figures 15B and 15C) Httex1p 97QP was expressed in HeLa cells together with FLAG-tagged TRIM5δ, TRIM27 (Figure 15B), and TRIM32 (Figure 15C). Cells were immunostained with anti-huntingtin antibody (green) and anti-FLAG antibody (red). Note that TRIM32 colocalized with Httex1p 97QP, despite the subcellular localization of Httex1p 97QP. (FIG. 15D) HeLa cells were transfected with Atxn1 82QP-GFP. Endogenous TRIM27 was detected with an anti-TRIM27 antibody (red). Arrowheads indicate endogenous TRIM27 structures that colocalized with Atxn1 82Q aggregates. Scale bar: 10 μm. [Figure 16A] Figure 16, including Figures 16A to 16D, shows the results of example experiments demonstrating the reduction of aggregated Atxn1 82Q by TRIM27, TRIM32, and TRIM5δ. (Figures 16A and 16B) Levels of Atxn1 82Q-GFP expressed alone (-) or together with the indicated FLAG-tagged TRIM proteins in HeLa cells. Cell lysates were analyzed by Western blot. The left panel of Figure 16A shows the ratio of Atxn1 82Q in the SS fraction to actin, and TRIM11 expression can be detected after prolonged exposure. (Figure 16C) Expression levels of Atxn1 82Q in HeLa cells treated with control (-) or TRIM27 siRNA. *, nonspecific band. (Figure 16D) PIASy does not inhibit Atxn1 82Q protein levels. Western blot analysis of HeLa cells transfected with Atxn1 82Q-GFP, PIASy, and PML as indicated. [Figure 16B] Figure 16, including Figures 16A to 16D, shows the results of example experiments demonstrating the reduction of aggregated Atxn1 82Q by TRIM27, TRIM32, and TRIM5δ. (Figures 16A and 16B) Levels of Atxn1 82Q-GFP expressed alone (-) or together with the indicated FLAG-tagged TRIM proteins in HeLa cells. Cell lysates were analyzed by Western blot. The left panel of Figure 16A shows the ratio of Atxn1 82Q in the SS fraction to actin, and TRIM11 expression can be detected after prolonged exposure. (Figure 16C) Expression levels of Atxn1 82Q in HeLa cells treated with control (-) or TRIM27 siRNA. *, nonspecific band. (Figure 16D) PIASy does not inhibit Atxn1 82Q protein levels. Western blot analysis of HeLa cells transfected with Atxn1 82Q-GFP, PIASy, and PML as indicated. [Figure 16C] Figure 16, including Figures 16A to 16D, shows the results of example experiments demonstrating the reduction of aggregated Atxn1 82Q by TRIM27, TRIM32, and TRIM5δ. (Figures 16A and 16B) Levels of Atxn1 82Q-GFP expressed alone (-) or together with the indicated FLAG-tagged TRIM proteins in HeLa cells. Cell lysates were analyzed by Western blot. The left panel of Figure 16A shows the ratio of Atxn1 82Q in the SS fraction to actin, and TRIM11 expression can be detected after prolonged exposure. (Figure 16C) Expression levels of Atxn1 82Q in HeLa cells treated with control (-) or TRIM27 siRNA. *, nonspecific band. (Figure 16D) PIASy does not inhibit Atxn1 82Q protein levels. Western blot analysis of HeLa cells transfected with Atxn1 82Q-GFP, PIASy, and PML as indicated. [Figure 16D]Figure 16, including Figures 16A to 16D, shows the results of example experiments demonstrating the reduction of aggregated Atxn1 82Q by TRIM27, TRIM32, and TRIM5δ. (Figures 16A and 16B) Levels of Atxn1 82Q-GFP expressed alone (-) or together with the indicated FLAG-tagged TRIM proteins in HeLa cells. Cell lysates were analyzed by Western blot. The left panel of Figure 16A shows the ratio of Atxn1 82Q in the SS fraction to actin, and TRIM11 expression can be detected after prolonged exposure. (Figure 16C) Expression levels of Atxn1 82Q in HeLa cells treated with control (-) or TRIM27 siRNA. *, nonspecific band. (Figure 16D) PIASy does not inhibit Atxn1 82Q protein levels. Western blot analysis of HeLa cells transfected with Atxn1 82Q-GFP, PIASy, and PML as indicated. [Figure 17A] Figure 17, including Figures 17A to 17C, shows the results of an example experiment demonstrating that TRIM27 and TRIM32 reduced aggregated Atxn1 82Q independently of PML. (Figure 17A) Partial colocalization of TRIM27 and PML. HeLa cells transfected with FLAG-TRIM27 were immunostained with anti-FLAG antibody (green) and anti-PML antibody (red). (Figure 17B) Colocalization of TRIM27 and Atxn1 82Q-GFP aggregates in PML+ / + and PML- / - MEFs. FLAG-TRIM27 was stained with anti-FLAG antibody (red). (Figure 17C) Atxn1 82Q-GFP was expressed alone or together with the indicated TRIM proteins in PML+ / + and PML- / - MEFs. Extracts were analyzed by filter phase contrast assay. A brighter exposure is shown in the right panel to better compare the effect of TRIM proteins on aggregates. [Figure 17B]Figure 17, including Figures 17A to 17C, shows the results of an example experiment demonstrating that TRIM27 and TRIM32 reduced aggregated Atxn1 82Q independently of PML. (Figure 17A) Partial colocalization of TRIM27 and PML. HeLa cells transfected with FLAG-TRIM27 were immunostained with anti-FLAG antibody (green) and anti-PML antibody (red). (Figure 17B) Colocalization of TRIM27 and Atxn1 82Q-GFP aggregates in PML+ / + and PML- / - MEFs. FLAG-TRIM27 was stained with anti-FLAG antibody (red). (Figure 17C) Atxn1 82Q-GFP was expressed alone or together with the indicated TRIM proteins in PML+ / + and PML- / - MEFs. Extracts were analyzed by filter phase contrast assay. A brighter exposure is shown in the right panel to better compare the effect of TRIM proteins on aggregates. [Figure 17C] Figure 17, including Figures 17A to 17C, shows the results of an example experiment demonstrating that TRIM27 and TRIM32 reduced aggregated Atxn1 82Q independently of PML. (Figure 17A) Partial colocalization of TRIM27 and PML. HeLa cells transfected with FLAG-TRIM27 were immunostained with anti-FLAG antibody (green) and anti-PML antibody (red). (Figure 17B) Colocalization of TRIM27 and Atxn1 82Q-GFP aggregates in PML+ / + and PML- / - MEFs. FLAG-TRIM27 was stained with anti-FLAG antibody (red). (Figure 17C) Atxn1 82Q-GFP was expressed alone or together with the indicated TRIM proteins in PML+ / + and PML- / - MEFs. Extracts were analyzed by filter phase contrast assay. A brighter exposure is shown in the right panel to better compare the effect of TRIM proteins on aggregates. [Figure 18A]Figure 18, including Figures 18A to 18G, shows the results of example experiments demonstrating that TRIM proteins depend on SUMO2 / 3 and the proteasome to remove insoluble Atxn1 82Q. (Figures 18A-18F) Atxn1 82Q-GFP was expressed alone or together with TRIM5δ, TRIM27, and TRIM32 in cells treated without or with MG132 (Figures 18A-18C), or in control or SUMO2 / 3 knockdown cells (Figures 18D-18F). Cell lysates were analyzed by Western blot. (Figure 18G) SUMOylation of purified HA-Atxn1 82Q-FLAG was performed in the presence of recombinant FLAG-TRIM11 and SUMO2 as indicated. HA-Atxn1 82Q-FLAG was isolated using denaturing immunoprecipitation. Reaction mixtures and IP samples were analyzed by Western blot. [Figure 18B] Figure 18, including Figures 18A to 18G, shows the results of example experiments demonstrating that TRIM proteins depend on SUMO2 / 3 and the proteasome to remove insoluble Atxn1 82Q. (Figures 18A-18F) Atxn1 82Q-GFP was expressed alone or together with TRIM5δ, TRIM27, and TRIM32 in cells treated without or with MG132 (Figures 18A-18C), or in control or SUMO2 / 3 knockdown cells (Figures 18D-18F). Cell lysates were analyzed by Western blot. (Figure 18G) SUMOylation of purified HA-Atxn1 82Q-FLAG was performed in the presence of recombinant FLAG-TRIM11 and SUMO2 as indicated. HA-Atxn1 82Q-FLAG was isolated using denaturing immunoprecipitation. Reaction mixtures and IP samples were analyzed by Western blot. [Figure 18C]Figure 18, including Figures 18A to 18G, shows the results of example experiments demonstrating that TRIM proteins depend on SUMO2 / 3 and the proteasome to remove insoluble Atxn1 82Q. (Figures 18A-18F) Atxn1 82Q-GFP was expressed alone or together with TRIM5δ, TRIM27, and TRIM32 in cells treated without or with MG132 (Figures 18A-18C), or in control or SUMO2 / 3 knockdown cells (Figures 18D-18F). Cell lysates were analyzed by Western blot. (Figure 18G) SUMOylation of purified HA-Atxn1 82Q-FLAG was performed in the presence of recombinant FLAG-TRIM11 and SUMO2 as indicated. HA-Atxn1 82Q-FLAG was isolated using denaturing immunoprecipitation. Reaction mixtures and IP samples were analyzed by Western blot. [Figure 18D] Figure 18, including Figures 18A to 18G, shows the results of example experiments demonstrating that TRIM proteins depend on SUMO2 / 3 and the proteasome to remove insoluble Atxn1 82Q. (Figures 18A-18F) Atxn1 82Q-GFP was expressed alone or together with TRIM5δ, TRIM27, and TRIM32 in cells treated without or with MG132 (Figures 18A-18C), or in control or SUMO2 / 3 knockdown cells (Figures 18D-18F). Cell lysates were analyzed by Western blot. (Figure 18G) SUMOylation of purified HA-Atxn1 82Q-FLAG was performed in the presence of recombinant FLAG-TRIM11 and SUMO2 as indicated. HA-Atxn1 82Q-FLAG was isolated using denaturing immunoprecipitation. Reaction mixtures and IP samples were analyzed by Western blot. [Figure 18E]Figure 18, including Figures 18A to 18G, shows the results of example experiments demonstrating that TRIM proteins depend on SUMO2 / 3 and the proteasome to remove insoluble Atxn1 82Q. (Figures 18A-18F) Atxn1 82Q-GFP was expressed alone or together with TRIM5δ, TRIM27, and TRIM32 in cells treated without or with MG132 (Figures 18A-18C), or in control or SUMO2 / 3 knockdown cells (Figures 18D-18F). Cell lysates were analyzed by Western blot. (Figure 18G) SUMOylation of purified HA-Atxn1 82Q-FLAG was performed in the presence of recombinant FLAG-TRIM11 and SUMO2 as indicated. HA-Atxn1 82Q-FLAG was isolated using denaturing immunoprecipitation. Reaction mixtures and IP samples were analyzed by Western blot. [Figure 18F] Figure 18, including Figures 18A to 18G, shows the results of example experiments demonstrating that TRIM proteins depend on SUMO2 / 3 and the proteasome to remove insoluble Atxn1 82Q. (Figures 18A-18F) Atxn1 82Q-GFP was expressed alone or together with TRIM5δ, TRIM27, and TRIM32 in cells treated without or with MG132 (Figures 18A-18C), or in control or SUMO2 / 3 knockdown cells (Figures 18D-18F). Cell lysates were analyzed by Western blot. (Figure 18G) SUMOylation of purified HA-Atxn1 82Q-FLAG was performed in the presence of recombinant FLAG-TRIM11 and SUMO2 as indicated. HA-Atxn1 82Q-FLAG was isolated using denaturing immunoprecipitation. Reaction mixtures and IP samples were analyzed by Western blot. [Figure 18G]Figure 18, including Figures 18A to 18G, shows the results of example experiments demonstrating that TRIM proteins depend on SUMO2 / 3 and the proteasome to remove insoluble Atxn1 82Q. (Figures 18A-18F) Atxn1 82Q-GFP was expressed alone or together with TRIM5δ, TRIM27, and TRIM32 in cells treated without or with MG132 (Figures 18A-18C), or in control or SUMO2 / 3 knockdown cells (Figures 18D-18F). Cell lysates were analyzed by Western blot. (Figure 18G) SUMOylation of purified HA-Atxn1 82Q-FLAG was performed in the presence of recombinant FLAG-TRIM11 and SUMO2 as indicated. HA-Atxn1 82Q-FLAG was isolated using denaturing immunoprecipitation. Reaction mixtures and IP samples were analyzed by Western blot. [Figure 19A] Figure 19, including Figures 19A to 19F, shows the results of an example experiment demonstrating the localization of TRIM proteins relative to Atxn1 82Q. Atxn1 82Q-GFP (green) was expressed in HeLa cells together with the indicated HA-tagged TRIM proteins. Cells were immunostained with an anti-HA antibody (red). Representative localization patterns for each TRIM protein are shown. (Figure 19A) Representative localization patterns for TRIM1 to TRIM16. (Figure 19B) Representative localization patterns for TRIM17 to TRIM32. (Figure 19C) Representative localization patterns for TRIM33 to TRIM41 and TRIM44 to TRIM41. (Figure 19D) Representative localization patterns for TRIM52, TRIM54 to TRIM58, TRIM62 to TRIM66, TRIM73 to TRIM74, and TRIM76. TRIM proteins, which colocalized with Atxn1 82Q-GFP in a significant number of cells, are shown in yellow. Scale bar: 10 μm. [Figure 19B]Figure 19, including Figures 19A to 19F, shows the results of an example experiment demonstrating the localization of TRIM proteins relative to Atxn1 82Q. Atxn1 82Q-GFP (green) was expressed in HeLa cells together with the indicated HA-tagged TRIM proteins. Cells were immunostained with an anti-HA antibody (red). Representative localization patterns for each TRIM protein are shown. (Figure 19A) Representative localization patterns for TRIM1 to TRIM16. (Figure 19B) Representative localization patterns for TRIM17 to TRIM32. (Figure 19C) Representative localization patterns for TRIM33 to TRIM41 and TRIM44 to TRIM41. (Figure 19D) Representative localization patterns for TRIM52, TRIM54 to TRIM58, TRIM62 to TRIM66, TRIM73 to TRIM74, and TRIM76. TRIM proteins, which colocalized with Atxn1 82Q-GFP in a significant number of cells, are shown in yellow. Scale bar: 10 μm. [Figure 19C] Figure 19, including Figures 19A to 19F, shows the results of an example experiment demonstrating the localization of TRIM proteins relative to Atxn1 82Q. Atxn1 82Q-GFP (green) was expressed in HeLa cells together with the indicated HA-tagged TRIM proteins. Cells were immunostained with an anti-HA antibody (red). Representative localization patterns for each TRIM protein are shown. (Figure 19A) Representative localization patterns for TRIM1 to TRIM16. (Figure 19B) Representative localization patterns for TRIM17 to TRIM32. (Figure 19C) Representative localization patterns for TRIM33 to TRIM41 and TRIM44 to TRIM41. (Figure 19D) Representative localization patterns for TRIM52, TRIM54 to TRIM58, TRIM62 to TRIM66, TRIM73 to TRIM74, and TRIM76. TRIM proteins, which colocalized with Atxn1 82Q-GFP in a significant number of cells, are shown in yellow. Scale bar: 10 μm. [Figure 19D]Figure 19, including Figures 19A to 19F, shows the results of an example experiment demonstrating the localization of TRIM proteins relative to Atxn1 82Q. Atxn1 82Q-GFP (green) was expressed in HeLa cells together with the indicated HA-tagged TRIM proteins. Cells were immunostained with an anti-HA antibody (red). Representative localization patterns for each TRIM protein are shown. (Figure 19A) Representative localization patterns for TRIM1 to TRIM16. (Figure 19B) Representative localization patterns for TRIM17 to TRIM32. (Figure 19C) Representative localization patterns for TRIM33 to TRIM41 and TRIM44 to TRIM41. (Figure 19D) Representative localization patterns for TRIM52, TRIM54 to TRIM58, TRIM62 to TRIM66, TRIM73 to TRIM74, and TRIM76. TRIM proteins, which colocalized with Atxn1 82Q-GFP in a significant number of cells, are shown in yellow. Scale bar: 10 μm. [Figure 19E] Figure 19, including Figures 19A to 19F, shows the results of an example experiment demonstrating the localization of TRIM proteins relative to Atxn1 82Q. Atxn1 82Q-GFP (green) was expressed in HeLa cells together with the indicated HA-tagged TRIM proteins. Cells were immunostained with an anti-HA antibody (red). Representative localization patterns for each TRIM protein are shown. (Figure 19A) Representative localization patterns for TRIM1 to TRIM16. (Figure 19B) Representative localization patterns for TRIM17 to TRIM32. (Figure 19C) Representative localization patterns for TRIM33 to TRIM41 and TRIM44 to TRIM41. (Figure 19D) Representative localization patterns for TRIM52, TRIM54 to TRIM58, TRIM62 to TRIM66, TRIM73 to TRIM74, and TRIM76. TRIM proteins, which colocalized with Atxn1 82Q-GFP in a significant number of cells, are shown in yellow. Scale bar: 10 μm. [Figure 19F]Figure 19, including Figures 19A to 19F, shows the results of an example experiment demonstrating the localization of TRIM proteins relative to Atxn1 82Q. Atxn1 82Q-GFP (green) was expressed in HeLa cells together with the indicated HA-tagged TRIM proteins. Cells were immunostained with an anti-HA antibody (red). Representative localization patterns for each TRIM protein are shown. (Figure 19A) Representative localization patterns for TRIM1 to TRIM16. (Figure 19B) Representative localization patterns for TRIM17 to TRIM32. (Figure 19C) Representative localization patterns for TRIM33 to TRIM41 and TRIM44 to TRIM41. (Figure 19D) Representative localization patterns for TRIM52, TRIM54 to TRIM58, TRIM62 to TRIM66, TRIM73 to TRIM74, and TRIM76. TRIM proteins, which colocalized with Atxn1 82Q-GFP in a significant number of cells, are shown in yellow. Scale bar: 10 μm. [Figure 20A] Figure 20, including Figures 20A and 20B, shows the results of a systematic analysis of TRIM proteins for Atxn1 82Q and Httex1p 97QP. Atxn1 82Q-GFP (Figure 20A) or Httex1p 97QP (Figure 20B) was coexpressed with the indicated TRIM proteins in HeLa cells. Cell lysates were analyzed by Western blot. The red- and green-labeled TRIM proteins decreased and increased the levels of polyQ proteins, respectively, whereas the black-labeled TRIM protein had no observable effect. Note that the effects of TRIM proteins may be affected by their expression levels, as described elsewhere herein. [Figure 20B]Figure 20, including Figures 20A and 20B, shows the results of a systematic analysis of TRIM proteins for Atxn1 82Q and Httex1p 97QP. Atxn1 82Q-GFP (Figure 20A) or Httex1p 97QP (Figure 20B) was coexpressed with the indicated TRIM proteins in HeLa cells. Cell lysates were analyzed by Western blot. The red- and green-labeled TRIM proteins decreased and increased the levels of polyQ proteins, respectively, whereas the black-labeled TRIM protein had no observable effect. Note that the effects of TRIM proteins may be affected by their expression levels, as described elsewhere herein. [Figure 21A] Figure 21, including Figures 21A to 21C, shows the results of an example experiment demonstrating that recombinant TAT-TRIM11 reduces the levels of misfolded proteins. HeLa cells were transfected with Atxn1 82Q-GFP, Atxn1 30Q, or Htt97Q-GFP and subsequently incubated with recombinant TRIM11 or SUMO2 protein. (Figure 21A) Treatment of HeLa cells with TRIM11 strongly reduced the levels of Atxn1 82Q. (Figure 21B) Treatment of HeLa cells with TRIM11 also strongly reduced the levels of Htt97Q. (Figure 21C) SUMO2 had only a minimal effect on the levels of Atxn1 82Q. [Figure 21B]Figure 21, including Figures 21A to 21C, shows the results of an example experiment demonstrating that recombinant TAT-TRIM11 reduces the levels of misfolded proteins. HeLa cells were transfected with Atxn1 82Q-GFP, Atxn1 30Q, or Htt97Q-GFP and subsequently incubated with recombinant TRIM11 or SUMO2 protein. (Figure 21A) Treatment of HeLa cells with TRIM11 strongly reduced the levels of Atxn1 82Q. (Figure 21B) Treatment of HeLa cells with TRIM11 also strongly reduced the levels of Htt97Q. (Figure 21C) SUMO2 had only a minimal effect on the levels of Atxn1 82Q. [Figure 21C] Figure 21, including Figures 21A to 21C, shows the results of an example experiment demonstrating that recombinant TAT-TRIM11 reduces the levels of misfolded proteins. HeLa cells were transfected with Atxn1 82Q-GFP, Atxn1 30Q, or Htt97Q-GFP and subsequently incubated with recombinant TRIM11 or SUMO2 protein. (Figure 21A) Treatment of HeLa cells with TRIM11 strongly reduced the levels of Atxn1 82Q. (Figure 21B) Treatment of HeLa cells with TRIM11 also strongly reduced the levels of Htt97Q. (Figure 21C) SUMO2 had only a minimal effect on the levels of Atxn1 82Q. [Figure 22] FIG. 22 shows the amino acid sequence of Tat-TRIM11 used in the experimental examples. [Figure 23] Figure 23, including Figures 23A to 23F, shows the results of experiments demonstrating staining of RNF4 in human brain samples. Immunostaining of Huntington's disease brain tissue with anti-RNF4 (green). RNF4 showed diffuse nuclear localization (Figures 23A-C) or formed foci (Figures 23D-F) (indicated by arrowheads). Scale bar: 10 μm. [Figure 24]Figure 24, including Figures 24A to 24H, shows the results of experiments demonstrating colocalization of RNF4 with intraneuronal inclusions in SCA1 patients. Immunostaining of SCA1 brain tissue with anti-polyQ antibody (1C2) and anti-RNF4 antibody. Scale bar: 10 μm. [Figure 25] Figure 25, including Figures 25A through 25L, shows the results of experiments demonstrating the colocalization of RNF4 with intraneuronal inclusions in SCA1 patients. Figure 25 shows immunostaining of HD brain tissue with anti-Htt, anti-ubiquitin, and two separate RNF4 antibodies. Note that Htt and ubiquitin form ring-shaped structures (Figures 25A through 25H) or uniformly distributed inclusions (Figures 25I through 25L) with the RNF4 signal in the center. [Figure 26] Figure 26, including Figures 26A to 26H, shows the results of experiments demonstrating the colocalization of RNF4 with inclusions in neurons of HD patients. Immunostaining of Htt and RNF4 in HD brain tissue is shown. Two different RNF4 antibodies (numbers 1 and 2) were used. Scale bar: 10 μm. [Figure 27A] Figure 27, comprising Figures 27A through 27D, shows the results of experiments demonstrating the sumoylation of Atxn1 82Q, p53, and α-synuclein. Figure 27A shows an experiment in which sumoylation of Atxn1 82Q was analyzed when coexpressed with TRIM11 WT, TRIM11 MUT, or PML. 10 μM MG132 was added for 4 hours before lysis. Figure 27B shows in vitro sumoylation of purified Atxn1 82Q incubated with TRIM11 WT or TRIM11 MUT in the presence of E1, E2, and SUMO2. Figure 27C shows in vitro sumoylation of purified Flag-p53 incubated with TRIM11 or PML in the presence of E1, E2, and SUMO2. FIG. 27D shows in vitro sumoylation of α-synuclein incubated with TRIM11 WT in the presence or absence of E1, E2 and SUMO2. [Figure 27B]Figure 27, comprising Figures 27A through 27D, shows the results of experiments demonstrating the sumoylation of Atxn1 82Q, p53, and α-synuclein. Figure 27A shows an experiment in which sumoylation of Atxn1 82Q was analyzed when coexpressed with TRIM11 WT, TRIM11 MUT, or PML. 10 μM MG132 was added for 4 hours before lysis. Figure 27B shows in vitro sumoylation of purified Atxn1 82Q incubated with TRIM11 WT or TRIM11 MUT in the presence of E1, E2, and SUMO2. Figure 27C shows in vitro sumoylation of purified Flag-p53 incubated with TRIM11 or PML in the presence of E1, E2, and SUMO2. FIG. 27D shows in vitro sumoylation of α-synuclein incubated with TRIM11 WT in the presence or absence of E1, E2 and SUMO2. [Figure 27C] Figure 27, comprising Figures 27A through 27D, shows the results of experiments demonstrating the sumoylation of Atxn1 82Q, p53, and α-synuclein. Figure 27A shows an experiment in which sumoylation of Atxn1 82Q was analyzed when coexpressed with TRIM11 WT, TRIM11 MUT, or PML. 10 μM MG132 was added for 4 hours before lysis. Figure 27B shows in vitro sumoylation of purified Atxn1 82Q incubated with TRIM11 WT or TRIM11 MUT in the presence of E1, E2, and SUMO2. Figure 27C shows in vitro sumoylation of purified Flag-p53 incubated with TRIM11 or PML in the presence of E1, E2, and SUMO2. FIG. 27D shows in vitro sumoylation of α-synuclein incubated with TRIM11 WT in the presence or absence of E1, E2 and SUMO2. [Figure 27D]Figure 27, comprising Figures 27A through 27D, shows the results of experiments demonstrating the sumoylation of Atxn1 82Q, p53, and α-synuclein. Figure 27A shows an experiment in which sumoylation of Atxn1 82Q was analyzed when coexpressed with TRIM11 WT, TRIM11 MUT, or PML. 10 μM MG132 was added for 4 hours before lysis. Figure 27B shows in vitro sumoylation of purified Atxn1 82Q incubated with TRIM11 WT or TRIM11 MUT in the presence of E1, E2, and SUMO2. Figure 27C shows in vitro sumoylation of purified Flag-p53 incubated with TRIM11 or PML in the presence of E1, E2, and SUMO2. FIG. 27D shows in vitro sumoylation of α-synuclein incubated with TRIM11 WT in the presence or absence of E1, E2 and SUMO2. [Figure 28A] Figure 28, which includes Figures 28A through 28G, shows the results of experiments demonstrating that TRIM11 is recruited to Atxn1 82Q aggregates. Figure 28A shows immunofluorescence analysis of GFP-Hsp70 transfected in 293T cells. Figure 28B shows immunofluorescence analysis of GFP-TRIM11 transfected in 293T cells. Figure 28C shows immunofluorescence analysis demonstrating that Hsp70 can be recruited to Atxn1 82Q aggregates. Figure 28D shows immunofluorescence analysis demonstrating that TRIM11 can be recruited to Atxn1 82Q aggregates. Figure 28E shows immunoblot analysis of detergent-soluble and insoluble fractions of cells transfected with Atxn1 82Q, TRIM11, or Hsp70. Where indicated, 10 μM MG132 was added for 3 hours. Figure 28F shows immunoblot analysis of detergent-soluble and insoluble fractions of cells transfected with Atxn1 82Q, TRIM11 WT (wild-type), or TRIM11 MUT (mutant). Where indicated, 10 μM MG132 was added for 3 hours. Figure 28G shows an immunoblot of HCT116 transfected with the indicated plasmids. After 48 hours, cells were lysed and then stained with 20 μM thioflavin-T (ThT). [Figure 28B] Figure 28, which includes Figures 28A through 28G, shows the results of experiments demonstrating that TRIM11 is recruited to Atxn1 82Q aggregates. Figure 28A shows immunofluorescence analysis of GFP-Hsp70 transfected in 293T cells. Figure 28B shows immunofluorescence analysis of GFP-TRIM11 transfected in 293T cells. Figure 28C shows immunofluorescence analysis demonstrating that Hsp70 can be recruited to Atxn1 82Q aggregates. Figure 28D shows immunofluorescence analysis demonstrating that TRIM11 can be recruited to Atxn1 82Q aggregates. Figure 28E shows immunoblot analysis of detergent-soluble and insoluble fractions of cells transfected with Atxn1 82Q, TRIM11, or Hsp70. Where indicated, 10 μM MG132 was added for 3 hours. Figure 28F shows immunoblot analysis of detergent-soluble and insoluble fractions of cells transfected with Atxn1 82Q, TRIM11 WT (wild-type), or TRIM11 MUT (mutant). Where indicated, 10 μM MG132 was added for 3 hours. Figure 28G shows an immunoblot of HCT116 transfected with the indicated plasmids. After 48 hours, cells were lysed and then stained with 20 μM thioflavin-T (ThT). [Figure 28C]Figure 28, which includes Figures 28A through 28G, shows the results of experiments demonstrating that TRIM11 is recruited to Atxn1 82Q aggregates. Figure 28A shows immunofluorescence analysis of GFP-Hsp70 transfected in 293T cells. Figure 28B shows immunofluorescence analysis of GFP-TRIM11 transfected in 293T cells. Figure 28C shows immunofluorescence analysis demonstrating that Hsp70 can be recruited to Atxn1 82Q aggregates. Figure 28D shows immunofluorescence analysis demonstrating that TRIM11 can be recruited to Atxn1 82Q aggregates. Figure 28E shows immunoblot analysis of detergent-soluble and insoluble fractions of cells transfected with Atxn1 82Q, TRIM11, or Hsp70. Where indicated, 10 μM MG132 was added for 3 hours. Figure 28F shows immunoblot analysis of detergent-soluble and insoluble fractions of cells transfected with Atxn1 82Q, TRIM11 WT (wild-type), or TRIM11 MUT (mutant). Where indicated, 10 μM MG132 was added for 3 hours. Figure 28G shows an immunoblot of HCT116 transfected with the indicated plasmids. After 48 hours, cells were lysed and then stained with 20 μM thioflavin-T (ThT). [Figure 28D]Figure 28, which includes Figures 28A through 28G, shows the results of experiments demonstrating that TRIM11 is recruited to Atxn1 82Q aggregates. Figure 28A shows immunofluorescence analysis of GFP-Hsp70 transfected in 293T cells. Figure 28B shows immunofluorescence analysis of GFP-TRIM11 transfected in 293T cells. Figure 28C shows immunofluorescence analysis demonstrating that Hsp70 can be recruited to Atxn1 82Q aggregates. Figure 28D shows immunofluorescence analysis demonstrating that TRIM11 can be recruited to Atxn1 82Q aggregates. Figure 28E shows immunoblot analysis of detergent-soluble and insoluble fractions of cells transfected with Atxn1 82Q, TRIM11, or Hsp70. Where indicated, 10 μM MG132 was added for 3 hours. Figure 28F shows immunoblot analysis of detergent-soluble and insoluble fractions of cells transfected with Atxn1 82Q, TRIM11 WT (wild-type), or TRIM11 MUT (mutant). Where indicated, 10 μM MG132 was added for 3 hours. Figure 28G shows an immunoblot of HCT116 transfected with the indicated plasmids. After 48 hours, cells were lysed and then stained with 20 μM thioflavin-T (ThT). [Figure 28E]Figure 28, which includes Figures 28A through 28G, shows the results of experiments demonstrating that TRIM11 is recruited to Atxn1 82Q aggregates. Figure 28A shows immunofluorescence analysis of GFP-Hsp70 transfected in 293T cells. Figure 28B shows immunofluorescence analysis of GFP-TRIM11 transfected in 293T cells. Figure 28C shows immunofluorescence analysis demonstrating that Hsp70 can be recruited to Atxn1 82Q aggregates. Figure 28D shows immunofluorescence analysis demonstrating that TRIM11 can be recruited to Atxn1 82Q aggregates. Figure 28E shows immunoblot analysis of detergent-soluble and insoluble fractions of cells transfected with Atxn1 82Q, TRIM11, or Hsp70. Where indicated, 10 μM MG132 was added for 3 hours. Figure 28F shows immunoblot analysis of detergent-soluble and insoluble fractions of cells transfected with Atxn1 82Q, TRIM11 WT (wild-type), or TRIM11 MUT (mutant). Where indicated, 10 μM MG132 was added for 3 hours. Figure 28G shows an immunoblot of HCT116 transfected with the indicated plasmids. After 48 hours, cells were lysed and then stained with 20 μM thioflavin-T (ThT). [Figure 28F]Figure 28, which includes Figures 28A through 28G, shows the results of experiments demonstrating that TRIM11 is recruited to Atxn1 82Q aggregates. Figure 28A shows immunofluorescence analysis of GFP-Hsp70 transfected in 293T cells. Figure 28B shows immunofluorescence analysis of GFP-TRIM11 transfected in 293T cells. Figure 28C shows immunofluorescence analysis demonstrating that Hsp70 can be recruited to Atxn1 82Q aggregates. Figure 28D shows immunofluorescence analysis demonstrating that TRIM11 can be recruited to Atxn1 82Q aggregates. Figure 28E shows immunoblot analysis of detergent-soluble and insoluble fractions of cells transfected with Atxn1 82Q, TRIM11, or Hsp70. Where indicated, 10 μM MG132 was added for 3 hours. Figure 28F shows immunoblot analysis of detergent-soluble and insoluble fractions of cells transfected with Atxn1 82Q, TRIM11 WT (wild-type), or TRIM11 MUT (mutant). Where indicated, 10 μM MG132 was added for 3 hours. Figure 28G shows an immunoblot of HCT116 transfected with the indicated plasmids. After 48 hours, cells were lysed and then stained with 20 μM thioflavin-T (ThT). [Figure 28G]Figure 28, which includes Figures 28A through 28G, shows the results of experiments demonstrating that TRIM11 is recruited to Atxn1 82Q aggregates. Figure 28A shows immunofluorescence analysis of GFP-Hsp70 transfected in 293T cells. Figure 28B shows immunofluorescence analysis of GFP-TRIM11 transfected in 293T cells. Figure 28C shows immunofluorescence analysis demonstrating that Hsp70 can be recruited to Atxn1 82Q aggregates. Figure 28D shows immunofluorescence analysis demonstrating that TRIM11 can be recruited to Atxn1 82Q aggregates. Figure 28E shows immunoblot analysis of detergent-soluble and insoluble fractions of cells transfected with Atxn1 82Q, TRIM11, or Hsp70. Where indicated, 10 μM MG132 was added for 3 hours. Figure 28F shows immunoblot analysis of detergent-soluble and insoluble fractions of cells transfected with Atxn1 82Q, TRIM11 WT (wild-type), or TRIM11 MUT (mutant). Where indicated, 10 μM MG132 was added for 3 hours. Figure 28G shows an immunoblot of HCT116 transfected with the indicated plasmids. After 48 hours, cells were lysed and then stained with 20 μM thioflavin-T (ThT). [Figure 29A] Figure 29, comprising Figures 29A to 29C, shows the results of experiments demonstrating the binding of TRIM11 to Atxn1 82Q. Figure 29A shows an experiment in which purified Flag-Atxn1 82Q immobilized on beads was incubated with GST or GST-TRIM11. Figure 29B shows an experiment in which purified Flag-Atxn1 82Q or Flag-Atxn1 30Q immobilized on beads was incubated with GST or GST-TRIM11. Figure 29C shows the binding of GST-TRIM11 and GST proteins to native (N) and urea-denatured (D) luciferase (luc) immobilized on Ni-NTA beads. [Figure 29B]Figure 29, comprising Figures 29A to 29C, shows the results of experiments demonstrating the binding of TRIM11 to Atxn1 82Q. Figure 29A shows an experiment in which purified Flag-Atxn1 82Q immobilized on beads was incubated with GST or GST-TRIM11. Figure 29B shows an experiment in which purified Flag-Atxn1 82Q or Flag-Atxn1 30Q immobilized on beads was incubated with GST or GST-TRIM11. Figure 29C shows the binding of GST-TRIM11 and GST proteins to native (N) and urea-denatured (D) luciferase (luc) immobilized on Ni-NTA beads. [Figure 29C] Figure 29, comprising Figures 29A to 29C, shows the results of experiments demonstrating the binding of TRIM11 to Atxn1 82Q. Figure 29A shows an experiment in which purified Flag-Atxn1 82Q immobilized on beads was incubated with GST or GST-TRIM11. Figure 29B shows an experiment in which purified Flag-Atxn1 82Q or Flag-Atxn1 30Q immobilized on beads was incubated with GST or GST-TRIM11. Figure 29C shows the binding of GST-TRIM11 and GST proteins to native (N) and urea-denatured (D) luciferase (luc) immobilized on Ni-NTA beads. [Figure 30A]Figure 30, which includes Figures 30A to 30D, shows the results of experiments demonstrating that TRIM11 reduces intracellular aggregates. Figure 30A shows an experiment in which HCT116 cells stably expressing GFP-Atxn1 82Q were lysed and then stained with 20 μM thioflavin-T (ThT). Figure 30B shows a sedimentation analysis of GFP-Atxn1 82Q-HCT116 cells transfected with TRIM11. Figure 30C shows an experiment in which HCT116 cells stably expressing GFP-Atxn1 82Q were transfected with TRIM11 WT or TRIM11 MUT. After 48 hours, the cells were lysed and stained with 20 μM ThT. Figure 30D shows a sedimentation analysis of GFP-Atxn1 82Q-HCT116 cells transfected with TRIM11 WT or TRIM11 MUT. [Figure 30B] Figure 30, which includes Figures 30A to 30D, shows the results of experiments demonstrating that TRIM11 reduces intracellular aggregates. Figure 30A shows an experiment in which HCT116 cells stably expressing GFP-Atxn1 82Q were lysed and then stained with 20 μM thioflavin-T (ThT). Figure 30B shows a sedimentation analysis of GFP-Atxn1 82Q-HCT116 cells transfected with TRIM11. Figure 30C shows an experiment in which HCT116 cells stably expressing GFP-Atxn1 82Q were transfected with TRIM11 WT or TRIM11 MUT. After 48 hours, the cells were lysed and stained with 20 μM ThT. Figure 30D shows a sedimentation analysis of GFP-Atxn1 82Q-HCT116 cells transfected with TRIM11 WT or TRIM11 MUT. [Figure 30C]Figure 30, which includes Figures 30A to 30D, shows the results of experiments demonstrating that TRIM11 reduces intracellular aggregates. Figure 30A shows an experiment in which HCT116 cells stably expressing GFP-Atxn1 82Q were lysed and then stained with 20 μM thioflavin-T (ThT). Figure 30B shows a sedimentation analysis of GFP-Atxn1 82Q-HCT116 cells transfected with TRIM11. Figure 30C shows an experiment in which HCT116 cells stably expressing GFP-Atxn1 82Q were transfected with TRIM11 WT or TRIM11 MUT. After 48 hours, the cells were lysed and stained with 20 μM ThT. Figure 30D shows a sedimentation analysis of GFP-Atxn1 82Q-HCT116 cells transfected with TRIM11 WT or TRIM11 MUT. [Figure 30D] Figure 30, which includes Figures 30A to 30D, shows the results of experiments demonstrating that TRIM11 reduces intracellular aggregates. Figure 30A shows an experiment in which HCT116 cells stably expressing GFP-Atxn1 82Q were lysed and then stained with 20 μM thioflavin-T (ThT). Figure 30B shows a sedimentation analysis of GFP-Atxn1 82Q-HCT116 cells transfected with TRIM11. Figure 30C shows an experiment in which HCT116 cells stably expressing GFP-Atxn1 82Q were transfected with TRIM11 WT or TRIM11 MUT. After 48 hours, the cells were lysed and stained with 20 μM ThT. Figure 30D shows a sedimentation analysis of GFP-Atxn1 82Q-HCT116 cells transfected with TRIM11 WT or TRIM11 MUT. [Figure 31A]Figure 31, which comprises Figures 31A through 31H, shows the results of experiments demonstrating that TRIM11 acts as a molecular chaperone that prevents aggregate formation. Figure 31A shows an experiment in which luciferase (10 nM) was incubated with 200 nM GST, 200 nM GST-TRIM11, or 200 nM Hsp70 at 45°C for the indicated times. Native luciferase activity was set as 100%. N=3. Figure 31B shows an experiment in which GFP (0.45 uM) was incubated with 200 nM GST, 200 nM GST-TRIM11, or 200 nM Hsp70 at 45°C for the indicated times. Native GFP fluorescence was set as 100%. N=3. Figure 31C shows the activity of transfected luciferase in HCT116 cells measured without heat shock as a control. After a 30-minute heat shock at 45°C or a 3-hour recovery in an incubator, luciferase activity was measured relative to the control. Figure 31D shows the activity of transfected luciferase in HCT116 cells measured without heat shock as a control. After a 60-minute heat shock at 45°C or a 1.5-hour or 3-hour recovery in an incubator, luciferase activity was measured relative to the control. Figure 31E shows immunoblot analysis of HCT116 cells stably expressing a control vector or Flag-TRIM11. Figure 31F shows ThT analysis demonstrating the prevention of β-amyloid fibril formation by GST, TRIM11, or Hsp70. Figure 31G shows a sedimentation assay demonstrating the prevention of Atxn1 82Q aggregate formation by lysozyme, GST, or TRIM11. Results were demonstrated by immunoblot and dot blot assays. Figure 31H shows a sedimentation assay demonstrating the prevention of p53 aggregate formation by LTRIM11. Where indicated, E1, E2, SUMO2, or ATP was applied. The results were demonstrated by immunoblot and dot blot assays. [Figure 31B]Figure 31, which comprises Figures 31A through 31H, shows the results of experiments demonstrating that TRIM11 acts as a molecular chaperone that prevents aggregate formation. Figure 31A shows an experiment in which luciferase (10 nM) was incubated with 200 nM GST, 200 nM GST-TRIM11, or 200 nM Hsp70 at 45°C for the indicated times. Native luciferase activity was set as 100%. N=3. Figure 31B shows an experiment in which GFP (0.45 uM) was incubated with 200 nM GST, 200 nM GST-TRIM11, or 200 nM Hsp70 at 45°C for the indicated times. Native GFP fluorescence was set as 100%. N=3. Figure 31C shows the activity of transfected luciferase in HCT116 cells measured without heat shock as a control. After a 30-minute heat shock at 45°C or a 3-hour recovery in an incubator, luciferase activity was measured relative to the control. Figure 31D shows the activity of transfected luciferase in HCT116 cells measured without heat shock as a control. After a 60-minute heat shock at 45°C or a 1.5-hour or 3-hour recovery in an incubator, luciferase activity was measured relative to the control. Figure 31E shows immunoblot analysis of HCT116 cells stably expressing a control vector or Flag-TRIM11. Figure 31F shows ThT analysis demonstrating the prevention of β-amyloid fibril formation by GST, TRIM11, or Hsp70. Figure 31G shows a sedimentation assay demonstrating the prevention of Atxn1 82Q aggregate formation by lysozyme, GST, or TRIM11. Results were demonstrated by immunoblot and dot blot assays. Figure 31H shows a sedimentation assay demonstrating the prevention of p53 aggregate formation by LTRIM11. Where indicated, E1, E2, SUMO2, or ATP was applied. The results were demonstrated by immunoblot and dot blot assays. [Figure 31C]Figure 31, which comprises Figures 31A through 31H, shows the results of experiments demonstrating that TRIM11 acts as a molecular chaperone that prevents aggregate formation. Figure 31A shows an experiment in which luciferase (10 nM) was incubated with 200 nM GST, 200 nM GST-TRIM11, or 200 nM Hsp70 at 45°C for the indicated times. Native luciferase activity was set as 100%. N=3. Figure 31B shows an experiment in which GFP (0.45 uM) was incubated with 200 nM GST, 200 nM GST-TRIM11, or 200 nM Hsp70 at 45°C for the indicated times. Native GFP fluorescence was set as 100%. N=3. Figure 31C shows the activity of transfected luciferase in HCT116 cells measured without heat shock as a control. After a 30-minute heat shock at 45°C or a 3-hour recovery in an incubator, luciferase activity was measured relative to the control. Figure 31D shows the activity of transfected luciferase in HCT116 cells measured without heat shock as a control. After a 60-minute heat shock at 45°C or a 1.5-hour or 3-hour recovery in an incubator, luciferase activity was measured relative to the control. Figure 31E shows immunoblot analysis of HCT116 cells stably expressing a control vector or Flag-TRIM11. Figure 31F shows ThT analysis demonstrating the prevention of β-amyloid fibril formation by GST, TRIM11, or Hsp70. Figure 31G shows a sedimentation assay demonstrating the prevention of Atxn1 82Q aggregate formation by lysozyme, GST, or TRIM11. Results were demonstrated by immunoblot and dot blot assays. Figure 31H shows a sedimentation assay demonstrating the prevention of p53 aggregate formation by LTRIM11. Where indicated, E1, E2, SUMO2, or ATP was applied. The results were demonstrated by immunoblot and dot blot assays. [Figure 31D]Figure 31, which comprises Figures 31A through 31H, shows the results of experiments demonstrating that TRIM11 acts as a molecular chaperone that prevents aggregate formation. Figure 31A shows an experiment in which luciferase (10 nM) was incubated with 200 nM GST, 200 nM GST-TRIM11, or 200 nM Hsp70 at 45°C for the indicated times. Native luciferase activity was set as 100%. N=3. Figure 31B shows an experiment in which GFP (0.45 uM) was incubated with 200 nM GST, 200 nM GST-TRIM11, or 200 nM Hsp70 at 45°C for the indicated times. Native GFP fluorescence was set as 100%. N=3. Figure 31C shows the activity of transfected luciferase in HCT116 cells measured without heat shock as a control. After a 30-minute heat shock at 45°C or a 3-hour recovery in an incubator, luciferase activity was measured relative to the control. Figure 31D shows the activity of transfected luciferase in HCT116 cells measured without heat shock as a control. After a 60-minute heat shock at 45°C or a 1.5-hour or 3-hour recovery in an incubator, luciferase activity was measured relative to the control. Figure 31E shows immunoblot analysis of HCT116 cells stably expressing a control vector or Flag-TRIM11. Figure 31F shows ThT analysis demonstrating the prevention of β-amyloid fibril formation by GST, TRIM11, or Hsp70. Figure 31G shows a sedimentation assay demonstrating the prevention of Atxn1 82Q aggregate formation by lysozyme, GST, or TRIM11. Results were demonstrated by immunoblot and dot blot assays. Figure 31H shows a sedimentation assay demonstrating the prevention of p53 aggregate formation by LTRIM11. Where indicated, E1, E2, SUMO2, or ATP was applied. The results were demonstrated by immunoblot and dot blot assays. [Figure 31E]Figure 31, which comprises Figures 31A through 31H, shows the results of experiments demonstrating that TRIM11 acts as a molecular chaperone that prevents aggregate formation. Figure 31A shows an experiment in which luciferase (10 nM) was incubated with 200 nM GST, 200 nM GST-TRIM11, or 200 nM Hsp70 at 45°C for the indicated times. Native luciferase activity was set as 100%. N=3. Figure 31B shows an experiment in which GFP (0.45 uM) was incubated with 200 nM GST, 200 nM GST-TRIM11, or 200 nM Hsp70 at 45°C for the indicated times. Native GFP fluorescence was set as 100%. N=3. Figure 31C shows the activity of transfected luciferase in HCT116 cells measured without heat shock as a control. After a 30-minute heat shock at 45°C or a 3-hour recovery in an incubator, luciferase activity was measured relative to the control. Figure 31D shows the activity of transfected luciferase in HCT116 cells measured without heat shock as a control. After a 60-minute heat shock at 45°C or a 1.5-hour or 3-hour recovery in an incubator, luciferase activity was measured relative to the control. Figure 31E shows immunoblot analysis of HCT116 cells stably expressing a control vector or Flag-TRIM11. Figure 31F shows ThT analysis demonstrating the prevention of β-amyloid fibril formation by GST, TRIM11, or Hsp70. Figure 31G shows a sedimentation assay demonstrating the prevention of Atxn1 82Q aggregate formation by lysozyme, GST, or TRIM11. Results were demonstrated by immunoblot and dot blot assays. Figure 31H shows a sedimentation assay demonstrating the prevention of p53 aggregate formation by LTRIM11. Where indicated, E1, E2, SUMO2, or ATP was applied. The results were demonstrated by immunoblot and dot blot assays. [Figure 31F]Figure 31, which comprises Figures 31A through 31H, shows the results of experiments demonstrating that TRIM11 acts as a molecular chaperone that prevents aggregate formation. Figure 31A shows an experiment in which luciferase (10 nM) was incubated with 200 nM GST, 200 nM GST-TRIM11, or 200 nM Hsp70 at 45°C for the indicated times. Native luciferase activity was set as 100%. N=3. Figure 31B shows an experiment in which GFP (0.45 uM) was incubated with 200 nM GST, 200 nM GST-TRIM11, or 200 nM Hsp70 at 45°C for the indicated times. Native GFP fluorescence was set as 100%. N=3. Figure 31C shows the activity of transfected luciferase in HCT116 cells measured without heat shock as a control. After a 30-minute heat shock at 45°C or a 3-hour recovery in an incubator, luciferase activity was measured relative to the control. Figure 31D shows the activity of transfected luciferase in HCT116 cells measured without heat shock as a control. After a 60-minute heat shock at 45°C or a 1.5-hour or 3-hour recovery in an incubator, luciferase activity was measured relative to the control. Figure 31E shows immunoblot analysis of HCT116 cells stably expressing a control vector or Flag-TRIM11. Figure 31F shows ThT analysis demonstrating the prevention of β-amyloid fibril formation by GST, TRIM11, or Hsp70. Figure 31G shows a sedimentation assay demonstrating the prevention of Atxn1 82Q aggregate formation by lysozyme, GST, or TRIM11. Results were demonstrated by immunoblot and dot blot assays. Figure 31H shows a sedimentation assay demonstrating the prevention of p53 aggregate formation by LTRIM11. Where indicated, E1, E2, SUMO2, or ATP was applied. The results were demonstrated by immunoblot and dot blot assays. [Figure 31G]Figure 31, which comprises Figures 31A through 31H, shows the results of experiments demonstrating that TRIM11 acts as a molecular chaperone that prevents aggregate formation. Figure 31A shows an experiment in which luciferase (10 nM) was incubated with 200 nM GST, 200 nM GST-TRIM11, or 200 nM Hsp70 at 45°C for the indicated times. Native luciferase activity was set as 100%. N=3. Figure 31B shows an experiment in which GFP (0.45 uM) was incubated with 200 nM GST, 200 nM GST-TRIM11, or 200 nM Hsp70 at 45°C for the indicated times. Native GFP fluorescence was set as 100%. N=3. Figure 31C shows the activity of transfected luciferase in HCT116 cells measured without heat shock as a control. After a 30-minute heat shock at 45°C or a 3-hour recovery in an incubator, luciferase activity was measured relative to the control. Figure 31D shows the activity of transfected luciferase in HCT116 cells measured without heat shock as a control. After a 60-minute heat shock at 45°C or a 1.5-hour or 3-hour recovery in an incubator, luciferase activity was measured relative to the control. Figure 31E shows immunoblot analysis of HCT116 cells stably expressing a control vector or Flag-TRIM11. Figure 31F shows ThT analysis demonstrating the prevention of β-amyloid fibril formation by GST, TRIM11, or Hsp70. Figure 31G shows a sedimentation assay demonstrating the prevention of Atxn1 82Q aggregate formation by lysozyme, GST, or TRIM11. Results were demonstrated by immunoblot and dot blot assays. Figure 31H shows a sedimentation assay demonstrating the prevention of p53 aggregate formation by LTRIM11. Where indicated, E1, E2, SUMO2, or ATP was applied. The results were demonstrated by immunoblot and dot blot assays. [Figure 31H]Figure 31, which comprises Figures 31A through 31H, shows the results of experiments demonstrating that TRIM11 acts as a molecular chaperone that prevents aggregate formation. Figure 31A shows an experiment in which luciferase (10 nM) was incubated with 200 nM GST, 200 nM GST-TRIM11, or 200 nM Hsp70 at 45°C for the indicated times. Native luciferase activity was set as 100%. N=3. Figure 31B shows an experiment in which GFP (0.45 uM) was incubated with 200 nM GST, 200 nM GST-TRIM11, or 200 nM Hsp70 at 45°C for the indicated times. Native GFP fluorescence was set as 100%. N=3. Figure 31C shows the activity of transfected luciferase in HCT116 cells measured without heat shock as a control. After a 30-minute heat shock at 45°C or a 3-hour recovery in an incubator, luciferase activity was measured relative to the control. Figure 31D shows the activity of transfected luciferase in HCT116 cells measured without heat shock as a control. After a 60-minute heat shock at 45°C or a 1.5-hour or 3-hour recovery in an incubator, luciferase activity was measured relative to the control. Figure 31E shows immunoblot analysis of HCT116 cells stably expressing a control vector or Flag-TRIM11. Figure 31F shows ThT analysis demonstrating the prevention of β-amyloid fibril formation by GST, TRIM11, or Hsp70. Figure 31G shows a sedimentation assay demonstrating the prevention of Atxn1 82Q aggregate formation by lysozyme, GST, or TRIM11. Results were demonstrated by immunoblot and dot blot assays. Figure 31H shows a sedimentation assay demonstrating the prevention of p53 aggregate formation by LTRIM11. Where indicated, E1, E2, SUMO2, or ATP was applied. The results were demonstrated by immunoblot and dot blot assays. [Figure 32A]Figure 32, which includes Figures 32A through 32G, shows the results of experiments demonstrating that HSF1 is not required for the regulation of TRIM11 transcription. Figure 32A shows an experiment in which HCT116 cells were treated with or without heat shock (42°C) for 1 hour and then allowed to recover for various periods of time. Whole cell lysates were immunoblotted with the indicated antibodies. Figure 32B shows an experiment in which HCT116 cells stably expressing Flag-TRIM11 were treated with or without heat shock (42°C) for 1 hour and then allowed to recover for various periods of time. Whole cell lysates were immunoblotted with the indicated antibodies. Figure 32C shows an experiment in which HeLa cells were treated with or without heat shock (42°C) for 1 hour and then allowed to recover for various periods of time. Whole cell lysates were immunoblotted with the indicated antibodies. Figure 32D shows an experiment in which A549 cells were treated with or without As2O3 for 30 minutes and then allowed to recover for various periods of time. Whole cell lysates were subjected to immunoblotting with the indicated antibodies. Figure 32E shows an experiment in which A549 cells were treated with or without H2O2 for 100 minutes and then allowed to recover for various periods of time. Whole cell lysates were subjected to immunoblotting with the indicated antibodies. Figure 32F shows semi-quantitative PCR analysis of TRIM11, HSP70, HSP90, and GAPDH in response to heat shock. Figure 32G shows an experiment in which A549 cells stably expressing vector or HSF1 were treated with or without heat shock and allowed to recover for 3 hours. Immunoblot and semi-quantitative PCR were analyzed. [Figure 32B]Figure 32, which includes Figures 32A through 32G, shows the results of experiments demonstrating that HSF1 is not required for the regulation of TRIM11 transcription. Figure 32A shows an experiment in which HCT116 cells were treated with or without heat shock (42°C) for 1 hour and then allowed to recover for various periods of time. Whole cell lysates were immunoblotted with the indicated antibodies. Figure 32B shows an experiment in which HCT116 cells stably expressing Flag-TRIM11 were treated with or without heat shock (42°C) for 1 hour and then allowed to recover for various periods of time. Whole cell lysates were immunoblotted with the indicated antibodies. Figure 32C shows an experiment in which HeLa cells were treated with or without heat shock (42°C) for 1 hour and then allowed to recover for various periods of time. Whole cell lysates were immunoblotted with the indicated antibodies. Figure 32D shows an experiment in which A549 cells were treated with or without As2O3 for 30 minutes and then allowed to recover for various periods of time. Whole cell lysates were subjected to immunoblotting with the indicated antibodies. Figure 32E shows an experiment in which A549 cells were treated with or without H2O2 for 100 minutes and then allowed to recover for various periods of time. Whole cell lysates were subjected to immunoblotting with the indicated antibodies. Figure 32F shows semi-quantitative PCR analysis of TRIM11, HSP70, HSP90, and GAPDH in response to heat shock. Figure 32G shows an experiment in which A549 cells stably expressing vector or HSF1 were treated with or without heat shock and allowed to recover for 3 hours. Immunoblot and semi-quantitative PCR were analyzed. [Figure 32C]Figure 32, which includes Figures 32A through 32G, shows the results of experiments demonstrating that HSF1 is not required for the regulation of TRIM11 transcription. Figure 32A shows an experiment in which HCT116 cells were treated with or without heat shock (42°C) for 1 hour and then allowed to recover for various periods of time. Whole cell lysates were immunoblotted with the indicated antibodies. Figure 32B shows an experiment in which HCT116 cells stably expressing Flag-TRIM11 were treated with or without heat shock (42°C) for 1 hour and then allowed to recover for various periods of time. Whole cell lysates were immunoblotted with the indicated antibodies. Figure 32C shows an experiment in which HeLa cells were treated with or without heat shock (42°C) for 1 hour and then allowed to recover for various periods of time. Whole cell lysates were immunoblotted with the indicated antibodies. Figure 32D shows an experiment in which A549 cells were treated with or without As2O3 for 30 minutes and then allowed to recover for various periods of time. Whole cell lysates were subjected to immunoblotting with the indicated antibodies. Figure 32E shows an experiment in which A549 cells were treated with or without H2O2 for 100 minutes and then allowed to recover for various periods of time. Whole cell lysates were subjected to immunoblotting with the indicated antibodies. Figure 32F shows semi-quantitative PCR analysis of TRIM11, HSP70, HSP90, and GAPDH in response to heat shock. Figure 32G shows an experiment in which A549 cells stably expressing vector or HSF1 were treated with or without heat shock and allowed to recover for 3 hours. Immunoblot and semi-quantitative PCR were analyzed. [Figure 32D]Figure 32, which includes Figures 32A through 32G, shows the results of experiments demonstrating that HSF1 is not required for the regulation of TRIM11 transcription. Figure 32A shows an experiment in which HCT116 cells were treated with or without heat shock (42°C) for 1 hour and then allowed to recover for various periods of time. Whole cell lysates were immunoblotted with the indicated antibodies. Figure 32B shows an experiment in which HCT116 cells stably expressing Flag-TRIM11 were treated with or without heat shock (42°C) for 1 hour and then allowed to recover for various periods of time. Whole cell lysates were immunoblotted with the indicated antibodies. Figure 32C shows an experiment in which HeLa cells were treated with or without heat shock (42°C) for 1 hour and then allowed to recover for various periods of time. Whole cell lysates were immunoblotted with the indicated antibodies. Figure 32D shows an experiment in which A549 cells were treated with or without As2O3 for 30 minutes and then allowed to recover for various periods of time. Whole cell lysates were subjected to immunoblotting with the indicated antibodies. Figure 32E shows an experiment in which A549 cells were treated with or without H2O2 for 100 minutes and then allowed to recover for various periods of time. Whole cell lysates were subjected to immunoblotting with the indicated antibodies. Figure 32F shows semi-quantitative PCR analysis of TRIM11, HSP70, HSP90, and GAPDH in response to heat shock. Figure 32G shows an experiment in which A549 cells stably expressing vector or HSF1 were treated with or without heat shock and allowed to recover for 3 hours. Immunoblot and semi-quantitative PCR were analyzed. [Figure 32E]Figure 32, which includes Figures 32A through 32G, shows the results of experiments demonstrating that HSF1 is not required for the regulation of TRIM11 transcription. Figure 32A shows an experiment in which HCT116 cells were treated with or without heat shock (42°C) for 1 hour and then allowed to recover for various periods of time. Whole cell lysates were immunoblotted with the indicated antibodies. Figure 32B shows an experiment in which HCT116 cells stably expressing Flag-TRIM11 were treated with or without heat shock (42°C) for 1 hour and then allowed to recover for various periods of time. Whole cell lysates were immunoblotted with the indicated antibodies. Figure 32C shows an experiment in which HeLa cells were treated with or without heat shock (42°C) for 1 hour and then allowed to recover for various periods of time. Whole cell lysates were immunoblotted with the indicated antibodies. Figure 32D shows an experiment in which A549 cells were treated with or without As2O3 for 30 minutes and then allowed to recover for various periods of time. Whole cell lysates were subjected to immunoblotting with the indicated antibodies. Figure 32E shows an experiment in which A549 cells were treated with or without H2O2 for 100 minutes and then allowed to recover for various periods of time. Whole cell lysates were subjected to immunoblotting with the indicated antibodies. Figure 32F shows semi-quantitative PCR analysis of TRIM11, HSP70, HSP90, and GAPDH in response to heat shock. Figure 32G shows an experiment in which A549 cells stably expressing vector or HSF1 were treated with or without heat shock and allowed to recover for 3 hours. Immunoblot and semi-quantitative PCR were analyzed. [Figure 32F]Figure 32, which includes Figures 32A through 32G, shows the results of experiments demonstrating that HSF1 is not required for the regulation of TRIM11 transcription. Figure 32A shows an experiment in which HCT116 cells were treated with or without heat shock (42°C) for 1 hour and then allowed to recover for various periods of time. Whole cell lysates were immunoblotted with the indicated antibodies. Figure 32B shows an experiment in which HCT116 cells stably expressing Flag-TRIM11 were treated with or without heat shock (42°C) for 1 hour and then allowed to recover for various periods of time. Whole cell lysates were immunoblotted with the indicated antibodies. Figure 32C shows an experiment in which HeLa cells were treated with or without heat shock (42°C) for 1 hour and then allowed to recover for various periods of time. Whole cell lysates were immunoblotted with the indicated antibodies. Figure 32D shows an experiment in which A549 cells were treated with or without As2O3 for 30 minutes and then allowed to recover for various periods of time. Whole cell lysates were subjected to immunoblotting with the indicated antibodies. Figure 32E shows an experiment in which A549 cells were treated with or without H2O2 for 100 minutes and then allowed to recover for various periods of time. Whole cell lysates were subjected to immunoblotting with the indicated antibodies. Figure 32F shows semi-quantitative PCR analysis of TRIM11, HSP70, HSP90, and GAPDH in response to heat shock. Figure 32G shows an experiment in which A549 cells stably expressing vector or HSF1 were treated with or without heat shock and allowed to recover for 3 hours. Immunoblot and semi-quantitative PCR were analyzed. [Figure 32G]Figure 32, which includes Figures 32A through 32G, shows the results of experiments demonstrating that HSF1 is not required for the regulation of TRIM11 transcription. Figure 32A shows an experiment in which HCT116 cells were treated with or without heat shock (42°C) for 1 hour and then allowed to recover for various periods of time. Whole cell lysates were immunoblotted with the indicated antibodies. Figure 32B shows an experiment in which HCT116 cells stably expressing Flag-TRIM11 were treated with or without heat shock (42°C) for 1 hour and then allowed to recover for various periods of time. Whole cell lysates were immunoblotted with the indicated antibodies. Figure 32C shows an experiment in which HeLa cells were treated with or without heat shock (42°C) for 1 hour and then allowed to recover for various periods of time. Whole cell lysates were immunoblotted with the indicated antibodies. Figure 32D shows an experiment in which A549 cells were treated with or without As2O3 for 30 minutes and then allowed to recover for various periods of time. Whole cell lysates were subjected to immunoblotting with the indicated antibodies. Figure 32E shows an experiment in which A549 cells were treated with or without H2O2 for 100 minutes and then allowed to recover for various periods of time. Whole cell lysates were subjected to immunoblotting with the indicated antibodies. Figure 32F shows semi-quantitative PCR analysis of TRIM11, HSP70, HSP90, and GAPDH in response to heat shock. Figure 32G shows an experiment in which A549 cells stably expressing vector or HSF1 were treated with or without heat shock and allowed to recover for 3 hours. Immunoblot and semi-quantitative PCR were analyzed. [Figure 33A]Figure 33, comprising Figures 33A through 33F, shows the results of experiments demonstrating that p53 is a factor in upregulating TRIM11 in response to heat shock. Figure 33A shows an immunoblot of HCT116 p53 wild-type or p53 null cells treated with heat shock and recovered. Figure 33B shows qPCR analysis of TRIM11 mRNA levels in HCT116 p53 wild-type or p53 null cells treated with heat shock and recovered. Figure 33C shows immunoblot and semi-quantitative PCR analysis of A549 cells stably expressing control (Ctrl) or p53 shRNA treated with or without heat shock and recovered for 3 hours. Figure 33D shows immunoblot and semi-quantitative PCR analysis of HCT116 cells transfected with Ctrl or p53 siRNA treated with or without heat shock and recovered for 3 hours. Figure 33E shows crystal violet analysis of viability of HCT116 cells heated and allowed to recover for 24 hours. KRIBB11 was added where indicated. Figure 33F shows the results of the relative cell numbers presented in Figure 33E analyzed by OD490. [Figure 33B]Figure 33, comprising Figures 33A through 33F, shows the results of experiments demonstrating that p53 is a factor in upregulating TRIM11 in response to heat shock. Figure 33A shows an immunoblot of HCT116 p53 wild-type or p53 null cells treated with heat shock and recovered. Figure 33B shows qPCR analysis of TRIM11 mRNA levels in HCT116 p53 wild-type or p53 null cells treated with heat shock and recovered. Figure 33C shows immunoblot and semi-quantitative PCR analysis of A549 cells stably expressing control (Ctrl) or p53 shRNA treated with or without heat shock and recovered for 3 hours. Figure 33D shows immunoblot and semi-quantitative PCR analysis of HCT116 cells transfected with Ctrl or p53 siRNA treated with or without heat shock and recovered for 3 hours. Figure 33E shows crystal violet analysis of viability of HCT116 cells heated and allowed to recover for 24 hours. KRIBB11 was added where indicated. Figure 33F shows the results of the relative cell numbers presented in Figure 33E analyzed by OD490. [Figure 33C]Figure 33, comprising Figures 33A through 33F, shows the results of experiments demonstrating that p53 is a factor in upregulating TRIM11 in response to heat shock. Figure 33A shows an immunoblot of HCT116 p53 wild-type or p53 null cells treated with heat shock and recovered. Figure 33B shows qPCR analysis of TRIM11 mRNA levels in HCT116 p53 wild-type or p53 null cells treated with heat shock and recovered. Figure 33C shows immunoblot and semi-quantitative PCR analysis of A549 cells stably expressing control (Ctrl) or p53 shRNA treated with or without heat shock and recovered for 3 hours. Figure 33D shows immunoblot and semi-quantitative PCR analysis of HCT116 cells transfected with Ctrl or p53 siRNA treated with or without heat shock and recovered for 3 hours. Figure 33E shows crystal violet analysis of viability of HCT116 cells heated and allowed to recover for 24 hours. KRIBB11 was added where indicated. Figure 33F shows the results of the relative cell numbers presented in Figure 33E analyzed by OD490. [Figure 33D]Figure 33, comprising Figures 33A through 33F, shows the results of experiments demonstrating that p53 is a factor in upregulating TRIM11 in response to heat shock. Figure 33A shows an immunoblot of HCT116 p53 wild-type or p53 null cells treated with heat shock and recovered. Figure 33B shows qPCR analysis of TRIM11 mRNA levels in HCT116 p53 wild-type or p53 null cells treated with heat shock and recovered. Figure 33C shows immunoblot and semi-quantitative PCR analysis of A549 cells stably expressing control (Ctrl) or p53 shRNA treated with or without heat shock and recovered for 3 hours. Figure 33D shows immunoblot and semi-quantitative PCR analysis of HCT116 cells transfected with Ctrl or p53 siRNA treated with or without heat shock and recovered for 3 hours. Figure 33E shows crystal violet analysis of viability of HCT116 cells heated and allowed to recover for 24 hours. KRIBB11 was added where indicated. Figure 33F shows the results of the relative cell numbers presented in Figure 33E analyzed by OD490. [Figure 33E]Figure 33, comprising Figures 33A through 33F, shows the results of experiments demonstrating that p53 is a factor in upregulating TRIM11 in response to heat shock. Figure 33A shows an immunoblot of HCT116 p53 wild-type or p53 null cells treated with heat shock and recovered. Figure 33B shows qPCR analysis of TRIM11 mRNA levels in HCT116 p53 wild-type or p53 null cells treated with heat shock and recovered. Figure 33C shows immunoblot and semi-quantitative PCR analysis of A549 cells stably expressing control (Ctrl) or p53 shRNA treated with or without heat shock and recovered for 3 hours. Figure 33D shows immunoblot and semi-quantitative PCR analysis of HCT116 cells transfected with Ctrl or p53 siRNA treated with or without heat shock and recovered for 3 hours. Figure 33E shows crystal violet analysis of viability of HCT116 cells heated and allowed to recover for 24 hours. KRIBB11 was added where indicated. Figure 33F shows the results of the relative cell numbers presented in Figure 33E analyzed by OD490. [Figure 33F]Figure 33, comprising Figures 33A through 33F, shows the results of experiments demonstrating that p53 is a factor in upregulating TRIM11 in response to heat shock. Figure 33A shows an immunoblot of HCT116 p53 wild-type or p53 null cells treated with heat shock and recovered. Figure 33B shows qPCR analysis of TRIM11 mRNA levels in HCT116 p53 wild-type or p53 null cells treated with heat shock and recovered. Figure 33C shows immunoblot and semi-quantitative PCR analysis of A549 cells stably expressing control (Ctrl) or p53 shRNA treated with or without heat shock and recovered for 3 hours. Figure 33D shows immunoblot and semi-quantitative PCR analysis of HCT116 cells transfected with Ctrl or p53 siRNA treated with or without heat shock and recovered for 3 hours. Figure 33E shows crystal violet analysis of viability of HCT116 cells heated and allowed to recover for 24 hours. KRIBB11 was added where indicated. Figure 33F shows the results of the relative cell numbers presented in Figure 33E analyzed by OD490. [Figure 34A]Figure 34, which includes Figures 34A through 34G, shows the results of experiments demonstrating that TRIM11 acts as a disaggregating agent to dissociate preformed aggregates. Figure 34A shows the disaggregation and reactivation of preformed luciferase aggregates using increasing concentrations of lysozyme, GST, or GST-TRIM11 (n=3). Figure 34B shows a sedimentation assay demonstrating heat-aggregated luciferase dissociated by GST or GST-TRIM11. Results were displayed by immunoblot. Figure 34C shows the disaggregation and reactivation of preformed GFP aggregates using increasing concentrations of lysozyme, GST, or GST-TRIM11 (n=3). Figure 34D shows a sedimentation assay demonstrating heat-aggregated GFP dissociated by GST or GST-TRIM11. Results were displayed by immunoblot. Figure 34E shows sedimentation assays demonstrating that preformed Atxn1 82Q aggregates were disaggregated by lysozyme, GST, or GST-TRIM11. Results were demonstrated by immunoblotting. Figure 34F shows sedimentation assays demonstrating preformed Atxn1 82Q aggregates (left) and p53 aggregates (right) disaggregated by 1 μM Hsp70 and 0.5 μM Hsp40. Figure 34G shows sedimentation assays demonstrating preformed Atxn1 82Q aggregates disaggregated by 0.5 μM GST, 0.5 μM TRIM11, 1 μM Hsp70, 0.5 μM Hsp40, or 1 μM Hsp104. [Figure 34B]Figure 34, which includes Figures 34A through 34G, shows the results of experiments demonstrating that TRIM11 acts as a disaggregating agent to dissociate preformed aggregates. Figure 34A shows the disaggregation and reactivation of preformed luciferase aggregates using increasing concentrations of lysozyme, GST, or GST-TRIM11 (n=3). Figure 34B shows a sedimentation assay demonstrating heat-aggregated luciferase dissociated by GST or GST-TRIM11. Results were displayed by immunoblot. Figure 34C shows the disaggregation and reactivation of preformed GFP aggregates using increasing concentrations of lysozyme, GST, or GST-TRIM11 (n=3). Figure 34D shows a sedimentation assay demonstrating heat-aggregated GFP dissociated by GST or GST-TRIM11. Results were displayed by immunoblot. Figure 34E shows sedimentation assays demonstrating that preformed Atxn1 82Q aggregates were disaggregated by lysozyme, GST, or GST-TRIM11. Results were demonstrated by immunoblotting. Figure 34F shows sedimentation assays demonstrating preformed Atxn1 82Q aggregates (left) and p53 aggregates (right) disaggregated by 1 μM Hsp70 and 0.5 μM Hsp40. Figure 34G shows sedimentation assays demonstrating preformed Atxn1 82Q aggregates disaggregated by 0.5 μM GST, 0.5 μM TRIM11, 1 μM Hsp70, 0.5 μM Hsp40, or 1 μM Hsp104. [Figure 34C]Figure 34, which includes Figures 34A through 34G, shows the results of experiments demonstrating that TRIM11 acts as a disaggregating agent to dissociate preformed aggregates. Figure 34A shows the disaggregation and reactivation of preformed luciferase aggregates using increasing concentrations of lysozyme, GST, or GST-TRIM11 (n=3). Figure 34B shows a sedimentation assay demonstrating heat-aggregated luciferase dissociated by GST or GST-TRIM11. Results were displayed by immunoblot. Figure 34C shows the disaggregation and reactivation of preformed GFP aggregates using increasing concentrations of lysozyme, GST, or GST-TRIM11 (n=3). Figure 34D shows a sedimentation assay demonstrating heat-aggregated GFP dissociated by GST or GST-TRIM11. Results were displayed by immunoblot. Figure 34E shows sedimentation assays demonstrating that preformed Atxn1 82Q aggregates were disaggregated by lysozyme, GST, or GST-TRIM11. Results were demonstrated by immunoblotting. Figure 34F shows sedimentation assays demonstrating preformed Atxn1 82Q aggregates (left) and p53 aggregates (right) disaggregated by 1 μM Hsp70 and 0.5 μM Hsp40. Figure 34G shows sedimentation assays demonstrating preformed Atxn1 82Q aggregates disaggregated by 0.5 μM GST, 0.5 μM TRIM11, 1 μM Hsp70, 0.5 μM Hsp40, or 1 μM Hsp104. [Figure 34D]Figure 34, which includes Figures 34A through 34G, shows the results of experiments demonstrating that TRIM11 acts as a disaggregating agent to dissociate preformed aggregates. Figure 34A shows the disaggregation and reactivation of preformed luciferase aggregates using increasing concentrations of lysozyme, GST, or GST-TRIM11 (n=3). Figure 34B shows a sedimentation assay demonstrating heat-aggregated luciferase dissociated by GST or GST-TRIM11. Results were displayed by immunoblot. Figure 34C shows the disaggregation and reactivation of preformed GFP aggregates using increasing concentrations of lysozyme, GST, or GST-TRIM11 (n=3). Figure 34D shows a sedimentation assay demonstrating heat-aggregated GFP dissociated by GST or GST-TRIM11. Results were displayed by immunoblot. Figure 34E shows sedimentation assays demonstrating that preformed Atxn1 82Q aggregates were disaggregated by lysozyme, GST, or GST-TRIM11. Results were demonstrated by immunoblotting. Figure 34F shows sedimentation assays demonstrating preformed Atxn1 82Q aggregates (left) and p53 aggregates (right) disaggregated by 1 μM Hsp70 and 0.5 μM Hsp40. Figure 34G shows sedimentation assays demonstrating preformed Atxn1 82Q aggregates disaggregated by 0.5 μM GST, 0.5 μM TRIM11, 1 μM Hsp70, 0.5 μM Hsp40, or 1 μM Hsp104. [Figure 34E]Figure 34, which includes Figures 34A through 34G, shows the results of experiments demonstrating that TRIM11 acts as a disaggregating agent to dissociate preformed aggregates. Figure 34A shows the disaggregation and reactivation of preformed luciferase aggregates using increasing concentrations of lysozyme, GST, or GST-TRIM11 (n=3). Figure 34B shows a sedimentation assay demonstrating heat-aggregated luciferase dissociated by GST or GST-TRIM11. Results were displayed by immunoblot. Figure 34C shows the disaggregation and reactivation of preformed GFP aggregates using increasing concentrations of lysozyme, GST, or GST-TRIM11 (n=3). Figure 34D shows a sedimentation assay demonstrating heat-aggregated GFP dissociated by GST or GST-TRIM11. Results were displayed by immunoblot. Figure 34E shows sedimentation assays demonstrating that preformed Atxn1 82Q aggregates were disaggregated by lysozyme, GST, or GST-TRIM11. Results were demonstrated by immunoblotting. Figure 34F shows sedimentation assays demonstrating preformed Atxn1 82Q aggregates (left) and p53 aggregates (right) disaggregated by 1 μM Hsp70 and 0.5 μM Hsp40. Figure 34G shows sedimentation assays demonstrating preformed Atxn1 82Q aggregates disaggregated by 0.5 μM GST, 0.5 μM TRIM11, 1 μM Hsp70, 0.5 μM Hsp40, or 1 μM Hsp104. [Figure 34F]Figure 34, which includes Figures 34A through 34G, shows the results of experiments demonstrating that TRIM11 acts as a disaggregating agent to dissociate preformed aggregates. Figure 34A shows the disaggregation and reactivation of preformed luciferase aggregates using increasing concentrations of lysozyme, GST, or GST-TRIM11 (n=3). Figure 34B shows a sedimentation assay demonstrating heat-aggregated luciferase dissociated by GST or GST-TRIM11. Results were displayed by immunoblot. Figure 34C shows the disaggregation and reactivation of preformed GFP aggregates using increasing concentrations of lysozyme, GST, or GST-TRIM11 (n=3). Figure 34D shows a sedimentation assay demonstrating heat-aggregated GFP dissociated by GST or GST-TRIM11. Results were displayed by immunoblot. Figure 34E shows sedimentation assays demonstrating that preformed Atxn1 82Q aggregates were disaggregated by lysozyme, GST, or GST-TRIM11. Results were demonstrated by immunoblotting. Figure 34F shows sedimentation assays demonstrating preformed Atxn1 82Q aggregates (left) and p53 aggregates (right) disaggregated by 1 μM Hsp70 and 0.5 μM Hsp40. Figure 34G shows sedimentation assays demonstrating preformed Atxn1 82Q aggregates disaggregated by 0.5 μM GST, 0.5 μM TRIM11, 1 μM Hsp70, 0.5 μM Hsp40, or 1 μM Hsp104. [Figure 34G]Figure 34, which includes Figures 34A through 34G, shows the results of experiments demonstrating that TRIM11 acts as a disaggregating agent to dissociate preformed aggregates. Figure 34A shows the disaggregation and reactivation of preformed luciferase aggregates using increasing concentrations of lysozyme, GST, or GST-TRIM11 (n=3). Figure 34B shows a sedimentation assay demonstrating heat-aggregated luciferase dissociated by GST or GST-TRIM11. Results were displayed by immunoblot. Figure 34C shows the disaggregation and reactivation of preformed GFP aggregates using increasing concentrations of lysozyme, GST, or GST-TRIM11 (n=3). Figure 34D shows a sedimentation assay demonstrating heat-aggregated GFP dissociated by GST or GST-TRIM11. Results were displayed by immunoblot. Figure 34E shows sedimentation assays demonstrating that preformed Atxn1 82Q aggregates were disaggregated by lysozyme, GST, or GST-TRIM11. Results were demonstrated by immunoblotting. Figure 34F shows sedimentation assays demonstrating preformed Atxn1 82Q aggregates (left) and p53 aggregates (right) disaggregated by 1 μM Hsp70 and 0.5 μM Hsp40. Figure 34G shows sedimentation assays demonstrating preformed Atxn1 82Q aggregates disaggregated by 0.5 μM GST, 0.5 μM TRIM11, 1 μM Hsp70, 0.5 μM Hsp40, or 1 μM Hsp104. [Figure 35A] Figure 35, comprising Figures 35A through 35D, shows the results of experiments demonstrating that full-length TRIM11 is required for refolding activity. Figure 35A shows a schematic of the TRIM11 structure. Figure 35B shows the disaggregation and reactivation of preformed luciferase aggregates using increasing concentrations of the indicated proteins (n=3). Figure 35C shows sedimentation assays demonstrating heated luciferase aggregates disaggregated by GST, TRIM11, RBCs, or B30.2. Figure 35D shows the disaggregation and reactivation of preformed luciferase aggregates using the indicated proteins (n=3). [Figure 35B]Figure 35, comprising Figures 35A through 35D, shows the results of experiments demonstrating that full-length TRIM11 is required for refolding activity. Figure 35A shows a schematic of the TRIM11 structure. Figure 35B shows the disaggregation and reactivation of preformed luciferase aggregates using increasing concentrations of the indicated proteins (n=3). Figure 35C shows sedimentation assays demonstrating heated luciferase aggregates disaggregated by GST, TRIM11, RBCs, or B30.2. Figure 35D shows the disaggregation and reactivation of preformed luciferase aggregates using the indicated proteins (n=3). [Figure 35C] Figure 35, comprising Figures 35A through 35D, shows the results of experiments demonstrating that full-length TRIM11 is required for refolding activity. Figure 35A shows a schematic of the TRIM11 structure. Figure 35B shows the disaggregation and reactivation of preformed luciferase aggregates using increasing concentrations of the indicated proteins (n=3). Figure 35C shows sedimentation assays demonstrating heated luciferase aggregates disaggregated by GST, TRIM11, RBCs, or B30.2. Figure 35D shows the disaggregation and reactivation of preformed luciferase aggregates using the indicated proteins (n=3). [Figure 35D] Figure 35, comprising Figures 35A through 35D, shows the results of experiments demonstrating that full-length TRIM11 is required for refolding activity. Figure 35A shows a schematic of the TRIM11 structure. Figure 35B shows the disaggregation and reactivation of preformed luciferase aggregates using increasing concentrations of the indicated proteins (n=3). Figure 35C shows sedimentation assays demonstrating heated luciferase aggregates disaggregated by GST, TRIM11, RBCs, or B30.2. Figure 35D shows the disaggregation and reactivation of preformed luciferase aggregates using the indicated proteins (n=3). [Figure 36A]Figure 36, comprising Figures 36A and 36B, shows the results of experiments demonstrating that binding of TRIM11 to a substrate is required for its disaggregation function. Figure 36A shows purified Flag-Atxn1 82Q immobilized on beads was incubated with GST, GST-TRIM11, GST-RBC, or GST-B30.2. Figure 36B shows purified Flag-Atxn1 82Q immobilized on beads was incubated with GST, GST-TRIM11, or other TRIM11 fragments. [Figure 36B] Figure 36, comprising Figures 36A and 36B, shows the results of experiments demonstrating that binding of TRIM11 to a substrate is required for its disaggregation function. Figure 36A shows purified Flag-Atxn1 82Q immobilized on beads was incubated with GST, GST-TRIM11, GST-RBC, or GST-B30.2. Figure 36B shows purified Flag-Atxn1 82Q immobilized on beads was incubated with GST, GST-TRIM11, or other TRIM11 fragments. [Figure 37A] Figure 37, comprising Figures 37A through 37E, shows the results of experiments demonstrating that TRIM11 performs disaggregation independently of its SUMO E3 ligase activity. Figure 37A shows an experiment in which luciferase (10 nM) was incubated with 200 nM GST, 200 nM GST-TRIM11 WT, or MUT at 45°C for the indicated times. Native luciferase activity was set to 100%. N=3. Figure 37B shows the disaggregation and reactivation of preformed luciferase aggregates by 200 nM GST, 200 nM GST-TRIM11 WT, or MUT. Figure 37C shows the binding of GST, GST-TRIM11 WT, or MUT to native (N) and urea-denatured (D) luciferase (luc) immobilized on Ni-NTA beads. Figure 37D shows immunofluorescence analysis of transfected GFP-TRIM11 MUT in 293T cells, and Figure 37E shows immunofluorescence analysis demonstrating that TRIM11 MUT can be recruited to aggregates of Atxn1 82Q. [Figure 37B] Figure 37, comprising Figures 37A through 37E, shows the results of experiments demonstrating that TRIM11 performs disaggregation independently of its SUMO E3 ligase activity. Figure 37A shows an experiment in which luciferase (10 nM) was incubated with 200 nM GST, 200 nM GST-TRIM11 WT, or MUT at 45°C for the indicated times. Native luciferase activity was set to 100%. N=3. Figure 37B shows the disaggregation and reactivation of preformed luciferase aggregates by 200 nM GST, 200 nM GST-TRIM11 WT, or MUT. Figure 37C shows the binding of GST, GST-TRIM11 WT, or MUT to native (N) and urea-denatured (D) luciferase (luc) immobilized on Ni-NTA beads. Figure 37D shows immunofluorescence analysis of transfected GFP-TRIM11 MUT in 293T cells, and Figure 37E shows immunofluorescence analysis demonstrating that TRIM11 MUT can be recruited to aggregates of Atxn1 82Q. [Figure 37C] Figure 37, comprising Figures 37A through 37E, shows the results of experiments demonstrating that TRIM11 performs disaggregation independently of its SUMO E3 ligase activity. Figure 37A shows an experiment in which luciferase (10 nM) was incubated with 200 nM GST, 200 nM GST-TRIM11 WT, or MUT at 45°C for the indicated times. Native luciferase activity was set to 100%. N=3. Figure 37B shows the disaggregation and reactivation of preformed luciferase aggregates by 200 nM GST, 200 nM GST-TRIM11 WT, or MUT. Figure 37C shows the binding of GST, GST-TRIM11 WT, or MUT to native (N) and urea-denatured (D) luciferase (luc) immobilized on Ni-NTA beads. Figure 37D shows immunofluorescence analysis of transfected GFP-TRIM11 MUT in 293T cells, and Figure 37E shows immunofluorescence analysis demonstrating that TRIM11 MUT can be recruited to aggregates of Atxn1 82Q. [Figure 37D]Figure 37, comprising Figures 37A through 37E, shows the results of experiments demonstrating that TRIM11 performs disaggregation independently of its SUMO E3 ligase activity. Figure 37A shows an experiment in which luciferase (10 nM) was incubated with 200 nM GST, 200 nM GST-TRIM11 WT, or MUT at 45°C for the indicated times. Native luciferase activity was set to 100%. N=3. Figure 37B shows the disaggregation and reactivation of preformed luciferase aggregates by 200 nM GST, 200 nM GST-TRIM11 WT, or MUT. Figure 37C shows the binding of GST, GST-TRIM11 WT, or MUT to native (N) and urea-denatured (D) luciferase (luc) immobilized on Ni-NTA beads. Figure 37D shows immunofluorescence analysis of transfected GFP-TRIM11 MUT in 293T cells, and Figure 37E shows immunofluorescence analysis demonstrating that TRIM11 MUT can be recruited to aggregates of Atxn1 82Q. [Figure 37E] Figure 37, comprising Figures 37A through 37E, shows the results of experiments demonstrating that TRIM11 performs disaggregation independently of its SUMO E3 ligase activity. Figure 37A shows an experiment in which luciferase (10 nM) was incubated with 200 nM GST, 200 nM GST-TRIM11 WT, or MUT at 45°C for the indicated times. Native luciferase activity was set to 100%. N=3. Figure 37B shows the disaggregation and reactivation of preformed luciferase aggregates by 200 nM GST, 200 nM GST-TRIM11 WT, or MUT. Figure 37C shows the binding of GST, GST-TRIM11 WT, or MUT to native (N) and urea-denatured (D) luciferase (luc) immobilized on Ni-NTA beads. Figure 37D shows immunofluorescence analysis of transfected GFP-TRIM11 MUT in 293T cells, and Figure 37E shows immunofluorescence analysis demonstrating that TRIM11 MUT can be recruited to aggregates of Atxn1 82Q. [Figure 38A]Figure 38, comprising Figures 38A through 38E, shows the results of experiments demonstrating that TRIM11 can preform α-synuclein amyloid fibrils and also disaggregate preformed α-synuclein fibrils. Figure 38A shows ThT analysis demonstrating the prevention of α-synuclein fibril formation by GST, TRIM11, Hsp70, Hsp40, or Hsp104. Figure 38B shows ThT analysis demonstrating the dose-dependent prevention of α-synuclein fibril formation by TRIM11. Figure 38C shows EM images of fibril formation of α-Syn monomers incubated with GST or GST-TRIM11. Figure 38D shows sedimentation assays demonstrating preformed α-Syn fibrils disaggregated by TRIM11 and Hsp104 A503S. Figure 38E shows ThT analysis demonstrating the disaggregation of preformed α-Syn fibrils by GST, TRIM11, or Hsp104. [Figure 38B] Figure 38, comprising Figures 38A through 38E, shows the results of experiments demonstrating that TRIM11 can preform α-synuclein amyloid fibrils and also disaggregate preformed α-synuclein fibrils. Figure 38A shows ThT analysis demonstrating the prevention of α-synuclein fibril formation by GST, TRIM11, Hsp70, Hsp40, or Hsp104. Figure 38B shows ThT analysis demonstrating the dose-dependent prevention of α-synuclein fibril formation by TRIM11. Figure 38C shows EM images of fibril formation of α-Syn monomers incubated with GST or GST-TRIM11. Figure 38D shows sedimentation assays demonstrating preformed α-Syn fibrils disaggregated by TRIM11 and Hsp104 A503S. Figure 38E shows ThT analysis demonstrating the disaggregation of preformed α-Syn fibrils by GST, TRIM11, or Hsp104. [Figure 38C]Figure 38, comprising Figures 38A through 38E, shows the results of experiments demonstrating that TRIM11 can preform α-synuclein amyloid fibrils and also disaggregate preformed α-synuclein fibrils. Figure 38A shows ThT analysis demonstrating the prevention of α-synuclein fibril formation by GST, TRIM11, Hsp70, Hsp40, or Hsp104. Figure 38B shows ThT analysis demonstrating the dose-dependent prevention of α-synuclein fibril formation by TRIM11. Figure 38C shows EM images of fibril formation of α-Syn monomers incubated with GST or GST-TRIM11. Figure 38D shows sedimentation assays demonstrating preformed α-Syn fibrils disaggregated by TRIM11 and Hsp104 A503S. Figure 38E shows ThT analysis demonstrating the disaggregation of preformed α-Syn fibrils by GST, TRIM11, or Hsp104. [Figure 38D] Figure 38, comprising Figures 38A through 38E, shows the results of experiments demonstrating that TRIM11 can preform α-synuclein amyloid fibrils and also disaggregate preformed α-synuclein fibrils. Figure 38A shows ThT analysis demonstrating the prevention of α-synuclein fibril formation by GST, TRIM11, Hsp70, Hsp40, or Hsp104. Figure 38B shows ThT analysis demonstrating the dose-dependent prevention of α-synuclein fibril formation by TRIM11. Figure 38C shows EM images of fibril formation of α-Syn monomers incubated with GST or GST-TRIM11. Figure 38D shows sedimentation assays demonstrating preformed α-Syn fibrils disaggregated by TRIM11 and Hsp104 A503S. Figure 38E shows ThT analysis demonstrating the disaggregation of preformed α-Syn fibrils by GST, TRIM11, or Hsp104. [Figure 38E]Figure 38, comprising Figures 38A through 38E, shows the results of experiments demonstrating that TRIM11 can preform α-synuclein amyloid fibrils and also disaggregate preformed α-synuclein fibrils. Figure 38A shows ThT analysis demonstrating the prevention of α-synuclein fibril formation by GST, TRIM11, Hsp70, Hsp40, or Hsp104. Figure 38B shows ThT analysis demonstrating the dose-dependent prevention of α-synuclein fibril formation by TRIM11. Figure 38C shows EM images of fibril formation of α-Syn monomers incubated with GST or GST-TRIM11. Figure 38D shows sedimentation assays demonstrating preformed α-Syn fibrils disaggregated by TRIM11 and Hsp104 A503S. Figure 38E shows ThT analysis demonstrating the disaggregation of preformed α-Syn fibrils by GST, TRIM11, or Hsp104. [Figure 39A] Figure 39, comprising Figures 39A through 39D, shows the results of experiments demonstrating that TRIM21 has a disaggregation function similar to that of TRIM11. Figure 39A shows the binding of GST, GST-TRIM11 WT, or MUT to native (N) and urea-denatured (D) luciferase (luc) immobilized on Ni-NTA beads. Figure 39B shows a sedimentation assay demonstrating heat-aggregated luciferase dissociated by GST or GST-TRIM21. Figure 39C shows the disaggregation and reactivation of preformed luciferase aggregates using increasing concentrations of GST or GST-TRIM21 (n=3). Figure 39D shows a luciferase assay in which luciferase (10 nM) was incubated with 200 nM GST or 200 nM GST-TRIM21 at 45°C for 1 minute. The native luciferase assay was set to 100%. N=3. [Figure 39B]Figure 39, comprising Figures 39A through 39D, shows the results of experiments demonstrating that TRIM21 has a disaggregation function similar to that of TRIM11. Figure 39A shows the binding of GST, GST-TRIM11 WT, or MUT to native (N) and urea-denatured (D) luciferase (luc) immobilized on Ni-NTA beads. Figure 39B shows a sedimentation assay demonstrating heat-aggregated luciferase dissociated by GST or GST-TRIM21. Figure 39C shows the disaggregation and reactivation of preformed luciferase aggregates using increasing concentrations of GST or GST-TRIM21 (n=3). Figure 39D shows a luciferase assay in which luciferase (10 nM) was incubated with 200 nM GST or 200 nM GST-TRIM21 at 45°C for 1 minute. The native luciferase assay was set to 100%. N=3. [Figure 39C] Figure 39, comprising Figures 39A through 39D, shows the results of experiments demonstrating that TRIM21 has a disaggregation function similar to that of TRIM11. Figure 39A shows the binding of GST, GST-TRIM11 WT, or MUT to native (N) and urea-denatured (D) luciferase (luc) immobilized on Ni-NTA beads. Figure 39B shows a sedimentation assay demonstrating heat-aggregated luciferase dissociated by GST or GST-TRIM21. Figure 39C shows the disaggregation and reactivation of preformed luciferase aggregates using increasing concentrations of GST or GST-TRIM21 (n=3). Figure 39D shows a luciferase assay in which luciferase (10 nM) was incubated with 200 nM GST or 200 nM GST-TRIM21 at 45°C for 1 minute. The native luciferase assay was set to 100%. N=3. [Figure 39D]Figure 39, comprising Figures 39A through 39D, shows the results of experiments demonstrating that TRIM21 has a disaggregation function similar to that of TRIM11. Figure 39A shows the binding of GST, GST-TRIM11 WT, or MUT to native (N) and urea-denatured (D) luciferase (luc) immobilized on Ni-NTA beads. Figure 39B shows a sedimentation assay demonstrating heat-aggregated luciferase dissociated by GST or GST-TRIM21. Figure 39C shows the disaggregation and reactivation of preformed luciferase aggregates using increasing concentrations of GST or GST-TRIM21 (n=3). Figure 39D shows a luciferase assay in which luciferase (10 nM) was incubated with 200 nM GST or 200 nM GST-TRIM21 at 45°C for 1 minute. The native luciferase assay was set to 100%. N=3. [Figure 40A] Figure 40, which includes Figures 40A through 40E, shows the results of experiments demonstrating the disaggregation of PML and Atxn1 82Q. Figure 40A shows Coomassie blue staining of purified Flag-PML6 from 293T cells. Figure 40B shows the disaggregation and reactivation of preformed GFP aggregates using increasing concentrations of lysozyme or Flag-PML6 (n=3). Figure 40C shows the disaggregation and reactivation of preformed GFP aggregates using lysozyme, Flag-PML6, or GST-TRIM11 (n=3). Figure 40D shows Coomassie blue staining of purified Flag-PML4 fragments from 293T cells. Figure 40E shows the disaggregation and reactivation of preformed GFP aggregates using various PML4 fragments (n=3). [Figure 40B]Figure 40, which includes Figures 40A through 40E, shows the results of experiments demonstrating the disaggregation of PML and Atxn1 82Q. Figure 40A shows Coomassie blue staining of purified Flag-PML6 from 293T cells. Figure 40B shows the disaggregation and reactivation of preformed GFP aggregates using increasing concentrations of lysozyme or Flag-PML6 (n=3). Figure 40C shows the disaggregation and reactivation of preformed GFP aggregates using lysozyme, Flag-PML6, or GST-TRIM11 (n=3). Figure 40D shows Coomassie blue staining of purified Flag-PML4 fragments from 293T cells. Figure 40E shows the disaggregation and reactivation of preformed GFP aggregates using various PML4 fragments (n=3). [Figure 40C] Figure 40, which includes Figures 40A through 40E, shows the results of experiments demonstrating the disaggregation of PML and Atxn1 82Q. Figure 40A shows Coomassie blue staining of purified Flag-PML6 from 293T cells. Figure 40B shows the disaggregation and reactivation of preformed GFP aggregates using increasing concentrations of lysozyme or Flag-PML6 (n=3). Figure 40C shows the disaggregation and reactivation of preformed GFP aggregates using lysozyme, Flag-PML6, or GST-TRIM11 (n=3). Figure 40D shows Coomassie blue staining of purified Flag-PML4 fragments from 293T cells. Figure 40E shows the disaggregation and reactivation of preformed GFP aggregates using various PML4 fragments (n=3). [Figure 40D]Figure 40, which includes Figures 40A through 40E, shows the results of experiments demonstrating the disaggregation of PML and Atxn1 82Q. Figure 40A shows Coomassie blue staining of purified Flag-PML6 from 293T cells. Figure 40B shows the disaggregation and reactivation of preformed GFP aggregates using increasing concentrations of lysozyme or Flag-PML6 (n=3). Figure 40C shows the disaggregation and reactivation of preformed GFP aggregates using lysozyme, Flag-PML6, or GST-TRIM11 (n=3). Figure 40D shows Coomassie blue staining of purified Flag-PML4 fragments from 293T cells. Figure 40E shows the disaggregation and reactivation of preformed GFP aggregates using various PML4 fragments (n=3). [Figure 40E] Figure 40, which includes Figures 40A through 40E, shows the results of experiments demonstrating the disaggregation of PML and Atxn1 82Q. Figure 40A shows Coomassie blue staining of purified Flag-PML6 from 293T cells. Figure 40B shows the disaggregation and reactivation of preformed GFP aggregates using increasing concentrations of lysozyme or Flag-PML6 (n=3). Figure 40C shows the disaggregation and reactivation of preformed GFP aggregates using lysozyme, Flag-PML6, or GST-TRIM11 (n=3). Figure 40D shows Coomassie blue staining of purified Flag-PML4 fragments from 293T cells. Figure 40E shows the disaggregation and reactivation of preformed GFP aggregates using various PML4 fragments (n=3). [Figure 41A] Figure 41, which includes Figures 41A and 41B, shows the results of experiments demonstrating TRIM11 in mouse primary hippocampal neurons. Figure 41A shows MTT analysis demonstrating that GST or TRIM11 inhibited α-Syn-induced cell death. Figure 41B shows immunofluorescence analysis of p-α-Syn or p62 in hippocampal neurons treated with α-Syn fibers. [Figure 41B]Figure 41, which includes Figures 41A and 41B, shows the results of experiments demonstrating TRIM11 in mouse primary hippocampal neurons. Figure 41A shows MTT analysis demonstrating that GST or TRIM11 inhibited α-Syn-induced cell death. Figure 41B shows immunofluorescence analysis of p-α-Syn or p62 in hippocampal neurons treated with α-Syn fibers. [Figure 42A] Figure 42, comprising Figures 42A to 42C, shows the results of experiments demonstrating that TRIM11 is upregulated in cortical and hippocampal neurons in response to heat shock. Figure 42A shows an immunoblot of mouse primary cortical neurons treated with 42°C heat shock for 30 minutes and allowed to recover for 3 hours. Figure 42B shows an immunoblot of mouse primary hippocampal neurons treated with 42°C heat shock for 30 minutes and allowed to recover for 3 hours. Figure 42C shows semi-quantitative PCR analysis of TRIM11, HSP70, HSP90, and GAPDH in response to heat shock in hippocampal neurons. [Figure 42B] Figure 42, comprising Figures 42A to 42C, shows the results of experiments demonstrating that TRIM11 is upregulated in cortical and hippocampal neurons in response to heat shock. Figure 42A shows an immunoblot of mouse primary cortical neurons treated with 42°C heat shock for 30 minutes and allowed to recover for 3 hours. Figure 42B shows an immunoblot of mouse primary hippocampal neurons treated with 42°C heat shock for 30 minutes and allowed to recover for 3 hours. Figure 42C shows semi-quantitative PCR analysis of TRIM11, HSP70, HSP90, and GAPDH in response to heat shock in hippocampal neurons. [Figure 42C]Figure 42, comprising Figures 42A to 42C, shows the results of experiments demonstrating that TRIM11 is upregulated in cortical and hippocampal neurons in response to heat shock. Figure 42A shows an immunoblot of mouse primary cortical neurons treated with 42°C heat shock for 30 minutes and allowed to recover for 3 hours. Figure 42B shows an immunoblot of mouse primary hippocampal neurons treated with 42°C heat shock for 30 minutes and allowed to recover for 3 hours. Figure 42C shows semi-quantitative PCR analysis of TRIM11, HSP70, HSP90, and GAPDH in response to heat shock in hippocampal neurons.
[0026] Detailed Description The present invention relates to the discovery of a role for the tripartite motif (TRIM) protein family member and SUMO-dependent ubiquitin ligase RNF4 in the recognition and degradation of misfolded proteins, which play a role in the pathology of various neurodegenerative disorders.
[0027] In one aspect, the present invention provides compositions and methods for treating or preventing diseases or disorders associated with misfolded proteins or protein aggregates. TRIM proteins, as chaperone proteins, have been demonstrated herein to play a role in targeting misfolded proteins for degradation by proteasomes and in disaggregating protein aggregates or inclusion bodies. Thus, in certain aspects, the present invention can be used to eliminate intracellular or extracellular misfolded proteins, protein aggregates, or protein inclusion bodies.
[0028] For example, in certain embodiments, the present invention provides compositions and methods for treating or preventing neurodegenerative disorders in a subject in need thereof. For example, in certain embodiments, the present invention provides compositions and methods for treating or preventing neurodegenerative disorders that are poly-glutamine (polyQ) disorders (in which CAG codon repeats encode proteins with polyglutamine tracts that can lead to misfolded protein aggregates). Exemplary polyQ disorders include, but are not limited to, spinocerebellar ataxia (SCA) type 1 (SCA1), SCA2, SCA3, SCA6, SCA7, SCA17, Huntington's disease, and dentatorubral-pallidoluysian atrophy (DRPLA). In certain embodiments, the present invention provides compositions and methods for treating neurodegenerative disorders associated with misfolded proteins or protein aggregates, including, but not limited to, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), transmissible spongiform encephalopathies (prion diseases), tauopathies, and frontotemporal lobar degeneration (FTLD). However, the present invention is not limited to the treatment or prevention of neurodegenerative disorders, but rather encompasses the treatment or prevention of any disease or disorder associated with misfolded proteins or protein aggregates. Other such diseases and disorders include, but are not limited to, AL amyloidosis, AA amyloidosis, familial Mediterranean fever, senile systemic amyloidosis, familial amyloidotic polyneuropathy, hemodialysis-associated amyloidosis, apolipoprotein AI amyloidosis, apolipoprotein AII amyloidosis, apolipoprotein AIV amyloidosis, hereditary amyloidosis of the Finnish type, lysozyme amyloidosis, fibrinogen amyloidosis, hereditary cerebral amyloid angiopathy of the Icelandic type, type II diabetes mellitus, medullary thyroid carcinoma, atrial amyloidosis, hereditary cerebral hemorrhage with amyloidosis, pituitary prolactinoma, amyloidosis confined to injection sites, aortic medial amyloidosis, hereditary lattice corneal dystrophy, corneal amyloidosis associated with trichiasis, cataract, calcifying epithelial odontogenic tumor, pulmonary alveolar proteinosis, inclusion body myositis, and cutaneous lichen amyloidosis.In particular embodiments, the present invention encompasses the treatment or prevention of cancers associated with aggregation of mutant p53, including, but not limited to, bladder cancer, astrocytoma, laryngeal carcinoma, lymphoma, and adenocarcinoma.
[0029] In one aspect, the present invention encompasses the use of one or more TRIM proteins to stabilize misfolded proteins. In certain aspects, stabilization of functional misfolded proteins via one or more TRIM proteins described herein can treat or prevent diseases or disorders associated with misfolded proteins. For example, in one embodiment, stabilization of a cystic fibrosis transmembrane conductance regulator (CFTR) mutant via one or more TRIM proteins described herein would allow the mutant CFTR to function instead of being degraded. It is contemplated that the use of TRIM proteins to stabilize misfolded proteins can be used to treat cystic fibrosis and other diseases associated with the degradation of partially functional proteins. Protein stabilization via one or more TRIM proteins described herein can be used to treat any disease or disorder associated with the degradation of functional mutant proteins, including, but not limited to, cystic fibrosis and lysosomal storage diseases such as Gaucher disease and Fabry disease.
[0030] In one aspect, the present invention provides compositions and methods for increasing the expression, activity, or both of TRIM proteins. In certain embodiments, the compositions comprise nucleic acid molecules, expression vectors, proteins, peptides, small molecules, etc. that increase the expression, activity, or both of one or more TRIM proteins.
[0031] In one aspect, the present invention provides compositions and methods for increasing the expression, activity, or both of one or more SUMO-targeting ubiquitin ligases (STUbLs). In certain embodiments, the compositions comprise nucleic acid molecules, expression vectors, proteins, peptides, small molecules, etc. that increase the expression, activity, or both of one or more STUbLs.
[0032] definition Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described.
[0033] As used herein, each of the following terms has the meaning associated with it in this section.
[0034] The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. For example, "an element" means one element or more than one element.
[0035] As used herein, "about," when referring to a measurable number, such as an amount, a time range, etc., is meant to encompass variations of ±20%, ±10%, ±5%, ±1%, or ±0.1% from the stated number, as such variations are appropriate for practicing the disclosed methods.
[0036] The term "abnormal" when used in the context of an organism, tissue, cell, or component thereof refers to such organism, tissue, cell, or component thereof that differs in at least one observable or detectable characteristic (e.g., age, treatment, time of day, etc.) from such organism, tissue, cell, or component thereof that exhibits the "normal" (expected) respective characteristic. A characteristic that is normal or expected for one cell or tissue type may be abnormal for a different cell or tissue type.
[0037] A "disease" is a state of health in an animal in which the animal is unable to maintain homeostasis and which will continue to deteriorate if the disease is not remitted.
[0038] In contrast, an animal "disorder" is a health state in which the animal is able to maintain homeostasis, but which is less favorable than if the disorder were not present. If left untreated, the disorder does not necessarily cause a further deterioration in the animal's health.
[0039] A disease or disorder is "alleviated" if the severity of a sign or symptom of the disease or disorder, the frequency with which such sign or symptom occurs in a patient, or both, is reduced.
[0040] An "effective amount" or "therapeutically effective amount" of a compound is the amount of the compound sufficient to provide a beneficial effect to the subject to which the compound is administered. An "effective amount" of a delivery vehicle is the amount sufficient to effectively bind to or deliver the compound.
[0041] As used herein, "instructional material" includes publications, records, illustrations, or any other medium of expression that can be used to communicate the usefulness of the compounds, compositions, vectors, or delivery systems of the invention in the kits to effect alleviation of the various diseases or disorders listed herein. Optionally, or alternatively, the instructional material may describe one or more methods of alleviating a disease or disorder in a mammalian cell or tissue. The instructional material of the kits of the invention may, for example, be affixed to a container containing the identified compound, composition, vector, or delivery system of the invention, or may be shipped together with a container containing the identified compound, composition, vector, or delivery system. Alternatively, the instructional material may be shipped separately from the container, with the intention that the instructional material and the compound be used jointly by the recipient.
[0042] The terms "patient," "subject," "individual," and the like are used synonymously herein and refer to any animal or cells thereof that can be subjected to the methods described herein, whether in vitro or in vivo. In certain non-limiting embodiments, the patient, subject, or individual is a human.
[0043] A "therapeutic" treatment is a treatment administered to a subject who exhibits signs or symptoms of a disease or disorder with the intent of reducing or eliminating such signs or symptoms.
[0044] As used herein, "treating a disease or disorder" means reducing the severity and / or frequency of signs or symptoms of the disease or disorder occurring in a patient.
[0045] As used herein, the phrase "biological sample" is intended to include any sample containing cells, tissues, or bodily fluids in which nucleic acid or polypeptide expression is present or can be detected. Samples that are liquid in nature are referred to herein as "bodily fluids." Biological samples can be obtained from a patient by a variety of techniques, such as, for example, by scraping or swabbing an area of the subject or by using a needle to obtain a bodily fluid. Methods for collecting various biological samples are well known in the art.
[0046] As used herein, "immunoassay" refers to any binding assay that uses an antibody that can specifically bind to a target molecule to detect and quantitate the target molecule.
[0047] The term "specifically binds" as used herein with respect to an antibody refers to an antibody that recognizes a specific antigen but does not substantially recognize or bind to other molecules in a sample. For example, an antibody that specifically binds to an antigen from one species may also bind to antigens from one or more species. However, such interspecies cross-reactivity does not itself change the classification of the antibody as being specific. In another example, an antibody that specifically binds to an antigen may also bind to different allelic forms of the antigen. However, such cross-reactivity does not itself change the classification of the antibody as being specific.
[0048] In some cases, the terms "specific binding" or "specifically binds" may be used in reference to the interaction of an antibody, protein, or peptide with a second chemical species, where the interaction is dependent on the presence of a particular structure (e.g., an antigenic determinant or epitope) on the chemical species; for example, an antibody may recognize and bind to a particular protein structure rather than the entire protein. If an antibody is specific for epitope "A," then the presence of a molecule containing epitope A (i.e., free, unlabeled A) in a reaction containing labeled "A" and the antibody will reduce the amount of labeled A that binds to the antibody.
[0049] The "coding region" of a gene consists of nucleotide residues on the coding strand of the gene and nucleotides on the non-coding strand of the gene that are homologous or complementary, respectively, to the coding region of an mRNA molecule produced by transcription of the gene.
[0050] The "coding region" of an mRNA molecule consists of nucleotide residues of the mRNA molecule that either fit into the anticodon region of a transfer RNA molecule during translation of the mRNA molecule or encode a stop codon. Thus, the coding region may include nucleotide residues that include codons for amino acid residues that are not present in the mature protein encoded by the mRNA molecule (e.g., amino acid residues in a protein export signal sequence).
[0051] "Complementary," as used herein to refer to nucleic acids, refers to the broad concept of sequence complementarity between regions of two nucleic acid strands or between two regions of the same nucleic acid strand. It is known that an adenine residue in a first nucleic acid strand can form specific hydrogen bonds ("base pairing") with a residue in a second nucleic acid strand antiparallel to the first strand if the residue is thymine or uracil. Similarly, it is known that a cytosine residue in a first nucleic acid strand can form base pairs with a residue in a second nucleic acid strand antiparallel to the first strand if the residue is guanine. A first region of a nucleic acid is complementary to a second region of the same or a different nucleic acid if, when the two regions are aligned antiparallel, at least one nucleotide residue in the first region can base pair with a residue in the second region. Preferably, the first region comprises a first portion and the second region comprises a second portion, such that when the first and second portions are arranged in antiparallel, at least about 50%, preferably at least about 75%, at least about 90%, or at least about 95% of the nucleotide residues in the first portion are capable of base pairing with nucleotide residues in the second portion, and more preferably, all nucleotide residues in the first portion are capable of base pairing with nucleotide residues in the second portion.
[0052] "Isolated" means changed or removed from the natural state. For example, a nucleic acid or peptide that is naturally present in its normal form in a living animal is not "isolated," but the same nucleic acid or peptide that has been partially or completely separated from the coexisting materials of its natural form is "isolated." An isolated nucleic acid or protein can exist in substantially purified form, or it can exist in a non-native environment, such as a host cell.
[0053] An "isolated nucleic acid" refers to a nucleic acid segment or fragment separated from sequences that naturally flank it, i.e., a DNA fragment that has been removed from sequences that normally flank the fragment, i.e., sequences that flank the fragment in the genome in which it naturally occurs. The term also applies to nucleic acids that have been substantially purified from other components that naturally accompany the nucleic acid, i.e., RNA or DNA or proteins that naturally accompany it in the cell. Thus, the term includes recombinant DNA that is incorporated into, for example, a vector, an autonomously replicating plasmid or virus, or the genomic DNA of a prokaryote or eukaryote, or exists as a separate molecule independent of other sequences (i.e., as a cDNA or genomic fragment or cDNA fragment generated by PCR or restriction enzyme digestion). It also includes recombinant DNA that is part of a hybrid gene encoding additional polypeptide sequences.
[0054] In the context of the present invention, the following abbreviations are used for commonly occurring nucleobases: "A" refers to adenosine, "C" refers to cytosine, "G" refers to guanosine, "T" refers to thymidine, and "U" refers to uridine.
[0055] The term "polynucleotide" as used herein is defined as a chain of nucleotides. Furthermore, a nucleic acid is a polymer of nucleotides. Therefore, as used herein, nucleic acid and polynucleotide are synonymous. Those skilled in the art have general knowledge that a nucleic acid is a polynucleotide that can be hydrolyzed into monomeric "nucleotides." Monomeric nucleotides can be hydrolyzed into nucleosides. As used herein, polynucleotide includes, but is not limited to, all nucleic acid sequences obtained by any means available in the art, including, but not limited to, recombinant means, i.e., cloning nucleic acid sequences from recombinant libraries or cell genomes using conventional cloning techniques and PCR, and by synthetic means.
[0056] As used herein, the terms "peptide," "polypeptide," and "protein" are used synonymously and refer to compounds comprising amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and there is no limit on the maximum number of amino acids that a protein or peptide sequence may contain. A polypeptide includes any peptide or protein containing two or more amino acids connected to each other by peptide bonds. As used herein, the term refers to both short chains, also commonly referred to in the art as peptides, oligopeptides, and oligomers, as well as longer chains, of which there are many types, commonly referred to in the art as proteins. "Polypeptide" includes, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, and fusion proteins, among others. A polypeptide includes natural peptides, recombinant peptides, synthetic peptides, or combinations thereof.
[0057] As used herein, "conjugated" refers to the covalent attachment of one molecule to a second molecule.
[0058] A "variant," as the term is used herein, refers to a nucleic acid or peptide sequence that differs in sequence from a reference nucleic acid or peptide sequence, respectively, but retains essential biological properties of the reference molecule. Changes in the sequence of a nucleic acid variant may not change the amino acid sequence of the peptide encoded by the reference nucleic acid, or may result in amino acid substitutions, additions, deletions, fusions, and truncations. Sequence changes in peptide variants are typically limited or conservative, so that the sequences of the reference peptide and variant are closely similar overall and, in many regions, identical. The amino acid sequences of a variant and reference peptide may differ by any combination of one or more substitutions, additions, or deletions. Nucleic acid or peptide variants can be naturally occurring, such as allelic variants, or they can be variants that are not known to occur naturally. Non-naturally occurring variants of nucleic acids and peptides can be made by mutagenesis techniques or by direct synthesis.
[0059] As used herein, a "modulator of one or more TRIM proteins" is a compound that alters the expression, activity, or biological function of a TRIM protein compared to the expression, activity, or biological function of the TRIM protein in the absence of the modulator.
[0060] As used herein, a "modulator of RNF4" is a compound that alters the expression, activity, or biological function of RNF4 compared to the expression, activity, or biological function of RNF4 in the absence of the modulator.
[0061] Ranges: Throughout this disclosure, various aspects of the invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, the description of a range such as 1 to 6 should be considered to have specifically disclosed subranges such as 1 to 3, 1 to 4, 1 to 5, 2 to 4, 2 to 6, 3 to 6, etc., as well as individual numbers within that range, e.g., 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the broadness of the range.
[0062] explanation In one aspect, the present invention provides compositions and methods for treating or preventing diseases or disorders associated with misfolded proteins or protein aggregates. For example, the present invention provides compositions and methods for increasing the recognition and clearance of misfolded proteins. In certain embodiments, the present invention provides SUMO-mediated ubiquitination and eventual degradation of misfolded proteins. In certain embodiments, the present invention provides disaggregation of protein aggregates or inclusion bodies. Thus, the present invention can be used to eliminate both intracellular and extracellular misfolded proteins, protein aggregates, or protein inclusion bodies.
[0063] The present invention relates to the discovery of a role for RNF4, a tripartite motif (TRIM) protein family member and SUMO-targeting ubiquitin ligase (STUbL), in the recognition and degradation of misfolded proteins, which plays a role in the pathology of various diseases and disorders, including many neurodegenerative diseases and disorders.
[0064] The data presented herein demonstrate that TRIM protein family members colocalize with misfolded proteins and mediate their degradation. Furthermore, RNF4 is described herein as a ubiquitin ligase that mediates the ubiquitination and degradation of misfolded proteins. Accordingly, the present invention provides compositions that increase the expression, activity, or both of one or more TRIM proteins, one or more STUbLs, or a combination thereof. For example, it has been demonstrated that TRIM proteins and nucleic acid molecules encoding recombinant TRIM proteins promote the degradation of misfolded proteins.
[0065] In one embodiment, the composition comprises a modulator of the expression or activity of one or more TRIM proteins. For example, in one embodiment, the modulator increases the expression or activity of one or more TRIM proteins. The one or more TRIM proteins may include any member of the TRIM protein family, including, for example, mammalian and non-mammalian members. In certain embodiments, the modulator increases the expression or activity of one or more of human TRIM3, TRIM4, TRIM5, TRIM6, TRIM7, TRIM9, TRIM11, TRIM13, TRIM14, TRIM15, TRIM16, TRIM17, TRIM19 (also referred to herein as "PML"), TRIM20, TRIM21, TRIM24, TRIM25, TRIM27, TRIM28, TRIM29, TRIM32, TRIM34, TRIM39, TRIM43, TRIM44, TRIM45, TRIM46, TRIM49, TRIM50, TRIM52, TRIM58, TRIM59, TRIM65, TRIM67, TRIM69, TRIM70, TRIM74, and TRIM75; and mouse TRIM30.
[0066] In one embodiment, the composition comprises a modulator of one or more STUbLs. For example, in one embodiment, the modulator increases the expression or activity of one or more STUbLs. Exemplary STUbLs include, but are not limited to, RNF4 and RNF111 (also known as Arcadia).
[0067] In one embodiment, the composition comprises a modulator of one or more TRIM proteins and a modulator of one or more STUbLs.
[0068] The present invention provides methods for treating or preventing a disease or disorder associated with misfolded proteins or protein aggregates in a subject in need thereof. It is herein found that increasing the level of expression or activity of a TRIM protein or STUbL can promote the degradation of misfolded proteins, thereby treating the disease or disorder in the subject.
[0069] Examples of neurodegenerative diseases or disorders that can be treated or prevented by the compositions and methods of the present invention include, but are not limited to, polyQ disorders such as SCA1, SCA2, SCA3, SCA6, SCA7, and SCA17, Huntington's disease...
Claims
1. A composition for treating or preventing a disease or disorder associated with misfolded proteins or protein aggregates, the composition comprising a modulator of one or more TRIM proteins.
2. The composition of claim 1 , wherein the modulator increases the expression or activity of one or more TRIM proteins.
3. The composition of claim 1 , wherein the modulator is at least one of the group consisting of a compound, a protein, a peptide, a peptidomimetic, an antibody, a ribozyme, a small molecule compound, a nucleic acid, a vector, and an antisense nucleic acid.
4. The modulator may be selected from the group consisting of human TRIM3, TRIM4, TRIM5, TRIM6, TRIM7, TRIM9, TRIM11, TRIM13, TRIM14, TRIM15, TRIM16, TRIM17, TRIM19 (also referred to herein as "PML"), TRIM20, TRIM21, TRIM24, TRIM25, TRIM27, TRIM28, TRIM29, TRIM32, TRIM33, TRIM34, TRIM35, TRIM36, TRIM37, TRIM38, TRIM39, TRIM40, TRIM41, TRIM42, TRIM43, TRIM44, TRIM45, TRIM46, TRIM47, TRIM48, TRIM49, TRIM50, TRIM51, TRIM52, TRIM53, TRIM54, TRIM55, TRIM56, TRIM57, TRIM58, TRIM59, TRIM60, TRIM61, TRIM62, TRIM63, TRIM64, TRIM65, TRIM66, TRIM67, TRIM68, TRIM69, TRIM70, TRIM71, TRIM72, TRIM73, TRIM74, TRIM75, TRIM76, TRIM77, TRIM78, TRIM79, TRIM80, TRIM81, TRIM82, TRIM83, TRIM84, TRIM85, TRIM86, TRIM87, TRIM88, TRIM89, TRIM90, TRIM91, TRIM92, TRIM93, TRIM94, TRIM95, TRIM96, TRIM97, TRIM98, TRIM99, TRIM100, TRIM101, TRIM102, TRIM103, TRIM104, TRIM105, TRIM106, TRIM107, TRIM108, TR 2. The composition of claim 1, which increases the expression or activity of at least one selected from the group consisting of mouse TRIM34, TRIM39, TRIM43, TRIM44, TRIM45, TRIM46, TRIM49, TRIM50, TRIM52, TRIM58, TRIM59, TRIM65, TRIM67, TRIM69, TRIM70, TRIM74, and TRIM75; and mouse TRIM30.
5. The composition of claim 1 , comprising an isolated peptide comprising one or more TRIM proteins.
6. The composition of claim 5 , wherein the isolated peptide further comprises a cell membrane penetrating peptide (CPP) that enables entry of the isolated peptide into a cell.
7. The composition of claim 6 , wherein the CPP comprises the protein transduction domain of HIV tat.
8. The composition of claim 1 , comprising an isolated nucleic acid molecule encoding one or more TRIM proteins.
9. The composition of claim 1 , wherein the disease or disorder is a polyQ disorder.
10. 2. The composition of claim 1, wherein the disease or disorder is a neurodegenerative disease or disorder selected from the group consisting of spinocerebellar ataxia (SCA) type 1 (SCA1), SCA2, SCA3, SCA6, SCA7, SCA17, Huntington's disease, dentatorubral-pallidoluysian atrophy (DRPLA), Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), transmissible spongiform encephalopathies (prion diseases), tauopathies, and frontotemporal lobar degeneration (FTLD).
11. The disease or disorder is selected from the group consisting of AL amyloidosis, AA amyloidosis, familial Mediterranean fever, senile systemic amyloidosis, familial amyloidotic polyneuropathy, hemodialysis-associated amyloidosis, apolipoprotein AI amyloidosis, apolipoprotein AII amyloidosis, apolipoprotein AIV amyloidosis, hereditary amyloidosis of the Finnish type, lysozyme amyloidosis, fibrinogen amyloidosis, hereditary amyloidosis of the Icelandic type, The composition of claim 1, wherein the disease is selected from the group consisting of hereditary cerebral amyloid angiopathy, type II diabetes mellitus, medullary thyroid carcinoma, atrial amyloidosis, hereditary cerebral hemorrhage with amyloidosis, pituitary prolactinoma, amyloidosis confined to the injection site, medial aortic amyloidosis, hereditary lattice corneal dystrophy, corneal amyloidosis associated with trichiasis, cataracts, calcifying epithelial odontogenic tumor, pulmonary alveolar proteinosis, inclusion body myositis, and cutaneous lichen amyloidosis.
12. The composition of claim 1 , wherein the disease or disorder is a cancer associated with aggregates of mutant p53.
13. A method for treating or preventing a disease or disorder associated with misfolded proteins or protein aggregates in a subject in need thereof, the method comprising administering to the subject a composition comprising a modulator of one or more TRIM proteins.
14. The method of claim 13 , wherein the modulator increases the expression or activity of one or more TRIM proteins.
15. The method of claim 13, wherein the modulator is at least one selected from the group consisting of a compound, a protein, a peptide, a peptidomimetic, an antibody, a ribozyme, a small molecule compound, a nucleic acid, a vector, and an antisense nucleic acid.
16. The modulator is selected from the group consisting of human TRIM3, TRIM4, TRIM5, TRIM6, TRIM7, TRIM9, TRIM11, TRIM13, TRIM14, TRIM15, TRIM16, TRIM17, TRIM19 (also referred to herein as "PML"), TRIM20, TRIM21, TRIM24, TRIM25, TRIM27, TRIM28, TRIM29, TRIM32, TRIM33, TRIM34, TRIM35, TRIM36, TRIM37, TRIM38, TRIM39, TRIM40, TRIM41, TRIM42, TRIM43, TRIM44, TRIM45, TRIM46, TRIM47, TRIM48, TRIM49, TRIM50, TRIM51, TRIM52, TRIM53, TRIM54, TRIM55, TRIM56, TRIM57, TRIM58, TRIM59, TRIM60, TRIM61, TRIM62, TRIM63, TRIM64, TRIM65, TRIM66, TRIM67, TRIM68, TRIM69, TRIM70, TRIM71, TRIM72, TRIM73, TRIM74, TRIM75, TRIM76, TRIM77, TRIM78, TRIM79, TRIM80, TRIM81, TRIM82, TRIM83, TRIM84, TRIM85, TRIM86, TRIM87, TRIM88, TRIM89, TRIM90, TRIM91, TRIM92, TRIM93, TRIM94, TRIM95, TRIM96, TRIM97, TRIM98, TRIM99, TRIM100, TRIM101, TRIM102, TRIM103, TRIM104, TRIM105, TRIM106, TRIM107, TRIM108, TRIM The method of claim 13, wherein the expression or activity of at least one selected from the group consisting of TRIM34, TRIM39, TRIM43, TRIM44, TRIM45, TRIM46, TRIM49, TRIM50, TRIM52, TRIM58, TRIM59, TRIM65, TRIM67, TRIM69, TRIM70, TRIM74, and TRIM75; and mouse TRIM30.
17. The method of claim 13 , wherein the composition comprises an isolated peptide comprising one or more TRIM proteins.
18. 20. The method of claim 17, wherein the isolated peptide further comprises a cell membrane penetrating peptide (CPP) that enables entry of the isolated peptide into a cell.
19. 20. The method of claim 18, wherein the CPP comprises the protein transduction domain of HIV tat.
20. The method of claim 13 , wherein the composition comprises an isolated nucleic acid molecule encoding one or more TRIM proteins.
21. The method of claim 13 , wherein the lesion is a polyQ lesion.
22. 14. The method of claim 13, wherein the disease or disorder is a neurodegenerative disorder selected from the group consisting of spinocerebellar ataxia (SCA) type 1 (SCA1), SCA2, SCA3, SCA6, SCA7, SCA17, Huntington's disease, dentatorubral-pallidoluysian atrophy (DRPLA), Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), transmissible spongiform encephalopathies (prion diseases), tauopathies, and frontotemporal lobar degeneration (FTLD).
23. The disease or disorder is selected from the group consisting of AL amyloidosis, AA amyloidosis, familial Mediterranean fever, senile systemic amyloidosis, familial amyloidotic polyneuropathy, hemodialysis-associated amyloidosis, apolipoprotein AI amyloidosis, apolipoprotein AII amyloidosis, apolipoprotein AIV amyloidosis, hereditary amyloidosis of the Finnish type, lysozyme amyloidosis, fibrinogen amyloidosis, hereditary amyloidosis of the Icelandic type, 14. The method of claim 13, wherein the disease is selected from the group consisting of hereditary cerebral amyloid angiopathy, type II diabetes mellitus, medullary thyroid carcinoma, atrial amyloidosis, hereditary cerebral hemorrhage with amyloidosis, pituitary prolactinoma, amyloidosis localized to the injection site, medial aortic amyloidosis, hereditary lattice corneal dystrophy, corneal amyloidosis associated with trichiasis, cataracts, calcifying epithelial odontogenic tumor, pulmonary alveolar proteinosis, inclusion body myositis, and cutaneous lichen amyloidosis.
24. 14. The method of claim 13, wherein the disease or disorder is cancer associated with aggregates of mutant p53.
25. The method of claim 13, comprising administering the composition to at least one neuronal cell of a subject.
26. A composition for treating or preventing a disease or disorder associated with the degradation of a functional mutant protein, the composition comprising a modulator of one or more TRIM proteins.
27. The composition of claim 26 , wherein the modulator increases the expression or activity of one or more TRIM proteins.
28. 27. The composition of claim 26, wherein the modulator is at least one of the group consisting of a compound, a protein, a peptide, a peptidomimetic, an antibody, a ribozyme, a small molecule compound, a nucleic acid, a vector, and an antisense nucleic acid.
29. 27. The composition of claim 26, wherein the disease or disorder is cystic fibrosis.
30. A method for treating or preventing a disease or disorder associated with the degradation of a functional mutant protein in a subject in need thereof, comprising administering to the subject a composition comprising a modulator of one or more TRIM proteins.
31. The method of claim 30 , wherein the modulator increases the expression or activity of one or more TRIM proteins.
32. 31. The method of claim 30, wherein the modulator is at least one selected from the group consisting of a compound, a protein, a peptide, a peptidomimetic, an antibody, a ribozyme, a small molecule compound, a nucleic acid, a vector, and an antisense nucleic acid.
33. 31. The method of claim 30, wherein the disease or disorder is cystic fibrosis.
34. A composition for treating or preventing a disease or disorder associated with misfolded proteins or protein aggregates, the composition comprising one or more modulators of SUMO-targeted ubiquitin ligase (STUbl).
35. The composition of claim 34 , wherein the modulator increases the expression or activity of one or more STUbLs.
36. 35. The composition of claim 34, wherein the modulator is at least one of the group consisting of a compound, a protein, a peptide, a peptidomimetic, an antibody, a ribozyme, a small molecule compound, a nucleic acid, a vector, and an antisense nucleic acid.
37. The composition of claim 34, wherein the modulator increases the expression or activity of RNF4.
38. A method for treating or preventing a disease or disorder associated with misfolded proteins or protein aggregates in a subject in need thereof, the method comprising administering to the subject a composition comprising one or more modulators of STUbL.
39. The method of claim 38, wherein the modulator increases the expression or activity of one or more STUbLs.
40. 39. The method of claim 38, wherein the modulator is at least one of the group consisting of a compound, a protein, a peptide, a peptidomimetic, an antibody, a ribozyme, a small molecule compound, a nucleic acid, a vector, and an antisense nucleic acid.
41. The method of claim 38, wherein the modulator increases the expression or activity of RNF4.
42. A method for producing a recombinant protein comprising administering to a cell engineered to express the recombinant protein a modulator of one or more TRIM proteins.
43. 43. The method of claim 42, wherein the modulator comprises an isolated peptide comprising one or more TRIM proteins.
44. 43. The method of claim 42, wherein the modulator comprises an isolated nucleic acid molecule encoding one or more TRIM proteins.
Citation Information
Patent Citations
Method for Treating Polyglutamine Expansion Neurodegenerative Diseases
US20090208455A1
Conjugates of proteins and multivalent cell-penetrating peptides and their uses
WO2014086835A1
